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Abstract
Schizophrenia is a serious and debilitating mental illness with a lifetime risk of -1%
in the human population. Family, twin and adoption studies have provided strong
evidence for there being a genetic component involved in schizophrenia but the
nature of this component is still unclear. Genetic linkage studies have failed to
provided strong candidate genes involved in schizophrenia. The identification of
cytogenetic abnormalities which are associated with disease provides a valuable
alternative method for discovering susceptibility genes involved in disease. We have
identified a balanced translocation t(1:11 )(q43:q14.3) which co-segregates with
psychosis in a large Scottish pedigree. A positional cloning strategy has been
undertaken to elucidate the relationship between the translocation and the
psychiatric diagnosis in this family, based on the hypothesis that a gene or genes
involved in mental illness reside at or near the translocation breakpoint on
chromosome 1 and/or 11.This thesis takes several approaches to identifying genes
residing around the translocation breakpoint which may be involved with the
psychiatric diagnosis in this family.
• Candidate gene approach:
Two actinin genes ACTN 2 and ACTN 3, were considered as potential candidate
genes, having previously been described as mapping to the general region of the
translocation breakpoint on chromosome 1 and 11 respectively. High resolution
mapping employing somatic cell hybrid and YAC DNA from the region indicated that
these two genes were >2Mb from the breakpoint, lying outwith the YAC contigs, and
were therefore not considered further as candidates.
• High resolution mapping of expressed sequence tagged sites from
chromosome 11
This approach utilised resources available from the Human Genome Project to
identify transcripts from the chromosome 11 breakpoint region. High resolution
mapping of several expressed sequence tagged sites (EST's) which had been
described as mapping in the vicinity of the breakpoint on chromosome 11, was
achieved using the same approach as with the actinin genes. Of the 18 EST's
mapped none were close enough to the chromosome 11 breakpoint to be
considered further as candidates.
• Allelic Association Study using markers from chromosome 1 and 11
breakpoint regions
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An allelic association study was undertaken using two polymorphic markers,
identified as lying in close proximity to the chromosome 1 and 11 breakpoint, to test
for linkage disequilibrium with a postulated schizophrenia susceptibility gene in a
random population of schizophrenia subjects and unipolar depressed subjects
compared with a matched normal control population. This study showed no
differences in allele frequencies between the affected and control group, evidence
against a nearby gene of major effect in the populations studied.
• Coincident Sequence Cloning
In order to identify foetal brain expressed sequences from the region spanning the
chromosome 1 breakpoint a cDNA selection based technique, coincident sequence
cloning was employed. Two products from the library produced were identified as
novel cDNA transcripts and were characterised by sequence and expression
studies. These can now be followed up as potential susceptibility factors for
psychosis in this family.
The analysis of the actinin genes and high resolution mapping of EST's in the
region of the translocation breakpoint has allowed elimination of these candidates
from being involved in the psychiatric diagnosis in this family. The coincident
sequence cloning experiment in contrast has supplied two novel gene fragments
whose candidacy can be further evaluated by means of expression studies,
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C cytosine
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EDTA ethylenediamine tetra-acetic acid disodium salt
EE expressed emotion
EFA essential fatty acid
EL end ligation
ERP event related potential
EST expressed sequence tag
EtBr ethidium bromide
FAS foetal alcohol syndrome
FISH fluorescence in-situ hybridisation
G guanosine
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HCI hydrochloric acid
HF hybrid fishing
HGMP human genome mapping project
HLA human lymphocyte antigen
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IBD identity by descent
ICD International Classification of Diseases
IDDM insulin-dependent diabetes mellitus
IPTG isopropylthio-|3-D-galactoside
IQ intelligence quotient
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KH2P04 potassium dihydrogen phosphate
kV kilovolts
I litre
LMP low melting point
LOD logarithm of odds










MPA minor physical abnormality
MRC Medical Research Council
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid












ORF open reading frame
p pico
PAC P1 artificial chromosome
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Schizophrenia is a serious and debilitating disorder representing one of the severest
forms of the psychoses. It is characterised by mental anguish and impaired
judgement and is sometimes so debilitating that the sufferer may permanently lose
touch with reality. Schizophrenia is found in all countries, societies and cultures and
affects approximately 1% of the world population. It is a distressing disorder for both
the sufferer and for their family who often have to shoulder the responsibility
providing care. Current treatments merely ameliorate the severest symptoms
working more efficiently in some sufferers than others and leaving many facing a
future of increasing social isolation.
In Britain, mental illness accounts for 14% of the inpatient NHS budget, 23% of the
NHS drug budget and approximately one quarter of the homeless population are
estimated to have had contact with psychiatric services (MRC field review:
Biological Psychiatry 1993). Mental illness therefore poses a significant financial
and social problem.
The aetiology of most mental illnesses is complex involving the interaction of
various risk factors including genetic predisposition along with social and
environmental factors. Although it has been established that a genetic component
exists for schizophrenia the nature of this component remains elusive, primarily due
to issues such as unknown mode of inheritance, phenotypic uncertainty, genetic
heterogeneity, late onset and variable penetrance.
Schizophrenia is both a difficult and challenging disorder to study genetically but
recently the field has advanced with new methodologies finally coming to fruition.
There is now a real possibility that the genes responsible for the condition can be
identified allowing the provision of better therapeutic treatments and understanding
for those who are afflicted.
1.2 Schizophrenia
Schizophrenia is the term used to describe one of the principle forms of
major mental illness which affects the human population. The term schizophrenia
(the splitting of personality) used in 1950 by Eugen Bleuler to denote the breakdown
of integration between emotions thought and actions, owes its origins as a separate
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clinical entity to Emil Kraeplin, who in the nineteenth century, based on symptoms
and long term outcome, divided "madness" (not due to coarse brain disease) into
manic depressive insanity and dementia praecox. The latter is known today as
schizophrenia.
1.2.1 Symptoms of schizophrenia
The core symptoms of schizophrenia were first described at the beginning of
the 19th century by Pinel and Haslam although it is likely that schizophrenia has
existed for considerably longer than this. The symptoms were later classified by
Kraeplin (1919) into dementia praecox. The symptoms of schizophrenia are highly
variable both between individuals and across time in the same individual, often
being similar in nature, but very different in form. Some of the most prolific
symptoms characterising schizophrenia are listed below. Some individuals will
suffer several of these symptoms whereas others will not show clear signs of any,
although this may change with the course of their illness, reflecting the syndromic
nature of the disorder;
• Thought disorder.
The form and flow of thought is disjointed and the train of thought of an
afflicted individual may be difficult to follow due to lack of structure,
coherence and a loosening of associations. The thought process may be
reduced or slowed and may result in poverty of speech.
• Abnormal beliefs and delusions.
These may take a variety of forms. The individual may feel that their
thoughts are being controlled by some external influence or may suffer
delusions of persecution or grandeur.
• Prominent or auditory hallucinations.
These are perhaps the most dramatic and certainly the most visible
symptoms seen in schizophrenia. Again they can vary widely in terms of
their nature and it is believed that the fundamental defect may concern




These may interchange between depression, euphoria and anxiety. There
seems to be disconnection between mood and other functioning such that
moods are often expressed inappropriately. This is often referred to as
incongruent mood.
• Motor alterations.
Restlessness, hyperactivity or general increased motor functioning may
be displayed or alternatively a reduction in motor activity may be seen
with long periods of inactivity and immobility. Alteration of motor activity
between these two extremes is often termed catatonic schizophrenia.
• Alteration of social functioning.
This may involve withdrawal from social interaction and may be partial or
extreme. Alteration may also occur in terms of breaking social
conventions.
Schizophrenia symptoms are often loosely categorised as being either positive or
negative in nature. Positive symptoms include delusions, hallucinations, thought
disorder such as incoherence, tangential movement of thought and loosening of
association, and increased motor function and are termed positive as they are
considered to represent excess normal function. Negative symptoms of
schizophrenia represent deficit to normal function and are defined as being poverty
of thought or speech, loss of emotional responsiveness, blunting of emotions,
apathy, attention deficit reduced motor function and social withdrawal (Rao and
Moller 1994). The latter often imply a more chronic state.
1.2.2 Diagnosis of schizophrenia
Despite the fact that schizophrenia was described as a separate clinical entity over
eighty years ago there is still debate about its definition. With the lack of a reliable,
unique biological marker to aid the diagnosis of schizophrenia, psychiatrists are
dependent entirely on the symptoms seen at clinical presentation for diagnosing
schizophrenia and the other major psychoses. Demarcation of the major clinical
picture of schizophrenia and other psychoses is not well defined as there appears to
be no point of rarity among them, resulting in distinct blurring of the boundaries of
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the disease and making diagnosis difficult. Several classification systems have
been devised for diagnosing schizophrenia, many reflecting fashionable ideas of the
aetiology of the disease and none proving to be any more valid a definition of the
disease than the next. Having a large number of differing criteria for diagnosing the
psychoses has been problematic causing interpretation and comparison of data to
be difficult if not impossible.
One of the first widely used diagnostic criteria (at least in Europe) was that of
Schneider and his so called "first rank symptoms". These symptoms included
hearing thoughts spoken aloud, hallucinations in the form of a commentary, thought
broadcasting, thought withdrawal or insertion and delusional perception. Such
symptoms when present in an individual were considered by Schneider to enable
the diagnosis of schizophrenia.
Modern operational diagnostic criteria such as the Diagnostic and Statistical Manual
of Mental Disorders (DSM MIR and recently the updated DSM IV, American
Psychiatric Association 1994), Research Diagnostic Criteria (RDC Spitzer 1978)
and International Classification (ICD 10, World Health Organisation 1992)) attempt
to classify schizophrenia and other mental and personality disorders based on a
narrower range of symptoms than those of Schneider and often also on the course
of disease. Such systems have been widely accepted throughout the world and
have provided a common language within psychiatry. These criteria have
superseded Schneiders first rank symptoms having been proved to be both reliable
and consistent, although still subjective, perhaps remaining so until more is known
about the aetiology of the disorder (Farmer et al 1994, Fogelson et al 1991).
Despite periodic revisions of these criteria with the aim of "improving" the
definitions, producing slight alterations in the diagnostic categories, there is some
indirect evidence relating to the genetic validity of these operational criteria from
McGuffin et al (1984).
1.2.3 Subtypes of schizophrenia
Kraeplin recognised three subtypes of schizophrenia based on his experience of
affected individuals - hebephrenic, catatonic and paranoid. A fourth type simple
schizophrenia was added later by Bleuler. The DSM IIIR recognises five subtypes of
schizophrenia (Gallant et al 1990):
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Catatonic Type - The essential feature of this subtype is psychomotor disturbance.
Diagnostic criteria for this subtype state that the clinical picture should be
predominated by any of the following; stupor, negativism, rigidity, excitement or
posturing.
Disorganised type - Marked loosening of associations, incoherence, grossly
disorganised behaviour and flat or inappropriate affect characterise this subtype. It
is associated with extreme social impairment and a chronic unremitting course.
Other classifications term this subtype as hebephrenic.
Paranoid type - Preoccupation with one or more systematised delusion or frequent
auditory hallucinations related to a single theme and lack of catatonic symptoms are
the basis of this subtype.
Undifferentiated type - This is defined as being a type of schizophrenia in which
there are prominent delusions, hallucinations, incoherence and disorganised
behaviour and where the criteria for catatonic, disorganised and paranoid subtypes
are not met.
Residual type - This is diagnosed by the absence of prominent delusions,
hallucinations, incoherence and grossly disorganised behaviour but where there is
continuing evidence of signs of the illness - emotional blunting, social withdrawal
eccentric behaviour and illogical thinking are commonly seen in this subtype.
The ICD 10 classification is very similar to that of DSM 111R adding one further
category, schizophrenic depression to these five (World health Organisation 1992).
It is generally accepted that the tendency for these subtypes to breed true is weak
and that many individuals may change subtype as their illness progresses (Kendell
1987).
An alternative subtyping strategy was proposed by Crow (1980). Crow states; "It
seems that two syndromes can be distinguished in those diseases currently
described as being schizophrenia and each may be associated with a particular
pathological process". Crow termed these two syndromes Type I and II, the former
being characterised largely by the positive symptoms of schizophrenia, such as
delusions, hallucinations and thought disorder. Crow relates these symptoms to an
alteration in dopaminergic transmission. The negative symptoms of schizophrenia
such as blunting effect, apathy, poverty of thought or speech and loosening of
association characterise the Type II syndrome which may be caused by structural
changes in the brain rather than being related to the dopamine pathway. Subtyping
in this way may allow appropriate therapeutic treatment in that Type II syndrome
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may not be reversible if structural changes in the brain have occurred and therefore
may be resistant to neuroleptic treatments (Crow 1980).
1.2.4 The Schizophrenia spectrum
It has long been recognised that the relatives of schizophrenic individuals showed
an excess of odd and eccentric behaviour although they are not diagnosed as
schizophrenic (Battaglia and Torgersen 1996). These individuals have been shown
by Kendler et al (1985) to have an increased rate of schizoaffective disorder,
paranoid personality disorder and the atypical psychoses but not unipolar disorder,
anxiety disorder or alcoholism. The concept of the schizophrenia spectrum
originated from the Danish adoption study by Kety et al (1988) who first designated
sub-syndromal disorders as being "borderline" or "latent" schizophrenia. The
proposed spectrum disorders include schizoaffective disorder, affective illness with
mood incongruent delusions, atypical psychosis, delusional disorder, various
personality disorders including schizotypal, schizoid, paranoid and borderline
personality (Prescott and Gottesman 1993). The spectrum concept implies a
continuum of liability for schizophrenia, those with less liability displaying a less
severe disease. There is some evidence from family twin and adoption studies that
schizotypal and paranoid personality disorders are genetically related to
schizophrenia (Baron et al 1985, Torgersen et al 1984 and 1993, Battaglia and
Torgersen 1996).
Kraeplin's dichotomy versus the continuum view point;
Kraeplin's notion that schizophrenia and affective disorder were aetiologicaliy
distinct diseases has been widely debated in the literature, being challenged by
many who believe that schizophrenia and affective disorder merely represent the
two extreme ends of a continuum of liability. The term affective disorder covers a
group of illnesses in which mood disturbances predominate. There are two main
forms of affective disorder, unipolar and bipolar affective disorder (sometimes called
manic depression), the latter suffering from episodes of mania as well as
depression. There are several methodologically superior family and twin studies
which indicate that schizophrenia and affective disorder have little shared liability,
with schizophrenia not aggregating in families of affectively ill probands and vice
versa (Baron and Gruen 1991, Kendler et al 1985, Kendler and Gruenberg 1984,
Baron et al 1985). However, there is also data which refute this, in particular the
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description of identical twins by Dalby et al (1986)^one which was diagnosed as
having mania and the other schizophrenia (there was no obvious environmental
evidence to support non-genetic psychosis). McGuffin et al (1982) similarly reported j
identical triplets two of which had been diagnosed as having schizophrenia and the
third with manic depression challenging the Kraeplin dichotomy. It is of course i
possible (though perhaps unlikely), as pointed out by Dalby et al, that genetic
liability to both conditions is present, with expression being moderated by
environmental or physiological factors.
In 1933 Kasanin introduced the term schizoaffective psychosis to describe a subset
of individuals who seemed to have symptoms of both affective disorder and
schizophrenia. The existence of such a disorder which seems to share common
attributes of both conditions has been taken by some as evidence for there being a
continuum extending from schizophrenia to affective disorder. Since schizoaffective
disorder was first described many studies have undertaken to elucidate the nature
of this condition and to establish it as a component of either affective disorder,
schizophrenia or as a separate heterogeneous group (Lapensee 1992), but none to
a satisfactory conclusion. Most studies of relatives of probands with schizoaffective
disorder have found an increased risk of both schizophrenia and affective disorders
as compared to normal control members (Prescott and Gottesman 1993).
Schizoaffective disorder has been subdivided in several studies into mainly
schizophrenic and mainly affective subtypes with some distinction to support this
division being found in family studies. However, the question as to whether
schizoaffective disorder represents a point on a continuum from affective disorder to
schizophrenia remains and can not be resolved conclusively until the aetiology of
the conditions are better understood.
1.2.5 Course and long term outcome of schizophrenia
Kraeplin's original classification of dementia praecox was one of chronic progressive
illness leading to severe disablement in cognitive and social functioning with few
individuals showing improvement at follow-up. Kraeplin did however acknowledge
that some patients recovered to near normality. One of the most consistent
observations of schizophrenic individuals has been the poor outcome compared to
individuals with other psychiatric disorders although the course of the disease is
highly variable across individuals. Some affected individuals will have one or several
episodes returning to near normality whereas others will endure unremitting
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deterioration or an intermediate course with gradually increasing disability. In-
between these two extremes lies a spectrum of possibilities with repeat acute
episodes and varying degrees of disablement (Wyatt et al 1988). Johnstone (1993)
reported that a mean of five admissions for relapse occurred in a group of 532
schizophrenia patients followed for 3-13 years after their initial index episode,
showing that in many cases schizophrenia is associated with recurrent or persistent
problems. It is however noted that not all patients fared badly and that the outcome
was variable. Some studies such as that of Harding et al (1987) in which patients
from Vermont State Hospital were followed up indicate a favourable outcome for a
significant proportion of patients. The patients, who had been ill for a mean of 16
years and hospitalised for a mean of 6 years, were followed up 32 years later and
68% were reported as having no signs or symptoms of schizophrenia. This study
has been criticised for bias in sample selection and it is suggested that this group of
individuals were not representative of schizophrenia in general. This study does still
imply a good prognosis for at least a subsection of affected individuals.
Hegarty et al (1994) did a meta-analysis of a large number of studies on outcome in
schizophrenia completed during 1895 to 1992 and reported that overall less than
half of patients diagnosed with schizophrenia show substantial clinical improvement
after approximately 6 years of follow-up. They also note that the proportion of
patients improving after the mid-century was significantly increased, probably
reflecting improved treatments, alteration of diagnostic categorisation and selection
bias related to changes in health care. All these factors plus the variable definition
of what constitutes a good outcome conspire to make interpretation of data
produced on long term outcome of schizophrenia difficult. Such factors must be
borne in mind when comparing studies on the outcome of schizophrenia.
Many studies have been done to elucidate which factors influence the course of
schizophrenia. One of the most important factors seems to be the level of social
competence prior to the onset of illness. Social competence includes such things as
getting a job and marriage. Poor premorbid functioning seems to predict a poor
outcome (Stoffelmayr 1983). There is some indication that the speed of onset may
be a prognostic factor, with insidious onset being related to poorer long term
outcome.
A World Health Organisation 2 year follow-up study which looked at determinants of
outcome of severe mental disorders (Sartorius et al 1986) reported that the
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outcome of schizophrenia differed in developing and developed countries with those
in the former faring better. This was confirmed in a later 5 year follow-up study of
the same cohort (Leff et al 1992). This study also found that a number of other
factors, as well as those mentioned above, were predictive of outcome (clinical or
social) such as the occurrence of a life event before onset, the acuteness of onset
of symptoms and initial social isolation.
There is also evidence that the chance of relapse can be affected by the emotional
environment provided by the family of the afflicted individual. High levels of criticism,
over involvement or any degree of hostility towards the affected individual constitute
so called expressed emotions (Leff 1992). Frequent contact with relatives who
display high expressed emotions increases the chances of relapse whereas contact
with relatives who have low expressed emotions seems to be protective
(Bebbington et al 1994).
1.3 Epidemiology
1.3.1 Incidence
Schizophrenia is found in all countries, societies and cultures and is associated with
a life time risk of approximately 1% (dependent on diagnostic criteria)(Hare et al
1987).
In 1986 the World Health Organisations (WHO) completed a study of the incidence
of schizophrenia in 10 countries diagnosing schizophrenia based on Present State
Examination (PSE) and ICD 9 diagnostic criteria (Sartorius et al 1986). They
reported remarkable stability of incidence rates across widely varying geographical
areas, providing strong support for the notion that schizophrenia occurs with
comparable frequency world wide. It must be noted however that this incidence rate
may include acute and reactive substance induced psychoses as the ICD 9 and
PSE do not accommodate for duration of illness unlike DSM 111R which requires six
months duration of illness prior to diagnosis.
There is some evidence for pockets of high incidence of schizophrenia such as in
Sweden, Ireland and Yugoslavia (Wyatt et al 1988, Eaton 1991). The reasons for
this increase is unclear but may be a reflection of differences in methodology and
diagnostic practices.
The stability of incidence rates for schizophrenia across varying countries and
cultures makes it an unusual disorder in that variation of disease rates are
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commonly seen in epidemiology and often provide clues as to the aetiology of the
disorder.
Several lines of evidence suggest that schizophrenia is decreasing in incidence in
western countries in recent years. Historical fluctuations in demographic profiles,
diagnostic practices and criteria for hospital admissions, make it difficult to resolve
this issue (Harrison and Mason 1993, Kendell et al 1993, Stromgren 1987, Eaton
1991). It does appear that there has been a relative decrease in the number of
severe cases of schizophrenia seen, with the hebephrenic and catatonic subtypes
being rare now (Harrison and Mason 1993, Eaton et al 1991). This is likely to be as
a result of better treatment strategies and the availability of antipsychotic drugs.
1.3.2 Age of onset
Schizophrenia is predominantly a disease of early adult life with average onset in
the second to fourth decades. The difference in the peak age of onset between
males and females has been widely reported and seems to hold true despite the
use of various methodologies (Faraone et al 1994). Males have a peak age of onset
occurring between 18-25 years whereas females have a broader peak of onset at
between 26-45 years (Stomgren 1987). Other studies have confirmed this
difference between male and female age of onset (Gorwood et al 1995). It has also
been shown that the gender difference in age of onset is present across cultures
implying a biological rather than a social aetiology (Beratis et al 1994). There has
been much speculation as to what this might be and as to whether there is a female
specific protective factor causing the difference in age of onset. There is some
evidence to suggest that this factor may be oestradiol and that this may enhance
the vulnerability threshold for schizophrenia resulting in a later age of onset in
females than in males (Riecher Rossler et al 1994).
The age of onset rather than the time of onset appears to be correlated in siblings
lending support to the notion that environmental factors contribute little to this
phenomenon (DeLisi 1992).
1.3.3 Seasonal variation in birth rate
Many independent studies have shown that there is an excess (10-20%) of winter
and spring births in individuals who go on to develop schizophrenia in comparison to
the normal population (Bradbury and Miller 1985). Several explanations of this
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phenomenon have been offered including (Pulver et al 1992, Pallast et al 1994,
Wyatt et al 1988);
• Seasonally varying factor (such as viral infection) occurs during intra-uterine or
post-partum period causing developmental abnormality which affects vulnerable
individuals and causes schizophrenia in later life. A neurodevelopmental
hypothesis for the aetiology of schizophrenia has been widely postulated and will
be discussed in later sections.
• Individuals who are vulnerable to schizophrenia because of genetic
predisposition have a biological advantage which is protective against seasonal
factors which may otherwise cause mortality.
Dassa et al (1996) report that the seasonal effect is more pronounced in females
than males and that it is seen primarily in non familial cases of schizophrenia
supporting the hypothesis of an environmental hazard. No consistent seasonality
effect was reported for any particular schizophrenia subtype but winter births have
been reported to be associated with later onset schizophrenia (Dassa et al 1996).
1.3.4 Gender differences
As mentioned previously, women as a group seem to have a later age of onset of
schizophrenia than men. This is not the only factor in which there seems to be a
gender difference. Females may also have a better outcome than men (Wyatt et al
1988) and appear to respond better to treatment as a general group compared to
males (Waddington et al 1993).
Pre-menstrual exacerbation of schizophrenia symptoms have been noted by
clinicians as well as increased difficulties in the post-partum and menopausal
period. It has also been noted that females fare better during pregnancy, leading to
the suggestion that oestrogen may act as a natural neuroleptic.
There may be a neurodevelopmental sex difference with delayed cerebral
development in males making them more prone to neurodevelopmental disorders.
Obstetric complications are more likely to be seen during the birth of males than
females who later develop schizophrenia, although the reason for this remains
obscure (Castle and Murray 1991). There has been some suggestion that such
obstetric complications may result in an earlier onset and more severe form of
schizophrenia although the evidence for this is weak and refuted by several studies
(Smith et al 1995). Male schizophrenics have been reported to have lower IQ and
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worse premorbid functioning than females who seem to have shorter stays in
hospital and a more affective component to their condition than men.
1.3.5 Reproductive fitness
It has been reported that individuals suffering from schizophrenia have a lower
fertility rate than that of the general population (Ritsner et al 1992, Haverkamp et al
1982). Some of this effect may be secondary, related to the decreased marriage of
afflicted individuals, due to stresses put on relationships as a result of the disorder.
The consistent finding that the prevalence of schizophrenia remains stable despite
this reduced fertility is puzzling. Several explanations have been offered;
• Carter and Watts (1971) reported increased fertility rates among the relatives of
schizophrenics compared to controls and this was also the finding of Erlenmeyer-
Kimling and Paradowski in 1966 when they compared the sisters of
schizophrenics with women in the general population. The persistence of
schizophrenia across generations may indicate that a selective advantage is
bestowed on the relatives (possibly genetic carriers) of schizophrenic individuals,
the so called "heterozygote effect". Such an affect is displayed by heterozygotes
carrying the sickle cell anaemia mutation which is protective against malaria.
There are also reports of schizophrenics being less afflicted by certain conditions
such as Rheumatoid arthritis, certain cancers and allergies for example (Knight
et al 1992, Carter and Watts 1971). Relatively few studies have been done on
such a selective advantage being present and studies on individuals with
schizophrenia spectrum conditions which may be associated with gene carrier
status are required.
• It has been proposed that schizophrenia may be associated with a high rate of
mutation which compensates for the reduced fertility (Ritsner et al 1992).
However, schizophrenia occurs at a higher frequency than can realistically be
explained by rates of genetic mutation in humans (Wyatt et al 1988). Anticipation
is the phenomenon of worsening prognosis and/or decreased age of onset in
subsequent generations in a family and has been described in several
neurological disorders including schizophrenia (see section 1.9.3). Unstable
trinucleotide repeats have been demonstrated as underlying several conditions
displaying anticipation and such an unstable mutation could provide a plausible
mechanism for a high mutation rate in schizophrenia (Bassett et al 1996).
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• It is likely that schizophrenia is not a single genetic entity but a heterogeneous
collection of genotypes. It may be possible that if several genes are involved that
the mutation rate within the normal range could, by occurring at several loci,
maintain the observed high prevalence of schizophrenia (Carter and Watts
1971).
There is some evidence of there being a sex difference in reproductive fitness in
schizophrenia with fitness being lower in males than females (Bassett et al 1996).
Imprinting may be important in psychiatric conditions although to date it has not
been demonstrated in schizophrenia.
Imprinting occurs when there is differential expression of genes depending on
parental origin. An example of genomic imprinting occurs in Prader-Willi and
Angelman syndromes where both result from microdeletions of the long arm of
chromosome 15 but if these deletions are paternally derived Prader-Willi syndrome
is manifested where as if maternally derived Angelman syndrome results. It is
possible that sex difference in reproductive fitness may obscure imprinting effects
(Bassett et al 1996).
1.4 Premorbid indicators of schizophrenia
Schizophrenia has been linked with childhood psychological abnormalities, an
excess of minor physical abnormalities and various brain morphologies. It may be
possible that individuals who later become afflicted with schizophrenia develop
abnormalities of various kinds in childhood which allow them to be differentiated as
high risk individuals for schizophrenia.
Done et al (1994) and Jones (1994) observed that individuals destined to become
schizophrenic may have a number of childhood abnormalities of personality and
intellect. Done et al (1994) investigated social adjustment in childhood of individuals
who later became afflicted with schizophrenia, in a prospective follow up study
based on ratings of social behaviour given by their teachers at the ages of 7 and 11
years. Ratings obtained from individuals followed up in the national child
development study who later went on to develop schizophrenia were compared to
those obtained from controls from the same cohort. The results indicated that
abnormalities of social adjustment were detectable in some individuals who develop
schizophrenia in later life (p<0.01). Done also reported gender differences in the
abnormal social behaviour seen, with girls appearing more withdrawn by the age of
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11 years, whereas boys tended to be more hostile and anxious for acceptance than
peers of this age.
Jones and colleagues (1994) studied sociodemographic, neurodevelopmental,
cognitive and behavioural factors in individuals who later developed schizophrenia,
in a British 1946 birth cohort. They found that those individuals who later developed
schizophrenia had delayed attainment of speech and problems with speech until
early adulthood, they reached motor milestones at a later age than normal, were
more socially withdrawn and anxious in adolescence with poorer educational
achievement in both childhood and adolescence. This, the authors suggest,
indicates that as with some other adult onset disorders the origins of schizophrenia
may be found in early life, but they do not exclude a dynamic process over a long
period of time.
There have been attempts to associate premorbid childhood behavioural
characteristics with abnormalities in brain morphology (Walker et al 1996). Walker
et al (1996) claim mild associations with structural brain abnormalities are apparent
in children with behavioural problems who later develop schizophrenia. Neurological
deviation in new boms at psychiatric risk has been shown by Blennow and McNeil
(1991).
1.5 Markers of schizophrenia
Several psychophysiological traits associated with schizophrenia have been
proposed as genetic markers for vulnerability to schizophrenia;
Eye Tracking:
Smooth pursuit eye tracking dysfunction has been reported to be present in 51% to
81% of schizophrenia individuals as opposed to 8% of the normal population
(Blackwood et al 1991). Normally as an individual follows an object across a visual
field a smooth pursuit eye movement system maintains the image at the centre of
the retina. Several eye movement systems can be distinguished; smooth pursuit
which is comparatively slow, the rapid eye system or saccadic and the vergence
system. All three are implicated in the following of a moving target. On following a
moving target the smooth pursuit system is initiated but is delayed causing the eye
to lag behind the movement. Saccadic eye movements serve to fix the fovea again
on the target. When the smooth pursuit system is turned on the saccadic system
should be switched off but in a large number of schizophrenics and their relatives
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this is not the case causing a high prevalence of both saccadic intrusion and
tracking. Impaired eye tracking can be reliably measured using a number of devices
and the abnormalities seem to be unaffected by neuroleptic drugs or clinical state
and have been shown to be highly heritable and although not specific to
schizophrenia seems to be found with a higher incidence than other psychiatric
conditions (Blackwood et al 1991, Holzman 1992, Keefe et al 1991). It has been
reported that heavy smoking among schizophrenics can normalise smooth pursuit
eye movement (see section 1.10).
Event related potentials;
Event related potentials refer to the broad spectrum of brain electrical activity which
occurs on sensory, motor or cognitive stimulation and can be measured using an
electroencephalographic wave signal. The most pronounced changes reported have
been in P300 wave (so called as it represents a positive polarity wave occurring at
300ms after stimulation) amplitude, which is reduced, and P300 wave latency,
which is delayed, after exposure to unexpected auditory or visual stimulation
(Holzman 1992, Blackwood et al 1991). Family and twin studies have confirmed the
heritability of this response (Holzman 1992).
P50 event related potential response
In this test two stimuli are given, the first a "conditioning stimulus" and a second the
"test stimulus" (usually auditory). The response to the second stimulus is normally
smaller in magnitude to that of the conditioning stimulus. In schizophrenics and their
relatives this response is not seen and the response to the second stimulus is
similar to that of the first (Holzman et al 1992, Freedman et al 1997). Smoking has
been shown to cause a deficit in the inhibition of the P50-evoked response to
repeated auditory stimuli in schizophrenic individuals (see section 1.10).
Continuous Performance Test
Continuous performance testing refers to a group of visual vigilance tasks in which
a continuous series of stimuli, presented briefly and in close succession, are
monitored. The subject is required to respond when a pre-designated target
stimulus or sequence appears. Schizophrenic individuals appear to make
significantly more errors (failure to respond to target or inappropriate response) and
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also have a slower response time than control subjects. This poor scoring is also
seen in the offspring and siblings of schizophrenic individuals.
Cognitive deficit markers such as those described above may have a role in
improving phenotypic definition and clarifying the boundaries of schizophrenia
spectrum disorders as well as identifying gene carriers for linkage analysis and
other genetic studies. However, more studies are needed before they can fulfil such
roles.
1.6 Neuropathology
Structural abnormalities in the brains of schizophrenics were described as early as
1927 using Pneumoencephalograms and have been described intermittently ever
since.
Various brain imaging techniques have become available in the last decade which
have allowed in vivo brain structure and function to be investigated in patients with
schizophrenia and normal controls. Computerized Tomography (CT) and magnetic
resonance imaging (MRI) have been used widely to study brain structure, the latter
being able to produce three dimensional reconstruction of the brain and excellent
grey/white matter resolution. Single Photon Emission Computed Tomography
(SPECT) and Positron Emission tomography (PET) have been used to assess
functional activity of the brain. Such techniques have improved our knowledge of
the pathophysiology of mental illness by demonstrating structural and
neurochemical abnormalities in a wide range of mental disorders (Andreasen 1988).
The most consistently reproduced structural brain abnormality seen in
schizophrenia is that of ventricular enlargement (Johnstone et al 1976). The
ventricles are fluid filled cavities in the brain and their enlargement is assumed to
accompany a decrease in neuronal tissue and thus would be expected to indicate a
compromise in brain function (Gershon and Rieder 1992). Only 6-40% of
schizophrenics show ventricular enlargement (Syvalahti et al 1994) and it is neither
specific or consistent with overlap occurring between affected and normal control
groups (Suddath et al 1990). Since ventricular volume increases with age it is
important that the control group is closely age matched to the affected group
(Cleghorn et al 1991). Increased ventricular size appears to be present before the
onset of psychosis and is non progressive in nature - as determined by several
studies on affected individuals at various stages of illness, raising the possibility that
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cerebral abnormalities occur early in development (Heyman et al 1992). The
hypothesis that schizophrenia is a neurodevelopmental disorder has been put
forward by several groups and has some evidence to support it. This will be further
discussed in section 1.10.
Suddath et al (1990) studied monozygotic twins discordant for schizophrenia and
found that enlarged ventricles and reduced hippocampi were consistent
neuropathological features of schizophrenia. Since monozygotic twins share
identical genes many have postulated the underlying neuropathological process can
not be wholly genetic. Two points are worth noting here. Firstly, although
monozygotic twins share identical genes they may not share identical environments
either pre- or post-natally which may result in developmental differences (Gilmore et
al 1996). Effects of pre-natal environment has been shown to be of greater
importance than previously though in a recent study on the heritability of IQ (Devlin
et al 1997). This study showed that prenatal environment could account for as much
as 20% of covariance in IQ heritability between twins and 5% between sibling.
Studies have shown that the offspring of the unaffected twin still have a higher than
normal risk of developing schizophrenia raising the possibility that a responsible
gene may not be expressed in certain individuals (reduced penetrance) and that
these individuals may act as gene carriers.
Other abnormalities of brain structure reported in schizophrenia include decreased
volume of temporal lobe structures such as the medial temporal lobe structures
hippocampus, parahippocampus and amygdala (Waddington et al 1993, Murray et
al 1992, Falkai et al 1988, Cernansky 1991).
Postmortem studies have indicated that brain weight and length are reduced in
schizophrenic individuals compared to controls.
Cellular changes which have been reported include decreased tissue quantity (grey
matter) and disorganisation of pyramidal and other neuronal cells in the
hippocampus and other limbic circuit structures. The hippocampus develops from
the ventricular zone exclusively and is half its adult volume at birth and adult size at
approximately two years. The smaller volume and decreased disorganised cell
structure are compatible with a developmental abnormality in schizophrenia (see
section 1.10).
Jakob and Beckmann (1986) reported that pre-alpha neurones were displaced from
their normal position in the upper layers of the entorhinal cortex to the
parahippocampal gyrus, suggesting a disturbance of neuronal migration. A large
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proportion of neuronal cells usually die in the developing nervous system, a process
which seems to eliminate early errors of connection. This process of neuronal
pruning has been suggested to be faulty in schizophrenia resulting in the
persistence of immature patterns and connections of these cells (Murray et al
1992).
It has been suggested that some structural brain abnormalities may be more
profound in the left hemisphere than the right hemisphere (Bracha 1991, Jakob and
Beckmann 1986, Crow 1990). These include ventricular enlargement, temporal lobe
size reduction and tissue loss. These changes are often subtle. During normal
development the left hemisphere lags behind the right hemisphere until the third
trimester when the two become equal. If an insult occurs during the "lag" period it is
possible that the less developed left hemisphere may be affected to a greater extent
than the right.
Several groups have shown gliotic changes, which would be expected to be found
in association with cellular abnormalities caused by damage to the central nervous
system, are absent in the brains of schizophrenics. The absence of this response
seems to suggest a developmental rather than a degenerative process (Murray et al
1992).
Functional changes
SPECT (Single Photon Emission Computed Tomography) has been used to
examine the brain at work. Decreased cerebral blood flow in the brains of some
schizophrenics has been reported by Ingvar and Franzen (1974). This is known as
"hypofrontality". More recently Weinberger's (1987) group used SPECT to look at
cerebral blood flow in subjects who were taking the Wisconsin card sort test which
is a test of working memory and abstract thinking. In normal subjects this test elicits
an increased blood flow in the frontal cortex. In schizophrenics less of an increase
in cerebral blood flow is seen and they do less well in the test than normal controls.
By identifying various tasks which produce specific patterns of activation in the
brains of normal individuals, such as the Wisconsin card sort test, it should be
possible to look at specific brain regions which are defective in schizophrenic
individuals. Many of these studies have been criticised on the basis of sample




Aberrant neurochemistry has long been suspected as having a pathological role in
the aetiology of schizophrenia and has lead to a plethora of studies investigating
neurotransmitters and their biochemical pathways. Although no neurotransmitter
has been directly causally related to the pathology to date many transmitters such a
dopamine and serotonin continue to be studied. Further discussion of
neurotransmitters can be found in section 1.11.
1.8 Treatment
Antipsychotic drug treatments
Neuroleptic (antipsychotic) drugs were introduced to psychiatric practise in the
1950's and undoubtedly improved the short term prognosis for schizophrenia,
apparently altering the course of the disease and preventing further deterioration
and relapses.
The neuroleptics are a diverse family of compounds which are all effective in
treating some of the symptoms of schizophrenia. They appear to most successful in
treating the positive symptoms of schizophrenia, such as delusions and
hallucinations although they (in particular the atypical neuroleptic Clozapine) may
have some benefit in the management of a subgroup of negative symptoms.
30% of patients taking neuroleptic drugs show only a limited improvement in acute
treatment trials but 7% do not respond even to lengthy treatment. Long term
maintenance therapy seems to prevent relapses in the majority of patients but 40%
will have a psychotic relapse within one year in comparison to two thirds who are
not drug maintained (Johnstone 1993).
Many patients experience side effects whilst taking neuroleptics in both long and
short term treatment strategies. Side effects include weight gain, lethargy,
anticholinergic side effects and in some cases symptoms resembling those seen in
Parkinsons disease such as akathisia (motor restlessness) and dystonia (muscle
spasm). Parkinsonian like symptoms persist in 20-40% of patients receiving
neuroleptic treatment and is a primary reason for non compliance. Tardive
dyskinesia (abnormal involuntary movements) are also experienced by a subgroup
of patients on long term treatment and there has been a suggestion that this is
related to chronic schizophrenia in which there is there has been structural changes




Electroconvulsive therapy was first used in the 1930's to treat schizophrenia. It
consists of passing an electric current through the brain of a patient in order to
produce a convulsion. Control trials conducted by Taylor and Fleminger (1980)
showed ECT to be useful in treating schizophrenic patients in conjunction with drug
therapies but the effect was short lived, disappearing after 12 weeks.
ECT treatment is now largely confined to treating severe cases of depression in
which it appears to have a more beneficial effect.
Non-physical treatments
Non-physical treatments based on psychological principals are advantageous to a
small group of patients suffering from schizophrenia. Social and psychological
treatments for schizophrenia have been described which aim to both restore the
patient to normal social functioning and to remove any precipitators of relapses.
Stress is a well known precipitator of schizophrenia episodes. Major life events
which cause an individual to have to adapt psychologically can also trigger relapses
of schizophrenia. The home emotional environment has been shown to be of
importance in relapse and as mentioned earlier, high expressed emotions of
relatives is undesirable (Bebbington and Kuipers 1994, Left 1992, Spring 1981).
Interventions capable of modifying the behaviour of family members have proved to
be successful in reducing relapses. Psychotherapy of various types has been used
to improve the coping skills of afflicted individuals to improve stress management
(Cullberg 1991).
A combination of these treatments, both antipsychotic drug and psychotherapy,
have proved to date to be the most effective way of treating schizophrenia.
1.9 Aetiology
1.9.1 Genetic Aetiology:
Family, twin and adoption studies have provided strong evidence for there being a
genetic component involved in the aetiology of schizophrenia.
Family studies
If schizophrenia aggregates in families it would be expected that the relatives of
affected individuals would manifest a higher incidence of the disease and its
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associated disorders than that seen in the general population. The risk should also
increase as the number of shared genes increases therefore first degree relatives
should be at greater risk than more extended generations (e.g. grandchildren)
(Tsuang et al 1991).
The majority of family studies done in schizophrenia have shown this relationship to
be true. The exceptions, Pope et al (1982) and Abrams and Taylor (1983) which
found similar rates of schizophrenia among family members of affected individuals,
have been strongly criticised by various authors on methodological grounds.
Although the figures from individual studies vary, depending on particular
methodology and diagnostic criteria used, generally the life time risk of
schizophrenia in the close relatives of schizophrenic individuals is significantly
higher than the general population rate of approximately 1%.
Tsuang et al (1991) assessed the risk of schizophrenia in first degree relatives of
schizophrenics to exceed that of the general population by 5-10 times. Prescott and
Gottesman (1993) estimates the figure to be 3-4 times and a similar figure is offered
by McGue et al (1989).
Several authors have combined data from several family studies to provide
consensus average figures for familial risk. The following table is an adaptation of
that produced by Gottesman 1991 based on European studies done between 1920
and 1987;
TABLE 1.1: Average Risks for developing schizophrenia amongst relatives of
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There would seem to be little doubt that schizophrenia manifests as a familial
disorder but family data alone are inadequate to infer genetic causality as they do
not distinguish between genetic and environmental influences.
It is evident that the risks of developing schizophrenia seen in family members do
not conform to those implied by classic Mendelian inheritance in which first degree
relatives would be expected to have 50% genetic risk and second degree relatives a
25% risk. This implies that a complex genetic and/or environmental pattern of
transmission is occurring. Twin and adoption studies have proved useful in
determining the extent of genetic versus environmental influence involved.
Twin studies
Monozygotic twins share 100% of their genes whereas dizygotic twins share on
average half of their genes. If the assumption that monozygotic and dizygotic twin
pairs share a common environment is made, then any difference in resemblance of
schizophrenia pathology between the types of twins is attributable to their difference
in genetic similarity. Although the principal is simple, carrying out twin studies in
schizophrenia is complicated by the relatively low numbers of twins available, both
affected and normal, difficulties in phenotype definition and errors in determining
zygosity. Despite these complications a number of well designed twin studies have
been done.
A twin pair is termed concordant if both members of the pair are affected and
discordant if only one member of the pair is affected. The concordance rate is the
probability that a co-twin is affected given that his or her co-twin is affected (La
Buda at al 1993).
Concordance rates vary widely according to methodology and diagnostic criteria
used to determine them but generally despite many different methodologies and
diagnostic criteria all showed at least a two fold increase in concordance between
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monozygotic twins as compared to dizygotic twins. Among the best methodological
studies are the Scandinavian twin studies done by Tienari (1963), Kringlen (1967)
and Fischer (1969) based on accurate and well kept national twin and health
records. Concordance rates reported in these studies were as follows;
Table 1.2; Twin concordance rates reported by three Scandinavian studies.
Monozygotic Dizygotic
Tienari (1963) 15% 7%
Kringlen (1967) 31% 8%
Fischer (1969) 24% 10%
In general the reported concordance rates lie between 35-58% for monozygotic
twins and 4-27% for dizygotic twins (Prescott et al 1993, Tsuang et al 1991,
Kringlen et al 1993, Carter and Watts 1971). Prescott et al (1993) proposed a
median concordance rate based on the results of several studies which had similar
methodology, of 48% for monozygotic twins and 15% for dizygotic twins.
It is important to note that no concordance rates of 100% have been reported
implying that although there is undoubtedly a substantial genetic component
involved there may also be a non genetic factor which may also be important in at
least some forms of schizophrenia. Alternatively, reduced penetrance of the genetic
component in the unaffected twin may offer a plausible explanation for the reduced
concordance rates. Fischer et al (1971) reported that the offspring of the unaffected
twin of a discordant monozygotic pair had the same risk of schizophrenia as the
offspring of the affected twin which may imply that the unaffected twin is carrying
genetic liability to schizophrenia allowing it to be passed onto the offspring but it for
some reason is not being expressed (incomplete penetrance). Subtle differences in
environment may explain this.
Taken together the twin studies, despite their methodological differences, suggest a




Adoption studies effectively allow separation of the genetic and environmental
components involved in disease since close biological relatives do not share the
same postnatal environment (assuming they have been adopted away to non
related individuals very early in life). There are several adoption study designs. The
prevalence rates of schizophrenia among adoptees born to schizophrenic parents
can be compared to those of non schizophrenic parents. One of the earliest studies
of this type was that of Heston et al in 1966 which compared a group of adults born
to schizophrenic mothers and who were separated two weeks after birth to a control
group from non schizophrenic parents (adoptees study). Schizophrenia was
diagnosed in 5 of the 47 individuals born to schizophrenic mothers compared to
none in the control group of 50 individuals. In addition, 50% of the group born to
schizophrenic mothers had some sort of psychosocial disability as adults.
Similar results were reported by Kety et al (1971 and 1978) and more recently by
Tienari et al (1994) who both compared prevalence of schizophrenia in the adopted
and biological relatives of schizophrenic offspring given up for adoption (the
adoptees relatives study) and reported an excess of schizophrenia among the
biological relatives and not the adopted relatives and non biological control group.
Kety's study in 1978 also included parental half siblings of the adopted
schizophrenic individuals. Half siblings share approximately 25% of there genes and
since these siblings were paternal (i.e. related by a common father) they do not
share common prenatal, perinatal or neonatal environments. The finding that these
individuals have a higher risk of developing both schizophrenia and related
disorders strongly indicates genetic factor in the transmission of schizophrenia.
Adoption studies which have looked at normal children adopted to schizophrenia
parents have done much to dispel the belief that schizophrenic like behaviour can
be "learned" - so called "vertical cross transmission". Such children show no higher
risk of developing schizophrenia than the general population (Tsuang et al 1991).
These results are consistent with shared genes rather than shared environment
underlying the increased risk of schizophrenia and associated disorders in the
relatives of schizophrenic subjects. Although each of these methods, family, twin
and adoption, can be individually criticised in terms of there methodology, together
they provide strong accumulative evidence to support the importance of genetic
influences on the vulnerability to develop schizophrenia.
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1.9.2 Mode of genetic transmission
Having established the importance of the genetic contribution in the causation of
schizophrenia researchers have attempted to determine how the schizophrenia
gene(s) are transmitted from generation to generation. There is no general
agreement on the mode of genetic transmission of schizophrenia and virtually every
genetic mechanism has been proposed at one time or another to explain the pattern
of inheritance. The classical Mendelian model of inheritance does not adequately
explain the genetic transmission seen in schizophrenia. If schizophrenia were
caused by a fully penetrant dominant gene it would be expected that 50% of
offspring with one schizophrenic parent would become schizophrenic. The observed
value is much lower (-16%). If schizophrenia were caused by a fully penetrant
recessive gene it would be expected that 100% of children with two schizophrenia
parents would be schizophrenic, again this value is far lower (-46%). Therefore it is
apparent that more complex models are needed to describe the mode of genetic
transmission in schizophrenia.
Three major models have been proposed;
I. Single Major Locus Model:
In its simplest form this model proposes that a single gene with complete
penetrance is responsible for the transmission of schizophrenia. A major problem
with this model is the explanation of the non Mendelian distribution of the disorder
as based on family and twin studies. This can be overcome by assuming reduced
penetrance (gene carriers may noi necessariiy manifest the iiiness) and aiiowing for
the existence of phenocopies (affected individuals need not have the disorder-
associated allele and may be environmentally induced). In more complex models
the addition of an environmentally related liability in the form of a threshold
construct is introduced. In the single major locus threshold model all individuals are
assumed to have a liability or predisposition to developing schizophrenia which is
determined by their genotype as well as environmental factors. If liability exceeds
the threshold level then the individual will become schizophrenic and if not they will
not develop schizophrenia.
There is generally little support for a single major locus model in the literature and
several studies have shown this model to be incompatible with the overall rates of
schizophrenia found in family and twin studies (O'Rourke et al 1982). Many studies
which provide statistical tests for model adequacy reject this model (Faraone 1985,
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McGue 1989 Tsuang 1991). It also seems unlikely that a collection of single gene
disorders can explain the genetic liability to schizophrenia. However, the rejection of
any genetic model may merely indicate that some of the non genetic assumptions of
the model are incorrect. For this reason many feel that such a model can not be
ruled out entirely (Faraone 1985).
II. Polygenic Models;
Polygenic models assume that genes found at more than one locus are responsible
for the familial pattern of schizophrenia. The polygenic model can be further sub¬
divided into Limited Loci Polygenic (LLP) and Multi Factorial Polygenic (MFP);
a. Limited Loci Polygenic model (LLP)
This model assumes that two or three loci are responsible for the genetic
transmission of schizophrenia. The application of quantitative techniques to genetic
models involving several genes segregating at several loci is hindered by the fact
that there are hundreds of possible loci models. Consequently modelling is done on
the basis of the biological significance of the model or on hypotheses formulated
about schizophrenia.
b. Multi Factorial Polygenic Model (MFP)
This model assumes that all individuals have a liability or predisposition to
developing schizophrenia. If this liability exceeds the threshold level then they will
develop schizophrenia. The model assumes the liability is composed of genetic and
environmental components each of which have small but additive effects. This
model differs from LLP model as it does not specify the number of loci involved,
instead it assumes there are many interchangeable loci. Many investigators favour
this model as it appears to account for several findings in family studies of
schizophrenia not explained adequately by other models, such as the varying
degrees of severity and the familial risk seen in schizophrenia. Twin studies are
most consistent with this model. One of the draw backs of this model however is its
inability to differentiate the relative contributions of genetic and environmental
elements. This problem is being tackled at least in part by "path analytical" MFP




Mixed models assume that a gene or genes of major effect act on a multifactorial
background, with or without environmental effects. Very few of these studies have
been done and the results are equivocal.
1.9.3 Anticipation and schizophrenia
The term anticipation is used to describe the increase in disease severity or
decrease in age of onset in succeeding generations within families. Anticipation has
been related to the expansion of trinucleotide repeats which cause at least ten
inherited neurodegenerative/neuromuscular illnesses in humans including
Huntington's disease, Fragile X syndrome and myotonic dystrophy. The
phenomenon of anticipation has been reported in schizophrenia (Gorwood et al
1996) which has lead several groups to investigate the possibility of unstable
trinucleotide repeats being aetiologically responsible for schizophrenia. The results
from such studies are conflicting with Morris et al (1995), and O'Donovan (1995)
reporting evidence for a modest excess of CAG repeat expansions in the genome
of schizophrenia compared to controls as assessed by the Repeat Expansion
Detection (RED) technique. The RED method utilises the ligase chain reaction.
During a repetitive cycling reaction total genomic DNA serves as a template for the
thermostable ligase to generate oligonucleotide multimers which represent
expanded repeats. These can be separated on a polyacrylamide gel and visualised.
When observed the CAG expansion was most marked in females, but others have
reported no such expansion (Vincent et al 1996, Petronis et al 1996).
Family and twin data has been re-evaluated in the light of the discovery of unstable
triplet repeats and Petronis and Kennedy (1995) concluded that such a mechanism
competes well with the traditional multifactorial polygenic theory of schizophrenia
with many deviations from Mendelian inheritance being explained by unstable DNA.
Such a paradigm also may provide an explanation for several unclear issues in
schizophrenia genetics such as discordance in monozygotic twins and the identical
risk to discordant twin offspring of developing schizophrenia. Also the age of onset
and perhaps even the phenotypic variation may be explained in terms of variation in
the number of expanded repeats. In Huntington's disease the size of the expansion
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of the CAG repeats appears to correlate to the age of onset which is decreased with
increasing number of triplet repeats.
The hypothesis of triplet repeat expansions being involved in the aetiology of
schizophrenia is particularly appealing for several reasons as they have been shown
to be involved in the pathogenesis of several neurodegenerative diseases such as
Huntington's disease in which there is selective neuropathology. The mechanism by
which triplet repeat expansion causes such a selective neuropathology and whether
the expansion is causative or a byproduct of the mechanism is unknown at this time
but the elucidation of this mechanism will enhance our knowledge as to how such
disease processes are selective and do not develop until later in life.
1.10 Environmental Aetiology:
Although there is strong evidence for a genetic component in schizophrenia,
environmental factors, both biological and psychosocial, are likely to play an
essential role in at least some cases of schizophrenia.
Several studies have implicated environmental factors in the aetiology of
schizophrenia. Some of these environmental factors may act in concert with an
underlying predisposition to schizophrenia and some may act alone to cause
schizophrenia.
The small but significant seasonal birth effect, where schizophrenics are more likely
to be born in the winter and spring, (see section 1.3.3) has lead many to postulate
that some seasonally varying environmental factor which damages the developing
foetus is responsible for at least some cases of schizophrenia, infectious agents,
environmental toxins and nutritional status are among the candidates proposed to
explain this effect. Currently, infectious agents are most favoured since many
display seasonal effects such as respiratory viral infections which are more
prominent in the winter months. Viral infections, particularly the influenza virus, have
been studied widely on the basis that infection at critical stages in gestation may
have a detrimental neurodevelopmental effect which predisposes to schizophrenia
in later life.
Mednick et al (1988) examined the effect of the epidemic of A2 influenza virus
which affected Helsinki in 1957 and reported that those exposed to the epidemic
during the second trimester of gestation were at elevated risk of developing
schizophrenia. Studies by Kendell and Kemp (1989) failed to replicate this finding in
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their Scottish sample but other studies such as that of O'Callaghan (1991) have
replicated the finding in different populations.
Structural brain abnormalities such as ventricular enlargement, reduction in
hippocampal volume, neuronal disorder and lack of gliosis have lead many to
believe that schizophrenia is of neurodevelopmental origin. A viral insult in the
second trimester of gestation which causes some developmental abnormality, is
consistent with a neurodevelopmental hypothesis.
It is possible that an autoimmune response to infection could be responsible for
schizophrenia (Knight et al 1992). It has been suggested that mothers who produce
the optimal immune response to a viral infection such as the influenza virus may
cause an autoimmune reaction in the foetus without causing any overt symptoms of
influenza in the mother. Several studies have indirect evidence for infection in
schizophrenia by demonstrating increased levels of immunoglobulins and
cytomegalovirus antibody titre in the cerebrospinal fluid of schizophrenics (Wright et
al 1993). In animals it has been demonstrated that antibodies directed against
specific brain regions can be induced by viral infection such as group A
Streptococcus and that anti influenza antibodies can cross react with human
hippocampal, cortical and cerebellar tissues (Wright et al 1993). Increased levels of
autoantibodies have also been demonstrated in the serum of schizophrenics and it
is of interest that autoimmune disease affects females more often than males and
that several studies have shown that the association between prenatal exposure to
influenza epidemics and subsequent development of schizophrenia is statistically
more significant in females. O'Callaghan (1994) did a study of 16 different viral
infections strains and showed that none of these viruses were associated with
increased incidence of schizophrenia indicating that the association seen with the
influenza virus may be of significance in the aetiology of schizophrenia.
It has also been suggested that a new mutated virus could be responsible for
schizophrenia but there is little evidence to support this.
Several studies show that complications occurring during birth or pregnancy are
more common in schizophrenics that control subjects (Eagles et al 1991)
particularly in male schizophrenics and are associated with earlier onset of
schizophrenia symptoms (O'Callaghan et al 1992). Asphyxia, intracranial
haemorrhage, ischaemia and malnutrition have been proposed as possible
mechanisms which could cause damage leading to later development of
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schizophrenia (Hemmings et al 1990, Murray et al 1992). It has been proposed that
birth complications are a result of earlier events. Minor physical abnormalities are
also found more commonly in several disorders including epilepsy and mental
retardation but have also been reported in schizophrenia again particularly in males
and are suggestive of an earlier developmental abnormality. It may be possible that
obstetric complications could lead to the disruption of the blood brain barrier leading
to increased susceptibility to viral or other pathogenic agents.
Schizophrenic individuals have also been found to have lower mean birth weights
compared to their unaffected siblings and normal controls (Rifkin et al 1994). In
monozygotic twins discordant for schizophrenia it been shown that the affected twin
is significantly more likely to be lighter than their co-twin, although this finding has
not been replicated (Rifkin et al 1994). Taken together these abnormalities suggest
a neurodevelopmental influence in early to mid-gestation.
Other environmental influences on schizophrenia include psycho-social influences
such as stress, socio-economic status and city residence. Schizophrenic individuals
may be rendered more sensitive to environmental stress by the underlying
abnormality which causes their schizophrenia. This may make them less able to
cope with "stressful" events with which normal individuals have no difficulty. Stress
is a general notion and what is stressful to one individual may not be to another. It is
generally recognised that stress is a trigger of schizophrenia relapse and that major
life events such as the death of a close relative, may precipitate episodes of
schizophrenia rather than cause them (see earlier).
A higher rate of schizophrenia is found in inner cities compared to rural areas as
shown by several studies including the Swedish city study of Lewis et al (1992).
There may be several reasons for this which may incorporate some of the factors
mentioned above, such as infectious agents being able to spread more easily in
cities due to close living proximity and increased stress associated with urban living.
Alternatively, the increase may be explained by "social drift" whereby affected
individuals migrate to areas of a particular kind in which the social demands on
them are less. Inner city areas provide less rigorous social demands on individuals
whose coping skills are reduced and therefore preferential migration may occur.
Pertinent to this argument is the high rate of schizophrenia seen among the lowest
social class levels of urban populations (Kohn 1976). This is likely to be due to the
downward social drift of affected individuals as a result of their disorder. Social
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status may tell us more about how affected individuals fare in society as opposed to
revealing any more information about the aetiology of the disorder.
It has been suggested that schizophrenia is more prevalent among African
Caribbeans living in Britain than among other ethnic groups and the white
population (Harrison et al 1988). This finding is controversial and in a similar study
King et al (1994) reported that the prevalence of psychosis among all ethnic
minority groups they studied was increased not just in Afro-Caribbeans. Although
the initial report by Harrison lead some to suspect a biological basis for the
difference in prevalence, King states that since the consistent finding of first or
second generation migrants of any ethnic group may be at greater risk of a
psychotic illness is suggestive of environmental factors. The greater stress which
migrants suffer as a result of their migration, discrimination, cultural change and
racism could play a role in the increased prevalence of psychotic disorders reported.
Another environmental contributor to the pathogenesis of schizophrenia which has
been offered is that of abnormal metabolism of dietary products creating toxins
which have a detrimental effect on brain function. This seems unlikely although in
the genetically inherited homocystinuria (in which an enzyme defect preventing
normal metabolism of the amino acid methionine occurs) psychiatric symptoms
result from ingestion of dietary products containing the amino acid methionine
(Hemmings 1990). Dohan 1982 suggests that in individuals who have genetic
vulnerability to schizophrenia who eat grain products will develop schizophrenia.
Dohan reported that the incidence of schizophrenia was highest in those countries
which eat wheat and rye and lowest in those which consumed barley and rice.
Abnormal metabolism of normal food stuff in situations of starvation may produce
toxins which affect the brain (Susser 1995).
1.11 Hypothesis on the aetiology of schizophrenia
A plethora of hypothesis on the aetiology of schizophrenia have emerged
incorporating genetic and/or environmental causes. Several hypothesis of the
aetiology of schizophrenia incorporating major environmental components have
been discussed in the previous section (1.10) such as viral, dietary and obstetric
complications etc. and will not be discussed further in this section.
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Neurotransmitter systems in schizophrenia
The role of the major neurotransmission pathways in the pathology of schizophrenia
has been intensively investigated. The neurotransmitters, their receptors and other
components involved in their production and functioning have all been scrutinised
with the aim of defining a pathological role for them in schizophrenia. To date none
have been conclusively found to be causally related to the pathogenesis of
schizophrenia although they continue to be studied.
* Dopamine
The dopaminergic system regulates motor function and a number of cognitive and
emotional functions which are transmitted through specific dopamine receptors.
The "dopamine hypothesis" is one of the oldest neurotransmitter theories and has
been criticised extensively since its conception in 1973. The impetus for considering
dopamine as an altered neurotransmitter involved in the pathogenesis of
schizophrenia came from two observations. Firstly, that high doses of
amphetamine, which acts by increasing dopamine release from nerve ending
stores, can induce psychosis indistinguishable from that seen in acute paranoid
schizophrenia. Secondly, that some antipsychotic drugs used to treat schizophrenia
act via the blockade of dopamine receptors (D2 subclass) and the action of these
drugs correlates particularly well with their clinical efficacy (although other
neurotransmitter receptors may also be affected). As originally conceived the
dopamine hypothesis posited that schizophrenic illness is a manifestation of a
hyperdopaminergic state. There are however several difficulties with the
hyperdopaminergia hypothesis. The many biochemical studies over the past two
decades have failed to provide conclusive evidence of over activity of dopamine
neurotransmission. The major dopamine metabolite, homovanillic acid (HVA)
reflects, at least in part, dopamine function and has been measured in cerebral
spinal fluid (CSF), plasma and urine. The results reported are conflicting, with some
studies reporting elevated levels in schizophrenics compared to controls and others
failing to demonstrate this. Direct measurements of HVA in post mortem brains
have similarly failed to unequivocally show raised dopaminergic function in
schizophrenia (Owen and Simpson 1994, Reynolds 1995). Post mortem brain
studies did show that the number of dopamine D2 receptors in schizophrenics was
elevated compared to normal control subjects. The source of this elevation is
disputed as many of these patients received some form of drug treatment prior to
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their death which may have caused up-regulation of these receptors. However,
some studies done on drug free patients seem to confirm the increased number
(Wong et al 1996).
Dopamine receptors belong to a super-family of receptors which exert their effect
through guanine nucleotide binding protein or G proteins. Five subtypes of
dopamine receptor are recognised; D1, D2, D3, D4 and D5. D1 receptors are
coupled to adenylate cyclase and are located in the brain cortex. D2 receptors are
negatively associated with adenylate cyclase and are found to be most prominent in
the striatal and limbic structures. D3 is similar to D2 in terms of location and
pharmacology although it generally has higher affinity for dopamine than D2. D4 is
again D2-like and is found in the amygdala and frontal cortex whereas D5
resembles D1.
The antipsychotic drug clozapine is effective in treating some forms of
schizophrenia resistant to treatment with classical neuroleptics and has fewer of the
extrapyramidal side affects associated with these drugs. Clozapine binds to D2
receptors with low affinity, but seems to bind to D4 receptors with higher affinity
(Meltzer 1994), indicating that D2 dopamine blockade is not the only pathway
involved. All of the dopamine receptors have been investigated for polymorphisms
to determine if susceptibility to schizophrenia could be linked to the presence of a
particular functional variant. (This will be discussed further in section 1.14).
Hyperdopamine function correlates well with positive but not the negative symptoms
of schizophrenia. Hypodopaminergic functioning in specific brain regions has been
proposed. Davis et al (1991) hypothesised that schizophrenia was characterised by
abnormally low prefrontal dopamine activity, causing the negative symptoms of
schizophrenia, leading to excessive dopamine activity in mesolimbic dopamine
neurones which causes the positive symptoms of schizophrenia. This hypothesis
has received little acclaim.
Several functional studies have been done on the dopamine receptors using
techniques such as positron emission tomography (PET) to visualise the receptors
in specific regions of the brain in various groups of individuals. Recently Okubo et al
(1997) showed by PET that binding of radioligand to the dopamine D1- like receptor
(the D1 and D5 receptor subtypes) was reduced in the prefrontal cortex of
schizophrenics and that this reduction was related to the severity of the negative
symptoms seen in these individuals and to poor performance in the Wisconsin card
sort test. Importantly this reduction was also seen in patients who had not been
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exposed to antipsychotic drugs which can cause reduction in the levels of such
receptors with chronic use. They proposed that dysfunction of the dopamine D1
receptor signalling in the prefrontal cortex may contribute to the negative symptoms
and cognitive deficits seen in schizophrenia. However, as with many of these
studies small numbers of individuals were used.
* Serotonin
Serotonin (5-hydroxytryptamine or 5-HT) was described as a neurotransmitter in
1950 and has been of continuing interest in relation to the pathogenesis of
schizophrenia. The hallucinogenic drug LSD is an effective 5HT antagonist and this
observation led to the hypothesis that schizophrenia might be related to a deficiency
of 5HT. 5HT agonists have been shown to have an antipsychotic effect which is
particularly effective at treating some of the negative symptoms of schizophrenia
(Bleich et al 1988). Parallel studies to those of dopamine have been done on the
major metabolite of 5HT - 5-hydroxyindolinic acid (5HIAA) in CSF, plasma and in
post mortem brains. 5HIAA is reported to be decreased and correlated with
ventricular enlargement in schizophrenia patients in some studies although, as with
dopamine, the results are conflicting (Bleich et al 1988, Reynolds 1995).
5HT receptors have also been studied in brain tissue from schizophrenic patients.
Several subtypes of 5HT receptor have been described (at least 14) and many have
been implicated in the neurochemical pathology of schizophrenia, either directly or
as a site of antipsychotic drug action (Roth 1994). Levels of the 5HT2 receptor in the
brain have been studied, but results are inconsistent, with decreased densities
being reported in several brain regions. Clozapine has a higher affinity for these
sites than for dopamine D2 receptors and its administration seems to lead to rapid
down regulation of these receptors and mixed D2 and 5HT2 receptor antagonists
have been suggested for use in treating schizophrenia (Reynolds 1995). Clozapine
and other antipsychotic agents have been found to have high affinity for several
other 5HT receptor subtypes such as 5HT6 and 5HT7 which may mediate some of
the clinical effects of these drugs. At present studies on these receptors are in their
infancy. Further work is needed to clarify their role in the pathogenesis of
schizophrenia.
* Acetylcholine
Anticholinergics may induce psychotic behaviour which may be related to the
reciprocal nature of the dopamine and cholinergic systems in the brain. The
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ubiquity of the cholinergic system in the limbic system of the brain and its
involvement in a wide range of behavioural functions indicates that acetylcholine
may play a role in psychosis. Tandon and Greden (1989) proposed that the
negative symptoms of schizophrenia reflected hyperfunction of the cholinergic
system in association with other neurotransmitter abnormalities, but there is little
direct evidence in support of this hypothesis. The consideration given to the
cholinergic system largely resulted from the effect of antimuscarinic drugs on
relieving the acute extrapyramidal side effects of antipsychotic drug treatment.
Clozapine has high affinity for muscarinic receptors and the reduced incidence of
extrapyramidal side effects seen with use of this drug is considered to be related
to this. Paucity of investigation of the cholinergic system in relation to
pathogenesis of schizophrenia leaves may unanswered questions.
• GABA (y-Aminobutyric Acid)
GABA is primarily synthesised by the inter-neurones in the cerebral cortex,
hippocampus and limbic structures. These inter-neurones interact with several
other neuronal systems including that of dopamine and glutamate. GABA is the
major inhibitory neurotransmitter in the brain binding to GABAa receptor subtypes
after synaptic release causing hyperpolarisation of the cellular membrane by
stimulating chloride release and inhibiting neuronal activity (Coon et al 1994).
Roberts (1972) first proposed that GABA systems may be deficient in
schizophrenia. GABA levels and GABA receptors have been reported to be
reduced in some regions of the brain (hippocampus and temporal lobe
structures), but as with the other neurotransmitters discussed thus far, there is
contradictory evidence for this. Reduced GABA neurones and increased
dopamine concentrations in the left amygdala have been reported (Reynolds
1995) and Reynolds speculates that this implies that neurones lost in
schizophrenia could result in hyperactivity of dopaminergic neurones.
• Glutamate
Glutamate is ubiquitously distributed in the brain and is the primary transmitter of
pyramidal neurones which are the principal excitatory neurones in the brain.
Excitatory responses are mediated through a number of receptor subtypes which
have a unique distribution being highest in the cortex, basal ganglia and
hippocampus (Owen and Simpson 1994).
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Initial interest in glutamate in terms of involvement in the pathology of
schizophrenia was due to the finding that glutamate was reduced in the CSF of
schizophrenic patients compared to controls, initiating the hypothesis that there
was impaired function of the glutamatergic neurones in schizophrenia. This
finding was not subsequently replicated but evidence that phencyclidine (PCP),
which can induce psychosis in susceptible subjects, acts by blocking the
ionotropic glutamate receptor n-methyl-D-aspartate (NMDA) ion channel
renewed speculation of its involvement. PCP psychosis includes both the positive
and negative symptoms of schizophrenia and is therefore thought to provide a
better model than that of amphetamine induced psychosis as it more closely
mimics the symptoms of schizophrenia. Further hypotheses about the role of
glutamatergic dysfunction in schizophrenia have evolved from an understanding
of the close interrelationship of dopamine and glutamate systems. Glutamate
receptors including the NMDA receptors can stimulate dopamine release. It has
been suggested by Toru et al (1994) that the relationship between dopamine and
glutamate may explain the subclassification in so much as in those patients with
primarily positive symptoms who are more likely to respond to antipsychotic
treatment a hyperdopaminergic state exists. In those with negative symptoms
refractory to antipsychotic treatment, abnormal neurotransmitter substances
such as glutamate hypofunction may be involved.
Binding to the Kainate receptor subtype of glutamate receptor has been reported
as decreased in the left hemisphere and increased in the frontal lobe consistent
with loss of neurones on which the receptor is found and is in keeping with other
reports of neurochemical indications of left temporal lobe dysfunction (Reynolds
1995).
Kerwin 1993 postulated that developmental abnormalities seen in the temporal
lobe are due to abnormal assembly of microtubule associated proteins (MAP),
the organisation and stability of which is influenced by glutamate. Reduction in
glutamate or its receptors may cause such abnormal assembly.
* Neuropeptides
Several of the neuroactive peptides have been investigated in relation to




Neurotensin is a tridecapeptide which is found in several dopaminergic terminal
regions including mesolimbic structures. Normal levels of neurotensin have been
reported in general although there are some contradictions to this.
Cholecystokinin (CCK) and Somatostatin;
CCK is found in some mesolimbic dopamine neurones although it is primarily
colocalized in cortical GABAergic neurones. Somatostatin interacts with many
neurotransmitter systems but is similarly primarily co-localized with GABAergic
neurones. Both CCK and somatostatin have been reported to be reduced in the
hippocampus, amygdala and frontal cortex. It is unclear if this reflects loss of
GABA neurones or specific neurotransmitter deficits.
• AIpha-7 Nicotinic Receptor
Schizophrenic individuals smoke at a higher prevalence rate (80%) than that
seen in the general population (30%). Smoking appears to improve sensory
gating, sustained attention and cognitive performance in patients with
schizophrenia (Deleon 1996). Smoking may also decrease negative symptoms
and extrapyramidal side effects and may also decrease the level of neuroleptic
drugs in the blood thereby decreasing the doses required. These effects have
been linked to the alpha-7 nicotinic receptor on chromosome 15. Using animal
models Freedman et al (1994) showed that blockade of this receptor caused
loss of the inhibitory gating response of auditory stimuli. Polymorphisms at the
alpha-7 receptor have been identified and related to the sensory gating effect.
Cerebral Diabetes
Holden et al (1994) proposed a causal hypothesis for schizophreniform disorders of
a form of cerebral diabetes. The underlying cerebral diabetic condition (so called
since it is consistent with Positron Emission Tomography scans showing seriously
abnormal glucose transport in schizophrenia) arises from decreased levels of P21
which is a GTP binding protein whose activity is regulated by GTPase activating
proteins. This produces a reduction in levels of tetrahydrobioterin, a cofactor for the
enzyme tyrosine hydroxylase and tryptophan hydroxylase which are involved in the
biosynthetic pathway of dopamine and serotonin. This decrease compromises the
activity of these two enzymes resulting in depression of dopamine and
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serotoninergic neurotransmission and down regulation of glycometabolism. When
such events occur at times of stress the blood brain barrier becomes more
permeable to heterocyclic amines (present in cigarette smoke, pollution of various
types and certain foodstuffs) the brain is "tipped over into a severe metabolic crisis
which causes schizophrenia".
The membrane hypothesis
Prostaglandins (PG), especially prostaglandin E are known to modulate monoamine
transmission. Activity of PGE may be decreased in schizophrenia resulting in
increased dopamine and noradrenaline transmission (Neylan and Vankammen
1990). Abnormalities in essential fatty acids (EFA), which are precursors for PGs,
form the basis of the membrane hypothesis (Horrobin and Huang 1993, Horrobin
1994). This proposes that the levels of EFA are decreased in the membranes of the
red blood cells of schizophrenics (which are similar in composition to that of cells in
the brain). The existence of defective acyl transferases, which insert certain types of
EFAs into membranes and excessively active phospholipase A, which removes EFA
from the membrane, are proposed to occur in the membrane hypothesis. Such
abnormalities could result in disruption of the membranes of brain cells causing
abnormalities in brain histology and in functioning of neurotransmitter systems (the
components of which are all associated with membranes). Consistent with this
hypothesis increased levels of phospholipase A have been reported in
schizophrenics (Gattaz 1990) and neuroleptic drugs have been shown to inhibit
phospholipase activity. Many of the epidemiological and pathological features of
schizophrenia may be explained by such a hypothesis (Horrobin 1994).
Alcohol
Lohr and Bracha (1989) suggest that prenatal alcohol exposure could be a
contributing factor to the development of schizophrenia in a small number of cases.
Alcohol appears to be able to cause harm to the foetus when consumed even in
small amounts. Enlarged ventricles have been reported in cases of foetal alcohol
syndrome and hippocampal abnormalities are commonly seen in rodents exposed
to alcohol. Lohr suggests that these data support the contention that prenatal
alcohol exposure can cause brain structural abnormalities which may result in
behavioural alterations. Late onset of symptoms may result from metabolic damage
which only manifests after hormonal changes associated with puberty.
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Epidemiological evidence that schizophrenia births peak in winter and that peak
beer sales occur in late summer are taken to point to the critical time of prenatal
exposure as being in early second trimester of gestation!
Handedness and the acquisition of language
Crow (1990) has hypothesised that schizophrenia results from a failure to develop
the normal asymmetry of the brain represented by the presence of the language
processing centre (Broca's region) in the temporal region on the left (in right handed
people). Temporal lobe asymmetry is a relatively late evolutionary phenomenon and
many believe that it is related to the acquisition of language skills.
Handedness is also believed to be derived from anatomical and physiological brain
asymmetries and to be under the control of a "cerebral dominance" gene (Taylor
and Amir 1995). The majority of the population are right handed (90%) but an
excess of left handedness has been reported in schizophrenics (Green et al 1989).
Post mortem studies and magnetic resonance imaging studies have also suggested
that schizophrenic subjects lack pronounced asymmetry (reviewed by Maddox
1997). This evidence coupled with the fact that brain abnormalities are more often
seen on the left side of the brain in schizophrenia has raised the possibility that
handedness, cerebral asymmetry and psychotic disorder may depend in part on the
same genetic locus. Crow has postulated that this hypothetical gene functions to
induce the development of the cerebral asymmetry that usually puts Broca's area
on the left and that a mutation would then account for its being on the right. Crow
(1990) has aiso postulated that this gene lies in the pseudoautosomai region of the
sex chromosomes (see section 1.14). Whilst unity hypotheses such as this are
attractive, the evidence to hand (see earlier) suggests that schizophrenia is unlikely
to be the result of a single gene disorder.
Neurodevelopmental abnormality
Structural brain imaging and epidemiology studies imply that schizophrenia may
have its origins in foetal life.
Structural brain studies have indicated that abnormalities such as ventricular
enlargement and decreased volume of the temporal lobe structures exist in some
schizophrenic patients. Abnormal neuronal migration, greater pyramidal cell disarray
(seen in some cases) and the lack of gliosis (glial cell reaction to neuronal
inflammation or damage) suggest a developmental rather than a degenerative
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process. Epidemiological indications that schizophrenia may be of developmental
origin include the observation of premorbid clinical abnormalities in childhood (of
personality and intellect), increased obstetric complications and increased winter
births among schizophrenics the latter of which may indicate contact with an early
environmental hazard such as a virus. All of these factors have been mentioned in
more detail in previous sections.
There are many hypotheses as to the aetiology of schizophrenia but despite much
experimentation, few have any convincing evidence to support them. Schizophrenia
is undoubtedly a complex challenging disorder and is likely to result from the
interaction of multiple genes of various effect sizes as well as environmental
influences. Given this complexity and our relative ignorance about the genetic
architecture of the higher central nervous system, finding susceptibility genes for
schizophrenia is far from easy. New technologies and innovative methodologies
have allowed progress to be made in positional cloning strategies in the field of
psychiatric genetics as well as that of other complex disorders with a genetic basis.
1.12 Positional Cloning
The isolation of genes by positional cloning strategies is based purely on
chromosomal location of the gene and requires no prior knowledge of its
biochemical function. Positional cloning strategies have been successfully employed
to elucidate genes involved in monogenic disorders such as cystic fibrosis
(Rommens et al 1989) and Huntington's disease (The Huntington's disease
collaborative research group 1993) but are now frequently being used to detect
genes involved in the more common and challenging complex disorders including
psychiatric illness.
Assignment of a disease gene to a chromosome and then sub-chromosomal region
can be accomplished in several ways:
1.12.1 Molecular cytogenetics
Chromosomal rearrangements which cosegregate with diseases such as deletions,
duplications, fragile sites and translocations provide an excellent starting point for
positional cloning strategies and have proved extremely successful approaches
particularly in cancer genetics where molecular events leading to the loss of a
tumour supressor gene or the generation of gene fusion products can often be
detected at the chromosomal level (Dallery et al 1995, Kerckaert et al 1993, Chen
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1993). Duchenne muscular dystrophy was the first disorder to be successfully
mapped using a chromosomal rearrangement (an X-autosome translocation,
Greenstein et al 1977) and many others have since followed, including chronic
Wilm's tumour and Fragile X syndrome (see Collins 1995 for a review).
Another type of rearrangement which has been associated with several diseases is
triplet repeat expansions which can be readily detected by Southern blot analysis.
Such expansions are found in Huntington's disease, Spinocerebellar and bulbar
muscular atrophy (SMBA), Spinocerebellar ataxia type one (SCA1), Machado-
Joseph disease and dentatorubral-pallidoluysian atrophy (DRPLA) and are of great
interest as they are late onset neurodegenerative diseases. The precise method by
which these triplet repeat expansions cause selective neuronal death and
neurodegeneration is as yet unclear (Perutz 1996) (see section 1.9.3).
1.12.2 Linkage Analysis
For diseases where a large collection of affected families exists, the gene can be
localised using genetic linkage analysis. Linkage occurs when a genetic marker
(reliably measured characters that have simple mode of transmission and are
polymorphic) and a disease gene lie in close proximity on the same chromosome
such that they are found together more often in affected family members than would
be expected by chance. Linked genes recombine less during meiosis than the
expected rate of 50% stated by Mendel's law of independent assortment. The
recombination fraction (9) can be determined by dividing the number of individuals
where there has been recombination by the total number of offspring and is
proportional to the distance between the two loci (within certain limits). In practise
statistical methods are used to determine the likelihood that the marker and disease
gene are segregating independently. The LOD score (log of the odds) is the method
usually employed to determine the likelihood of linkage at different recombination
fractions. It is estimated for a number of recombination fractions and peaks where it
reaches the maximum likelihood estimate of the recombination fraction. Linkage is
assumed if the LOD score is 3 or greater (corresponding to an odds on linkage of
1000:1 or greater). The use of closely spaced polymorphic markers allows the
region of linkage to be tightly defined as the markers which show the lowest
frequency of recombination are those which flank the disease gene. The higher the
number of meioses for study the better resolution is obtained. 100 meioses gives a
resolution of about 1% recombination which equates to a genetic distance of
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approximately 1 centimorgan (cM). In humans 1cM is roughly equivalent to 1Mb,
however this relationship does not always hold true as recombination rates and
physical distance vary throughout the genome.
Although linkage studies have proved successful in disorders where major gene
effects occur such as Huntington's disease (Huntington's disease collaborative
research group 1993) they have as yet been less successful in the more complex
diseases such as schizophrenia. Linkage studies using maximum likelihood
methods are based on precise specification of the genetic model (parametric
analysis). In complex diseases genetic heterogeneity, multiple disease susceptibility
loci, difficulties with precise phenotype definition, incomplete penetrance and non-
Mendelian mode of inheritance all conspire to make linkage analysis difficult.
Several methodological modifications and the use of larger sample sizes through
international collaborations have helped to improve the power of linkage analysis in
complex disorders. Non parametric linkage approaches, where the mode of
transmission does not need to be specified, have been developed as an alternative
to parametric linkage analysis. The affected sib pair (ASP) method is an approach
which compares the number of alleles shared by descent between two or more
affected sibs with the theoretical distribution of shared alleles under the assumption
of no linkage (Penrose et al 1953). Evidence of linkage is inferred if affected pairs
share more alleles at a given locus than would be statistically expected. This
approach also has the advantage that it is easier to collect pairs of affected siblings
than large multiplex families. The affected sib pair method is useful in detecting
genes of moderate (as opposed to major) effect but the method suffers from low
power and therefore very large sample sizes are required. Genetic heterogeneity,
informativeness of the marker, the number of sibships and assortative mating all
affect the power of this method and studies based on data from trios, with one or
two affected members have been recommended. This approach has been
successfully employed in complex diseases such as Alzheimer's disease (Baily-
Wilson and Bamba 1993) and type 1 diabetes mellitus (Davies et al 1994).
Association studies are another non parametric test requiring no major assumptions
other than the existence of a genetic contribution to the disorder. Association
studies contrast to conventional linkage analysis in that they compare the frequency
of marker alleles in a sample of unrelated affected subjects to that of a matched
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normal population. The demonstration of a significantly different distribution of allelic
variants in affected to unaffected individuals can result for several reasons;
I. Tight linkage disequilibrium between the marker and the disease
susceptibility locus such that an association with a particular allele is
maintained over many generations of recombination.
II. The marker locus may have some direct effect on susceptibility to
disease as well as being detectable as a polymorphic marker (pleiotropy).
III. Population stratification - where the population contains a disease and
marker allele more commonly than expected without a causal relationship
between them. In a mixed population any trait present at a higher
frequency in an ethnic group will show positive association with any allele
that happens to be more common in that group (Lander and Schork
1994).
Population stratification can lead to false claims of association but may be reduced
if the affected and control populations are ethnically well matched. Alternatively, the
Haplotype Relative Risk (HRR) method of Falk and Rubinstein (1987) and variations
of this method can be employed to overcome this difficulty. The control sample in
this association study is derived from parental alleles not inherited by the proband,
thus providing a perfect control for genetic background and avoiding the problem of
population stratification.
Once a positive association is found it is often subjected to a further test known as
the transmission disequilibrium test (TDT) to confirm linkage (Ewens and Spielman
1995). In this test a parent heterozygous for an associated allele A1 and a non
associated allele A2 should transmit the A1 allele more often than A2 to affected
offspring.
Association studies have several practical advantages over linkage studies, namely
not requiring large numbers of affected family members which are difficult to obtain.
They also don't require assumptions about the mode of inheritance and they have
considerable power to detect genes of weak to moderate effect, unlike linkage
where only genes of relatively major effect can be detected in practice. This is
highlighted by the case of the insulin gene which showed strong association to the
type 1 diabetes, but no linkage (this was also one of the first applications of the TDT
test to sort out this problem)(Julier et ai 1991). Linkage had been obscured because
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of the substantial proportion of homozygous parents (non segregating and therefore
not informative).
Association studies are currently conducted with markers close to or within a
candidate region as they are limited to only being useful in testing the actual
disease polymorphism or one in very tight linkage with it. Often this region may
have been broadly implicated initially by linkage analysis.
It is now possible to do genome wide scans for linkage to determine regions where
disease susceptibility genes may reside thanks to the great number of genetic
polymorphic markers mapped throughout the genome, largely thanks to the efforts
of the Human Genome Project. The results of such genomic scans and other
linkage and association studies performed in schizophrenia will be discussed in
section 1.14.
1.12.3 QTL Linkage
Complex disorders such as schizophrenia are likely to result from multiple gene
influences that, together with environmental variation, result in quantitative
(continuous) distributions of phenotypes. Genes of various effect size in multiple
gene systems that contribute to quantitative variation in a phenotype are often
referred to as quantitative traits loci (QTL). Finding such QTLs has been possible in
recent years by making use of animal models of various disorders and linkage
analysis such as in the rat model of hypertension (Hilbert et al 1991). In this study
linkage analysis (examining 49 DNA markers) in crosses between the stroke prone
spontaneously hypertensive rat and the normotensive control strain (Wistar-Kyoto)
led to the identification of two genes which significantly contributed to blood
pressure variation in the F2 population (BP/SP-1: chromosome 10, and BP/SP-2; X
chromosome) QTL linkage strategies have been utilised to study psychological
traits such as "emotionality" of mice (Flint et al 1995). In this case the "open field
activity" test was assessed to define emotionality of the mice. Subsequent
inbreeding by brother sister mating over 30 generations resulted in each F2 mouse
having a unique combination of alleles from the parent strains. The most and least
active mice were examined for 84 DNA markers spread throughout the mouse
chromosomes by linkage analysis. Three chromosomal regions were identified;
chromosome 1, 12 and 15. A QTL on chromosome 15 was found to be primarily
related to the open field activity.
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Many differing QTL approaches are being employed to many domains of behaviour
but statistical limitations mean that only reasonably large effects can be detected.
1.12.4 Synteny Homology
Comparative mapping, particularly of the mouse and human genome has proved
useful in isolating disease genes involved in human disorders. The human and
mouse genomes contain approximately 150 conserved regions with nearly identical
gene content (Meisler 1996). Regions which are conserved between species make
it possible to use gene identification and map position in one species to "predict"
location in the other and to recognise true homologies between mouse mutants and
human disease. The value of this technique is illustrated in the isolation of the gene
responsible for Usher 1B syndrome, the most common cause of deaf-blindness in
humans. The mouse deafness mutant Shaker 1 and Usher 1B had previously been
mapped to a conserved linkage group on mouse chromosome 7 and human
chromosome 11 q13 suggesting that they might be caused by a mutation in
orthologous genes. The shaker 1 gene was isolated in 1995 (Gibson et al) and was
found to be an unconventional myosin, myosin 7a, expressed in the hair cells of the
inner ear. This lead to the discovery of MY07A gene in humans in which mutations
were found in patients with Usher syndrome (Weil et al 1995).
It is also possible to use QTLs determined in mice as candidate QTLs in humans
due to synteny homology. For example the QTL found in hypertensive rats BP/SP-1
could reside on human chromosome 17q which is homologous to the rat region of
chromosome 10 to which this QTL was located. Similarly the QTL found on
chromosome 1 in emotionality studies in mice is syntenic to the long arm of human
chromosome 1. This allows these regions to be considered as candidate QTL
regions for hypertension and tearfulness and anxiety respectively (Hilbert et al
1991, Flint et al 1995).
1.12.5 Mouse Models
Mouse models of human disease have a substantial role to play in the isolation of
human genes. Induction of new mutants can be achieved using a variety of
methods such as chemical mutagenesis but transgenic insertions and embryonic
stem cell "knockouts" are providing increasing numbers of mouse mutations that are
homologous to mutations in humans. The mouse is an ideal animal model due to its
small size, short reproductive cycle and ease of genetic background manipulation
46
Chapter One Introduction
(i.e. ability to set up backcrosses, produce inbred strains etc) and is increasingly
finding application in identification of disease genes and also determination of their
function.
Such models are also finding application in determining the effects of genetic
background and in isolating modifier genes such as Mom-1. The multiple intestinal
neoplasia (Min) mouse is an excellent model for familial colon cancer. This mouse
carries a mutant mouse APC gene and develops many intestinal adenomas.
Genetic background has been shown to dramatically affect the tumour phenotype.
This modification is due to a modifier gene, Mom-1 (modifier of Min), which maps to
mouse chromosome 4 and can influence genetic variation in tumour number
Luongo et al 1994, Moser et al 1992, Su et al 1992, MacPhee et al 1995, Dietrich et
al 1993).
1.12.6 Physical mapping
Once the chromosomal region containing a disease gene has been narrowed down
it may be possible to identify candidate genes which lie in that region based on
known function or based on the availability of mapped Expressed Sequence Tag
sites (EST's) (see later section). If such candidates do not exist then isolation of
transcripts must be undertaken often the first step towards this is the production of
a physical map of the region. The estimated size of the region will determine the
number of markers required to produce a comprehensive physical map. Many
markers have been produced and mapped as a consequence of the Human
Genome Mapping Project and there is less need now to generate markers in the
subintervals of those already available by techniques such as Alu-PCR from
somatic cell hybrids and microdissection and microcloning of specific chromosomal
regions.
The isolation and mapping of genetic markers is a critical step in positional cloning.
The first class of polymorphic markers to be described were Restriction Fragment
Length Polymorphism's (RFLP) which create or remove a restriction enzyme site
such that digestion and hybridisation with an internal probe results in different band
sizes in different chromosomes. These markers are not very informative as they
tend only to have two alleles. Variable Number of Tandem Repeats (VNTR's)or
minisatellites have also been used as markers overcoming the problem of
insufficient allele number but are not evenly spread throughout the genome tending
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to be clustered at telomeres. Microsatellites are more abundant (approximately
every 30Kb), are more randomly distributed and are amenable to PCR amplification.
Such markers have largely been superseded by sequence-Tagged Sites (STS's)
which are short stretches (60-1000bp) of unique DNA sequence that can be
detected by PCR. STS's have the advantage that only the sequence of the
oligonucleotide primers for the PCR reaction is required to generate the STS and
this information can be stored in electronic form therefore making the STS
experimentally accessible to any laboratory without the need to obtain any cloned
material. This therefore provides a common language on genetic maps allowing
merging and integration of maps produced in different laboratories.
Human-rodent somatic cell hybrids have proved extremely useful in positional
cloning allowing the assignment of new genetic markers and probes either to a
particular chromosome or to specific regions on a chromosome, using Southern blot
hybridisation or polymerase chain reaction (PCR).
Somatic cell hybrids are produced from the fusion of rodent and human cells and
may be either monochromosomal (containing one human chromosome and rodent
background), regional/deletion (containing fragments of human DNA in a rodent
background), or radiation reduced (X-rays are used to break the human DNA into
small fragments and the broken fragments are recovered in rodent cells). The
technique of mapping using somatic cell hybrids is based on the loss or retention of
specific chromosome or chromosome fragments in the hybrid. The hybrids are
initially characterised using markers of known chromosomal position or by
Fluorescent in situ hybridisation (FISH) thus allowing ordering of the hybrids to or on
a chromosome. Monochromosomal panels first allow the marker/gene to be
assigned to a specific chromosome then hybrid panels containing smaller pieces of
that chromosome can be used to more precisely localise the marker/gene.
Somatic cell hybrids also provide some information about the order and distance of
markers/genes. Segments of DNA which are further apart on a chromosome are
more likely to be broken apart by radiation and segregate independently in the
hybrid than if they were closer together. Additional information on gene families
copy number and pseudogenes may also be gleaned by southern blot analysis of
Somatic cell hybrids. Radiation hybrid mapping is currently being widely used in the
Human Genome Mapping Project, providing a refinement of somatic cell hybrids
which allow high resolution mapping.
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Fluorescence in situ hybridisation (FISH) is widely used to determine map position
and the relative order of DNA probes on chromosomes. The technique broadly
consists of hybridising labelled probes to denatured target chromatin that has been
fixed on microscope slides followed by visualisation using immunocytochemical
staining procedures. Large genomic clones such as cosmids or Yeast Artificial
Chromosomes (YACs) are required for this technique but it has the advantage of
being able to detect gene amplifications, aneuploidy and subtle chromosomal
rearrangements as well as being able to estimate distances between probes.
It is also useful to have a long range restriction map of the region being positionally
cloned which can be achieved by Pulse Field Gel Electrophoresis (PFGE) (Brown
and Bird 1986). Using this technique and a combination of rare cutter enzymes it is
possible to refine physical distances between markers. As rare cutter enzymes
occur in GC-rich sequences the location of CpG islands, which are likely landmarks
for expressed genes, can be determined. The pulse field map of the region is also
useful for determining the extent of coverage of overlapping clones in a contig in
relation to actual genomic distance.
Once markers have been generated and mapped they can be used to generate a
clone map of the region of interest. In long range physical mapping Yeast Artificial
Chromosomes (YACs) are the cloning vector of choice. The large insert size of
YACs (100-2000kb) means that fewer markers and clones are required to anchor
and assemble the contig. YACs have been used to map several large chromosomal
regions and have been successfully employed in many positional cloning strategies.
There are several problems with YAC clones, the major one being the high
percentage of clones which are chimaeric (clone insert is from two independent
sources or chromosome regions and therefore does not represent a contiguous
stretch of DNA). YAC clones are also quite unstable and may become rearranged
or deleted over time.
Alternative cloning vectors to YAC's include bacterial based cloning systems such
as bacteriophage P1 cloning system (70-1 OOkb insert size), P1 derived artificial
chromosome (PAC - insert size 100-300kb) and the bacterial artificial chromosome
(BAC - insert size up to 300kb) and cosmids (insert size 35-45kb). All these systems
have the advantage of lower chimaerism, high transformation efficiency in library
generation, ease of purification and are in general more stable than YACs. Such




Genomic clones which are isolated from a region are analysed for insert size and
degree of overlap with other clones by marker content mapping and restriction
enzyme mapping. The clones or there derivatives can be used for chromosome
walking to close gaps in the contig and provide full coverage of the region. The
genomic clones also provide DNA for the isolation of additional markers for use in
techniques such as FISH, for generating sequence data and for gene identification.
1.12.7 Gene Identification
A major bottle neck in positional cloning has been the identification of transcribed
sequences and several ingenious methods have evolved to address this issue;
* Exon Trapping
Exon trapping is a method which facilitates the recovery of exons from random
pieces of cloned DNA. The basis of the strategy is that during the retroviral life
cycle, genomic sequences of non viral origin are correctly spliced and can be
recovered as cDNA copy of the introduced segment. There are three distinct
exon trapping methodologies that differ in the genomic target of interest. The
original method described by Duyk et al (1990) was to capture isolated 3' splice
sites residing within fragments of genomic DNA. Later approaches such as that
of Buckler et al (1991) focused on either complete internal exons or entire 3'
terminal exons (Krizman et al 1993). The choice of method is an important
consideration as for example internal exon trapping results in usually a single
exon of small size (20-200 bases) most of which contains useful protein coding
information which can be used in database searches but is difficult to use for
hybridisation screening of cDNA libraries to extend the sequence to full length.
The 3' terminal exon trapping method generates sequence derived from the last
exon of the gene and is generally much bigger in size but may consist mostly of
3'untranslated region which is less useful for database searching.
Several exon trapping vectors are available. Most are plasmid based, containing
a bacterial origin of replication, ampicillin resistance gene and a trapping
cassette made up of a eukaryotic enhancer/promoter driving transcription of a
two exon transcription unit with multiple cloning sites between the two exons. The
first exon functions as a 5' terminal exon and the second as a 3' terminal exon
capable of directing polyadenylation. Foreign fragments of genomic DNA are
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inserted between the two exons and any internal exons present are trapped
between the two vector exons by the cellular splicing mechanism.
Most DNA cloning vectors have been successfully employed as substrate in exon
trapping such as plasmid, phage .cosmids, BACs, YACs and even pooled
clones. cDNA selection is currently the most favoured method for the isolation of
gene sequences from a genomic region and has been successfully used in the
case of the Huntington's disease gene (The Huntington's disease collaborative
Research Group 1993). Exon trapping can not identify genes without introns or
exons with cryptic splice sites and also has the disadvantage that it is only
possible to use small DNA insert size.
♦ cDNA selection methods
Direct cDNA selection is an expression based gene identification technique that
can rapidly identify cDNA within large genomic regions. The concept underlying
direct selection is that large genomic regions such as YACs can be used to pull
out cognate cDNAs from a mixture of cDNAs. This is sometimes called
coincident cloning as it is the DNA which is coincident between the two mixtures
which is extracted. If one of the DNA sources is genomic DNA from the region in
which genes are required to be isolated and the other is cDNA from a particular
tissue then the DNA which is coincident between the two resources will consist of
gene fragments expressed in the specific tissue type.
Initially hybridisation of whole cDNA libraries on to immobilised genomic DNA
(YAC or cosmid) was used after initial pre-blocking of high copy repeats (Lovett
et al 1991, Parimoo et al 1991). This process was not particularly efficient
despite the introduction of a PCR step to generate sufficient material for cloning
and only gave 1000 fold enrichment (assessed by determining the relative
frequency of a particular DNA sequence in the starting material as compared to
the end product) which is insufficient to recover rare transcripts. A solution
hybridisation reaction was then introduced in which both the genomic DNA and
cDNA were in solution allowing the hybridisation conditions could be more easily
controlled (Lovett 1994) and biotin-streptavidin capture systems were employed
to separate the two resources. The basic procedure involves attaching a biotin
moiety to the genomic resource during a PCR amplification step. The cDNA is
pre-blocked for repeat sequences and both resources are denatured before
being mixed together and heteroduplexes allowed to form between coincident
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DNA. The denatured cDNA may be added to the genomic resource before or
after it has been immobilised on streptavidin coated magnetic beads. Any
coincident DNA is retained after stringent washing stages and can be eluted and
either be used in further rounds to improve enrichment or cloned into a suitable
vector after a further PCR amplification step and transformed into a bacterial
host to construct a library which can then be screened.
The cDNAs used can be complex pools derived from several tissue types and
the enrichment factors can be up to 103-106 (Brookes et al 1994) making the
technique especially useful when searching for cDNAs that are expressed at very
low levels in complex tissue sources. This technique is however prone to
contamination with artefactual products. Pre-blocking of YAC genomic resource
DNA with ribosomal yeast DNA and cDNA resource with human repetitive DNA
helps to avoid contamination from these resources(e.g. Cot1 DNA).
End ligation coincident sequence cloning is a stringent variation of the coincident
cloning technique which can enrich coincident sequences by 106 fold and is not
confounded by the presence of repetitive elements (Brookes et al 1994). This
technique is described in detail in the methods section 2.15. Basically, it allows
the recovery of heteroduplexes that are sufficiently well matched internally to
survive stringent washings and are perfectly base pair matched at their ends so
as to allow the ligation of "capture oligonucleotides" in a brief high temperature
ligation reaction which permits their recovery by amplification in a PCR reaction.
The high temperature ligation step means that this method is more stringent than
that described above and consequently less artefactual products should be
obtained.
* CpG islands;
CpG islands are areas of the human genome which are G + C rich and, unlike
the majority of vertebrate genomic DNA, don't show a reduced frequency of CpG
dinucleotides and are not methylated (Bird 1986). CpG islands are usually
located in or next to the 5' ends of genes. They commonly also contain the first
exon of these genes. CpG islands can be detected using rare cutter enzymes or
PCR techniques and used as hybridisation probes against cDNA libraries or
Northern blots in order to identify the genes associated with them. However, not
all genes are associated with CpG islands and for those that are associated
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further analysis must be done in order to determine whether they represent
transcribed sequences and if so, to isolate cDNAs representing these genes.
Screening of northern blots (mRNA derived from a tissue immobilised on a
membrane) with genomic clones such as cosmids or phage (YACs are too
complex to be used and must first be subcloned into either cosmids or phage)
can be done to identify transcripts present in the tissue derived RNA. These
transcripts must be present in sufficient amounts in order to be detected. The
subclones which detect transcripts can then be used to screen cDNA libraries
and are less complex probes than YACs. Similarly DNA subclones can be used
to screen DNA from a variety of different animal species which have been
immobilised on a membrane ("zoo blotting"). Detection of cross hybridisation
between species may indicate the presence of sequences that have been
evolutionarily conserved and therefore are likely to be essential for biological
function. The main disadvantage of these techniques is their laborious nature
when dealing with large genomic regions but they do have the advantage over
techniques such as cDNA selection and exon trapping of not being as technically
demanding.
♦ Subtractive hybridisation techniques;
Subtraction techniques have been used to isolate genes which are specific to a
particular tissue source or developmental stage. The technique uses a target
cDNA library, which is usually derived from the tissue where the gene is likely to
be expressed, and a so called driver cDNA library who's function is to subtract
out most of the ubiquitously expressed sequences. A typical experiment involves
mixing two DNA samples that have been cut by restriction enzyme digestion,
denaturing to form separate strands and reformation of heteroduplexes by
reannealing of complementary strands. The tester DNA is usually mixed with a
large excess of driver DNA to allow tester DNA fragments to predominantly form
hybrids with the driver fragments. If the driver fragments are labelled with a
hapten then separation of the driver and hybrid DNA can be achieved by affinity
chromatography (Lisitsyn 1995). This process was found to be highly inefficient
when trying to determine small differences between complex genomes and
Representational Difference Analysis (RDA) was devised to overcome some of
the initial limitations of the technique (Lisitsyn et al 1993).
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RDA allows small differences between the sequences of two DNA populations to
be determined. The efficiency is increased by initially cutting the driver and tester
DNA with a restriction enzyme as previously but then ligating oligonucleotide
adapters, allowing "whole genome" PCR preferentially of short fragments thereby
reducing the complexity of the resources. Differences in the two DNAs results
from restriction fragment length polymorphisms. The tester DNA is then ligated to
oligonucleotide adapters before mixing with excess driver DNA after
denaturation. On re-association target strand homodupexes with adapters ligated
to the 5' ends, driver tester hybrids and driver homoduplexes. The target
fragments can be selectively amplified after filling in of cohesive ends with Taq
DNA polymerase before further rounds of enrichment after ligation of a new
adapter to the tester sequence. RDA has been successfully applied to cancer
genetics
# Direct screening of cDNA libraries;
YACs and other genomic clone inserts can be used to directly screen cDNA libraries
removing the need to subclone and identifying multiple transcripts in a single
screening. This process is however not straight forward requiring large amounts of
DNA, long hybridisation times and giving high background as well as false positives
due to the complex nature of the probe. Also poorly represented cDNA clones may
be missed although normalisation of the library may circumvent this.
* Direct sequencing, Software trapping and similarity searching;
New automated sequencing methodologies are now making direct sequencing of
relatively large genomic regions a realistic alternative to other gene finding
techniques and will undoubtedly supersede such techniques in times to come. The
vast array of database packages available to determine structural components of
DNA sequences such as exon prediction programs (e.g. GRAIL, Xu et al 1996) are
continually evolving becoming more efficient thanks to improved complex
algorithms. Large scale sequencing strategies usually consist of shotgun cloning
the region of interest into lambda phage, sequencing these clones usually by single
pass automated sequencing, aligning the sequence into contigs using specially
designed computer packages such as the Staden alignment package (Staden
1996) and closing gaps by a variety of techniques most usually by end cloning
YACs. The sequencing effort currently being undertaken by the Human Genome
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Project is using this strategy in its effort to sequence all the transcribed sequences
in the human genome.
Once the sequence is obtained, rapid database searches such as (BLAST
searches, Pearson and Lipman 1988, Aitschul et al 1990) are carried out to
compare the sequence to all the known genes and expressed sequences already in
the database. Such databases are currently growing at an enormous rate and hold
large amounts of information not only on the sequence of the gene but of its
expression pattern, mapping position and even known homologs.
* Expressed Sequence Tags (EST's)
Partial sequencing of cDNA clones to generate expressed sequence tags (EST's) is
a rapid and powerful way to establish a profile of the expressed sequences in a
particular tissue or cell type. Large scale cDNA approaches are currently being
applied to a wide variety of tissues, organisms and developmental stages with a
number of strategies being employed to yield maximum information from the
libraries produced. The use of non-normalised libraries results in repeated
sequencing of some cDNA clones but does yield information about the relative
expression levels of active genes. Normalised libraries (which have been pre-
screened to remove certain common sequences) enrich for clones which are more
likely to be unique from one another (Sikela and Auffray 1993). The sequencing of
clones also differs in that some labs sequence just the 5' ends of directionally
cloned cDNA which is more likely to provide protein coding information useful for
functional class assignment. Sequencing of 3' ends provides mostly 3' untranslated
sequence which is less useful for functional assignments but since 3' UTR's are
usually quite divergent they are more gene specific which often makes mapping
easier.
The vast quantity of information produced from cDNA clone sequencing efforts is
held in several databases including dbEST and GENBANK and is readily accessible
through the world wide web (Boguski et al 1995).
Although there is a vast ever growing number of EST's held in these databases only
a minority of them have been mapped to precise chromosomal locations, but this





Once a gene has been identified in the most delimited region of DNA it becomes a
candidate gene for the disease and its potential role in disease must be tested. This
usually requires the demonstration that the disease is associated with a mutation in
that gene which may be a single base pair change to more gross alterations such
as deletions etc. While mutations can occur anywhere within the gene structure
(introns and regulatory elements) most mutations to date have been found in the
coding regions of genes. Gross gene rearrangements can be detected by pulse
field gel electrophoresis but usually if the mutation is not the result of a major genie
alteration more subtle mutations are demonstrated using techniques such as
denaturing gradient gel electrophoresis, chemical cleavage of mismatches, single
strand conformation polymorphism (SSCP) and direct DNA sequencing. SSCP has
gained widespread use and is based on the fact that single strand DNA molecules
adapt a secondary structure which dictates their migration rate through a gel in a
non size dependent manner. A single base change alteration can substantially alter
the conformation and therefore their migration through the gel is altered and can be
seen as a band shift in comparison with normal migration. In this technique small
fragments of 200-500bp (corresponding to exons usually) are amplified by PCR,
denatured and separated in a non denaturing polyacrylamide gel. Demonstration of
band shift will require sequencing of the DNA to establish the precise nature of the
mutation but this technique is of great value when screening large genes for
mutations (Orita et al 1989). New technologies such as the high throughput parallel
array technique are currently being developed to allow refinement of mutation
detection. These so called "DNA chips" consist of hundreds of thousands of
oligonucleotide sequences contained on a ~2cm3 chip (Southern 1996). The design
of these chips varies depending on the requirements but if mutation (or sequence)
analysis is required where every nucleotide must be interrogated then a complete
series of four oligonucleotides spanning each position in the sequence will be
designed, differing only in the identity of the central base. The relative intensity of
hybridisation to each quartet of oligonucleotide probes reveals the identity of the
central base. If a mutation has occurred then a different probe will light up because
of the mismatch. Complex computer packages can convert this vast amount of
information into comprehensible data and allow the rapid analysis of large numbers
of samples at a relatively reasonable cost. DNA chips are being made commercially
by companies such as Affymetrix and are now beginning to be used more widely in
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the genomics field, having found applications in expression analysis and mapping
as well as sequencing and mutation detection (Hacia et al 1996, Shoemaker et al
1996, DeRisi et al 1996).
Once a mutation has been detected it must be shown to be disease causing.
Mutations which alter the structure of the protein product in some way which may
alter its normal function is usually supportive evidence for its role in the disease.
Ultimate proof that it is the disease causing mutation may come from transgenic
studies by demonstrating that the mutation can cause the disease phenotype and
that the normal form of the gene can correct the abnormal phenotype.
Other evidence may be accumulated from expression analysis from RT-PCR
studies to see which specific tissues the gene is expressed in and also more
specifically by RNA in situ which allows more detailed expression analysis in
specific tissues. Evidence accrued from sequence information such as the presence
of structural motifs which may give indications of function and homologies to other
genes of known function either in humans or other organisms is often invaluable.
Tissue culture expression systems may also be employed to elucidate further
information.
1.13 The Human Genome Project:
The Human Genome Mapping Project aims to produce a transcript map of the
human genome by the year 2005 and ultimately to identify and establish a function
for all of the estimated 50,000 to 100,000 genes in the human genome. The Human
Genome Project also aims to provide new "infra structure" to genomic research by
universal provision of data, material resources and technology that will improve the
speed, cost and efficiency to aid biological research. The success of this process
has been in the sharing of resources by scientific researchers across the world. At
least 15 countries including Britain and America have programs for analysing the
genomes of a variety of organisms including microbes and plants as well as the
human genome. Many of the initial goals of these genome projects have already
been realised with completed sequences of the entire genome of several species
having been completed such as that of the bacteria Escherichia coli (1997) and
yeast Saccharomyces cerevisiae (1993).
The initial stage of the human project was to produce relatively low resolution
integrated cytogenetic, genetic and physical maps of all the human chromosomes.
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The first low resolution genetic linkage map of the human genome was published in
1992 and since then many high resolution physical maps of various chromosome
have been completed such as that for chromosome 7 and the X chromosome.
Several region of the genome are currently being sequenced in large scale projects
and an estimated 38.66Mb or 1.29% of the human genome has been sequenced to
date (July 1997). The advent of new sequencing technology and strategies for large
scale sequencing is rapidly accelerating the speed of this process and it is
estimated that there is a world capability of sequencing 20Mb/year - a figure which
will doubtless keep rising.
The Human Genome Project has had a remarkable effect on positional cloning
strategies with thousands of markers being available throughout the genome
(approx. every 100-200kb intervals) for linkage analysis. Once a region of linkage
has been determined (depending on where it is in the genome) database searching
can locate YACs from the region which can be ordered from centralised resource
centres and cosmid clones may also be available. It is also possible that the region
you are interested in will have had a number of EST's and other genes mapped to it
which instantly provide candidate genes which can be further investigated. A large
part of positional cloning can now be done by database searching and this fraction
is set to increase as the Human Genome Project steams ahead.
As the scientific community hoped the Human Genome Project has had a
phenomenal effect on the speed and ease with which human inherited diseases can
be studied.
1.14 Previous attempts to find genes involved in schizophrenia;
Several strategies have been used in linkage and association studies to localise
genes involved in schizophrenia. These include using a priori evidence for possible
involvement of a region in schizophrenia such as a cytogenetic abnormality or the
cosegregation of schizophrenia with another disease of known location.
Alternatively linkage studies have been done by genome scanning using markers
distributed throughout the whole genome.
Linkage Studies
♦ Chromosome 5
In the wake of a report by Bassett et al (1988) of a partial trisomy
chromosome 5 which cosegregated with schizophrenia in a single
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Canadian-Chinese family, linkage to markers located between 5q11 -q13
was reported by Sherrington et al (1988) in five Icelandic and two British
pedigrees. A maximum LOD score of 6.49 was reported with broad
spectrum diagnosis including alcoholism and schizophrenia spectrum
disorders for a dominant gene model with high penetrance. However, a
number of other studies using more informative markers in this region
failed to reproduce this linkage (Kennedy et al 1988, St.Clair et al 1989,
Crowe et al 1991, Macciardi et al 1992). The original linkage study was
then extended using more informative highly polymorphic markers and
the original LOD score was reduced substantially but remained positive at
LOD 3 when the phenotype was restricted to schizophrenia and spectrum
disorders. However, after new families were added to the original sample
no linkage could be found and the original report was deemed to have
been a false positive result.
♦ Chromosome 6
Wang et al (1995) and Straub et al (1995) both reported positive linkage
results to chromosome 6. Wang et al performed linkage analysis on 186
Irish multiplex families and reported a multipoint LOD score of 3.9 at
markers F13A1 and D6S260 (6P23) assuming locus heterogeneity and
with broad disease definition. Straub analysed 265 Irish pedigrees and
reported a LOD score off 3.51 assuming locus heterogeneity and
intermediate phenotype definition with markers in the region of 6p24-22.
Non-parametric analysis also yielded weaker but still positive findings
suggesting a potential vulnerability locus for schizophrenia.
Several groups attempted to replicate these findings using the same
markers as the original groups and varying results were obtained with
some authors refuting linkage in their families at these markers (Mowry et
al 1995, Gurling et al 1995) and others providing weakly positive results in
support of the original findings (Antonarakis et al 1995). More recently
Cao et al (1997) reported positive results for chromosome 6q using non-
parametric allele sharing identical by descent and multipoint maximum





Levinson et al (1996) reported a large collaborative study used
informative pedigrees to study markers on chromosome 3, 6 and 8.
Positive LOD scores were reported on chromosomes 6 and 8. The
chromosome 8 maximum LOD score was 3.06 and the authors report this
as being suggestive of a susceptibility locus for schizophrenia but that
multicentre collaborative follow up studies are required for replication.
♦ Chromosome 11
Several families have been reported where there is a balanced
translocation on the long arm of chromosome 11 q which appears to
cosegregate with psychotic illness (Smith et al 1989 -t(9:11 )(p22;q22.3),
St. Clair et al 1990 - t(1;11)(q43;q21), Holland et al 1990 (6;11)).
Several other lines of evidence make chromosome 11 q interesting. Two
independent pedigrees have been reported in which albinism
cosegregates with schizophrenia (Baron 1976, Clark and Buckley
1989).This is of interest since the gene for oculo-cutaneous albinism is
TYR (encoding tyrosinase) which maps to 11 q14-21. Tyrosinase is of
course also an important enzyme in the biosynthetic pathway of
dopamine. Several candidate genes such as the dopamine D2 receptor
gene also lie in this region of chromosome 11 q making it a strong
candidate region. However, results of linkage on this region of
chromosome 11 q have been largely negative, including those done on
the dopamine D2 receptor and tyrosinase (Moises et al 1991,Nanko et al
1992, Wang et al 1993).
♦ Chromosome 22
Pulver et al (1994) reported that chromosome 22q12-q13.1 showed
positive linkage (LOD score 1.54) on a whole genome scan of patients
from 39 systematically ascertained multiplex families. This study was
followed up by a collaboration with several other groups using families
from Ireland, USA, France and England to provide a combined replication
sample of 256 families. No evidence of linkage could be found for the
region 22q12-q13 leading the authors to conclude that the initial report
was either false linkage or that the region confers susceptibility to
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schizophrenia in only a small number of cases (Pulver et al 1996, Diehl et
al 1994, Gill et al 1996, Laurent et al 1994). Further studies done on
chromosome 22 have not yielded consistent results. Coon et al 1994 also
reported positive linkage to chromosome 22 in a genomic scan done
using 329 loci genotyped in 9 multiplex families but a similar genomic
scan done by Barr et al (1994) in North Sweden did not reveal any such
linkage. Polymeropoulos (1994) scanned 105 families with 10
chromosome 22 markers and found no evidence for linkage. Similarly
Kalsi et al (1995) looked at two markers on chromosome 22 D22S274
and D22S283 (22q12-q13) in 23 UK and Icelandic families and no
significant linkage was reported.
♦ Sex chromosomes
Collinge et al (1991) analysed a sample of 120 schizophrenic and
schizoaffective sib pairs and reported that sibs shared marker alleles at
DXYS14 locus more often than expected by random assortment. Positive
preliminary results for DXYS20 and DXYS17 markers in the
pseudoautosomal region were reported by d'Amato et al (1992) in 38 French
pedigrees. The pseudoautosomal region is a region found on the distal ends
of the short arms of both the X and Y chromosomes that undergoes crossing
over during male meiosis. Alleles in this region are more easily transmitted
to a same sex descendant and if dominant inheritance is assumed then
affected offspring will tend to be of the same sex when the disease is
inherited through the father (Leboyer 1992). Thus if the schizophrenia allele
is on the fathers X chromosome then affected offspring are more likely to be
female and if it is on the Y chromosome they will be male. Crow (1988)
reported that same sex affected sibling were more likely to be concordant for
schizophrenia. There are also reports that there is a high frequency of
cytogenetic abnormalities (such as aneuploidies XXY, XXX) of sex
chromosomes in schizophrenia (Crow 1988). This evidence was the basis of
Crow's pseudoautosomal hypothesis for susceptibility to schizophrenia.
Asherson et al 1992 excluded linkage to the pseudoautosomal region
(DXYS14) using six multiply affected families with schizophrenia. They did
however find an excess of same sex siblings over mixed sex siblings
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compared with that expected but conclude that this must arise through some
alternative mechanism.
Outside of the pseudoautosomal region, Xq27-q28 was reported as showing
linkage to bipolar disorder and was subsequently investigated for linkage to
schizophrenia by DeLisi et al (1991 and 1994) who excluded linkage to a
large part of this region with 10 multiplex families with schizophrenia.
1.15 Candidate genes
There have been many reports of studies done on loci thought to be candidate
genes for schizophrenia.
• Dopamine receptors;
Despite many attempts to demonstrate linkage or association to any of the
five dopamine receptors no consistent results have been reported (D1;
Campion et al 1994. D2; Campion et al 1994, Nanko et al 1994. D3; Yang et
al 1993, Nanko et al 1993, Nimgaonkar et al 1993, Nanko et al 1994. D4;
Sommer et al 1993, Nothen et al 1994, Barr et al 1993 Shaikh et al 1994,
Macciardi et al 1994, Seeman et al 1994, Lim et al 1994 (bipolar affective
disorder)).
A slightly more consistent finding has been reported for the dopamine D3
receptor of excess homozygosity (Crocq et al 1992, Mant et al 1994). This
finding has however not been replicated in other studies (Nothen et al 1993).
Recently Nimgaonkar et al 1996 reported that allele 1 homozygosity at the
D3RG locus increases the risk for and that this may also influence age of
onset. They do also state that this is likely to account for a small amount of
predisposition to schizophrenia and that liability may differ among Caucasian
and African-Americans consistent with a polygenic/multifactorial mode of
transmission. Durany et al (1996) have also recently reported homozygosity
at the D3 receptor gene.
The dopamine transporter gene which functions to terminate dopamine function by
the re-uptake into pre-synaptic terminals has also been widely studied but again no
consistent results have been obtained though most do not favour linkage or an





Mutations in the coding region of the (31 GABAa receptor have been sought by
Coon et al (1994) using SSCP analysis. Direct sequencing of an SSCP variant
revealed a C->G nucleotide transversion at codon 396 causing a histidine to
glutamine substitution at a highly conserved site in the peptide but no association
was found between this variant and schizophrenia.
• Serotonin (5HT)
Several authors have reported that the T102C polymorphism of the 5-
hydroxytryptamine type 2a receptor gene (allele 2) is associated with schizophrenia
(Williams et al 1996, Inayama et al 1996). Several subsequent studies failed to
reproduce this finding (Chen et al 1997, Erdmann et al 1996, Malhotra et al 1996).
Williams et al (1997) suggests this is due to the very small effect which requires a
large sample size such as they used in their European multicentre association study
of schizophrenia to improve the statistical power so as to detect the effect. They
conducted a meta-analysis of 15 association studies which have been done on
T102C 5HT2a and schizophrenia. Combining all the available data they conclude
that there is evidence of an association between the T102C 5HT2a polymorphism
and schizophrenia suggesting that the gene for the 5HT2a receptor or a locus in
linkage disequilibrium with it confers susceptibility to schizophrenia (Williams 1997).
Porphobilinogen deaminase (PBGD);
Sanders et al (1991) reported an allelic association between schizophrenia and a
polymorphism at the PBGD gene. PBGD gene is the site of pathogenic mutations
which cause acute intermittent porphyria which can produce mental disturbances
similar to those seen in schizophrenia and therefore is a possible candidate gene
for schizophrenia. The association study done by Sanders et al revealed a relative
risk for schizophrenia of more than 2 in individuals possessing the A2 allele.
Homozygotes for the A2 allele may also have an earlier age of onset. This finding
has not however been replicated (Owen et al 1992).
Dystrophin
Zatz et al (1993) reported a Brazilian family in which 4of 5 patients affected with
Becker Muscular Dystrophy (BMD) also had a diagnosis of schizophrenia or related
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spectrum disorders and suggested an association between the two conditions. This
would imply that a locus for schizophrenia is located on the short arm of the X
chromosome at Xp21 and the authors suggest that the psychiatric disorder may
result from an abnormal expression of the dystrophin gene in the brain. However,
there is little evidence to support this claim.
Beggs et al also reported that 2 out of a series of 35 patients with BMD had
schizophrenia (Beggs et al 1991).
Huntingtin
Huntington's disease is a rare, severe inherited neurological disorder whose primary
symptoms consist of involuntary choreiform movements and dementia. A small
percentage of Huntingtons disease patients display symptoms of schizophrenia.
Huntingtons disease results from an expansion of glutamine triplet repeats in the
Huntingtons disease gene located on chromosome 4 and this has lead to the
search for triplet repeat expansions in schizophrenia (see section 1.9.3). There has
been one report of a schizophrenic individual who did not have Huntingtons disease
having an expanded number of trinucleotide repeats within the Huntingtons disease
gene (St Clair 1994) but Rubinsztein et al 1994 reported that no such expansion
was found in the schizophrenic probands they studied.
Amyloid Precursor Protein (APP)
Mutations in the amyloid precursor protein (APP) have been reported as being
involved in early onset Alzheimer's disease which is a late onset disease causing
senile dementia. A large percentage of patients suffering from Alzheimer's disease
display psychotic symptoms and this has lead to APP being considered as a
candidate gene for schizophrenia. A point mutation in the APP gene has been
reported in a schizophrenic individual (Jones et al 1992) but this was not confirmed
in studies done on a further 100 schizophrenics by Jones et al or by Coon et al
(1993) who looked at 86 schizophrenics. This variant is likely not to be associated




In 1990 St Clair et al described a large Scottish pedigree (K26) in which
schizophrenia and related disorders cosegregated with a balanced translocation
t(1:11)(q43,q21).
This pedigree was detected by examining 282 pedigrees from the MRC
Cytogenetics Registry with familial autosomal anomalies for mental illness using
Research Diagnostic Criteria. 77 family members were included in the study (58
living and 19 dead). 23 members of the pedigree met Research Diagnostic Criteria
(Spitzer et al 1987) for mental and/or behavioural disorders. The schizophrenic
subjects also met DSM 111R criteria (American Psychiatric Association 1987).
Table 1.3: Number of individuals in pedigree K26 with mental illness
Disorder Number
Pedigree
of cases in K26
Schizophrenia 3
Schizoaffective Disorder 2
Major Depressive Disorder 6
Generalized anxiety Disorder 3
Minor Depressive Disorder 1
Alcoholism 3
Adolescent Psychiatric Disorder 5
No physical dysmorphisms or mental handicap were noted in this family. 34 of the
77 members of the family carried the t(1:11)(q43,q21) translocation and 16 of these
34 had a psychiatric diagnosis, the others were psychiatrically normal. Of the 43
family members who didn't have the translocation only 5 had a psychiatric diagnosis
and none of these was of major mental illness (1 generalised anxiety, 1 minor
depressive disorder and 3 alcoholism).
Linkage analysis was done and a range of gene frequencies and penetrances were
implemented. A maximum LOD score (against chance linkage of the translocation
with mental illness) of 2.19 was produced when the phenotype was restricted to
schizophrenia and schizoaffective disorder and rose to 3.33 when recurrent major
depression was included. A maximum LOD score of 4.34 was obtained when the
phenotype included cases of adolescent conduct and emotional disorder. The LOD
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score decreased to 1.37 however, when "uncertain phenotypes" such as
generalised anxiety, minor depression and chronic alcoholism were included.
The identification of a cytogenetic abnormality which cosegregates with mental
illness is an ideal starting point for defining the genetic component involved in the
disease process in this family. With the hypothesis that a gene or genes involved in
the psychiatric diagnosis in this family resides at or near the translocation
breakpoint on chromosome 1 and/or 11, a positional cloning strategy has been
employed to elucidate the relationship between the translocation and the psychiatric
diagnosis in this family.
The existence of two previous reports of chromosome 11 q translocations with
chromosome 9 and 6 (Smith et al 1989 and Holland et al 1990) which had less clear
cut cosegregation of mental illness, combined with the report of a large family in
which schizophreniform psychosis cosegregated with tyrosinase-negative oculo¬
cutaneous albinism (Baron et al 1976) and several candidate genes, such as the
dopamine D2 receptor gene, residing in close proximity to the translocation
breakpoint on chromosome 11 indicated that chromosome 11 q rather than
chromosome 1 may be the region of interest.
Lymphoblastoid cell lines were set up from family members who carried the
translocation and also from non carriers in the family. Genetic linkage, molecular
analysis and in situ hybridisation studies identified Tyrosinase (TYR) and D11S388
anonymous marker as flanking the chromosome 11 breakpoint (Fletcher et al
1993). The distance between these two markers is estimated to be 7.8cM
(NIH/CEPH Collaborative Mapping Group 1992).In order to generate more markers
within this region to aid positional cloning the translocation-derived chromosomes
were segregated into separate somatic cell hybrids using cell surface marker
selection techniques (Fletcher et al 1993).Analysis of these hybrids confirmed that
TYR was above the breakpoint and D11D388 was below the breakpoint. The
chromosome 1 breakpoint was also defined with available markers and found to lie
between markers D1S103 and D1S8.
Further mapping resources were obtained by X-irradiation of the chromosome 11
only hybrid J1C14 to produce four WJX irradiation hybrids (WJX 3, WJX 5, WJX 7
and WJX 11) which were assessed by PCR marker analysis and FISH with Human
Cot1 DNA probes. To generate more markers from the region a microdissection
and micro-cloning approach was adopted (Muir et al 1995). The breakpoint region
on the der 1 chromosome is visible as an area of discontinuity under a phase
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contrast microscope allowing its dissection. Two experiments were carried out both
producing 160 fragments which were digested with EcoR1 and cloned into lambda
phage. Over 1000 clones were derived from the two experiments and PCR of the
inserts using primers directed at the vector sequences indicated that the cumulative
insert size from both libraries (ignoring redundancy) was greater than 1Mb with the
average insert size of the cloned being 1.5Kb. The libraries were screened for
repeat sequences using (GT)25 dinucleotide repeat probe to remove any repeat
sequences. Of the 86 remaining clones 49 were assigned to chromosome 11 and
37 to chromosome 1. These clones were hybridised to Southern blots of the
somatic cell hybrids previously made to define a series of intervals on chromosome
11 (Fletcher et al 1993). FISH chromosome paints of pooled microdissection clones
confirmed the fidelity of the microdissection clones to the breakpoint region.
5 of the microdissection clones which lay closest to the chromosome 11 breakpoint
were used to screen ICI and ICRF YAC libraries (Anand et al 1990 and Lehrach et
al,1990). 23 YACs were identified and constructed into a 3Mb contig using
microdissection clone mapping and FISH for orientation. Confirmation of the contig
and closure of gaps was achieved by end cloning of YACs. One of the 23 YACs
was found to cross the translocation breakpoint (D0485) and this YAC was
subsequently screened for brain expressed sequences using a cDNA selection
technique, Coincident Sequence Cloning (CSC). This approach yielded an alpha
tubulin pseudogene located 250Kb proximal to the breakpoint and six novel cDNA
fragments which identify three novel genes located up to 700Kb proximal to the
breakpoint. The genie nature of these cDNA fragments has been confirmed by
sequence analysis, the presence of open reading frames and intron/exon
boundaries and by expression studies including Northern blots and zoo blots
(Devon et al 1997)
1.17 Aims of this thesis
This thesis has several aims:
1. To establish the precise location of two a actinin genes, ACTN 2 and ACTN 3, in
relation to the translocation breakpoint by high resolution mapping techniques.
These genes have been described as residing in the vicinity of the translocation
breakpoints on chromosome 1 and 11 (Beggs et al 1992) and as such represent
candidate genes for involvement in the psychiatric diagnosis seen in the
translocation family whose candidacy must be further determined.
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2 To establish the precise location of 20 ESTs with respect to the translocation
breakpoint by high resolution mapping. These EST had previously been mapped to
the general vicinity of the translocation breakpoint (Rosier et al 1995) and again
represented candidate genes whose candidacy needed to be further determined
initially by determining their proximity to the breakpoint.
3.To investigate linkage disequilibrium with a postulated schizophrenia susceptibility
gene, close to the translocation breakpoint, in a case controlled allelic association
study. This study will investigate two markers, in close proximity to the breakpoint
on chromosome 1 and 11, in a random population of schizophrenics, unipolar
depressives and normal controls.
4 To under take a search for genes in the region nearest the breakpoint on
chromosome 1 using a cDNA selection technique, coincident sequence cloning
CSC.






2 Materials and Methods:
Materials and Methods
All chemical were supplied by BDH unless otherwise stated.
All solutions and methods were taken from or adapted with minor modifications from
Sambrook et al (1989) unless otherwise stated.
2.1 Yeast Cell Culture and DNA Extraction
2.1.1 Media and solutions
All media were sterilised by autoclaving
AHC broth and agar
AHC is a rich selective medium which lacks uracil and tryptophan. It was used for
selective growth of YAC recombinants prior to the isolation of YAC DNA.
In 11 water dissolve 1.7g yeast nitrogen base (without amino acids and NH4S04)
(Difco), 5g NH4S04and 10g casein hydrolysate (low salt). Adjust pH to 5.8. 17-20g
of Bacto agar (Difco) were added to each litre of broth to make AHC agar.
Autoclave. Add 50ml filter sterilised 40% glucose and 10ml of 2mg/ml adenine
sulphate.
YPD broth and agar
YPD medium was used for growing yeast cultures.
In 1 litre water dissolve 20g bactopeptone (Difco), 5g yeast extract (Difco) and 5g
NaCI. Add 1.5% agar for YPD agar. Autoclave. Add 40% sterile glucose.
SCE )
In 500ml water dissolve 1M sorbitol, 0.1M Na3Ci, 60mM EDTA, pH7.
2.1.2 Extraction of yeast DNA
A 5ml yeast cell culture was grown overnight in AHC at 30°C and was centrifuged
for 4 mins at 3000rpm (in a Sorvall T6000). The pellet was resuspended in 10ml 1M
sorbitol, 0.1 M EDTA solution, pH7.4 and transferred to a microfuge tube. 0.4ml of
2.5mg/ml zymolyase was added to break down the cell wall, and the tube incubated
at 37°C for 2 hours. The tube was then centrifuged for 1 min at 11,000rpm, the
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supernatant discarded and the pellet resuspended in 10ml of 50mM Tris.HCI pH7.4,
20mM EDTA.
0.5ml of 20% SDS was added, and mixed in carefully but thoroughly, before
incubation at 65°C for 30 mins. The proteins were then precipitated by adding 4ml
5M KAc, pH5.4. The tube was then left on ice for 1 hr, then centrifuged at
100,000rpm for 5 mins. The supernatant was transferred to a fresh tube and 1
volume of isopropanol was added. This was mixed and left at room temperature for
5 mins, before centrifuging at 11,000 rpm for at least 10 mins. The supernatant was
then removed with a pastette, and the pellet left to air dry. The pellet was then
resuspended in 6ml 10mM Tris 1mM EDTA, pH 7.4 (TE). RNA was removed by
digesting with 30pl 10mg/ml pancreatic RNase (Sigma) at 37°C for 30 mins. The
DNA was then precipitated by adding 300pl 5M NaCI and 18ml 100% ethanol, and
then pelleted by centrifugation. The supernatant was then removed, the pellet was
washed in 500pl of cold 70% ethanol and air dried. The pellet was then
resuspended in 1ml TE, pH7.4.
2.2 Bacterial Cell Culture and Plasmid DNA Preparation
2.2.1 Media and solutions
All media were sterilised by autoclaving.
Terrific broth
In 900ml water dissolve 12g tryptone (Difco), 24g yeast extract (Difco), 4g glycerol.
Autoclave then add 100ml autoclaved phosphate solution (0.1 M kh2p04 & 0.72M
k2hpo4).
L-Broth and agar
In 1L of water dissolve 2.46g MgS04, 10g tryptone (Difco), 5g yeast extract (Difco)
and 10g NaCI. 15g agar (oxoid Ltd) was added per Litre broth for L-agar.
Ampicillin (Sigma)
Ampicillin was added to agar and broth in order to select for bacteria carrying
plasmids which confer resistance to this antibiotic.
Make stock at 50mg/ml in dH20, filter sterilise. Store at -20°C.
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Use at final concentration 50pg/ml.
Materials andMethods
5-Bromo-4-Chloro-3-lndolyl [3-D- Galactopyranoside (X-Gal) (Sigma)
X-Gal acts as a substrate for (3-Galactosidase. It was added to agar for the growth
of plasmids carrying blue/white colour selection (see section 2.5.6).
Make stock at 20mg/ml in DMF (Sigma). Store protected from light at -20°C.
Use at final concentration of 40pg/ml.
Isopropyl [3-D- Thioqalactopyranoside (IPTG) (Sigma)
IPTG is a derepressor of the Lac operon. It was added to agar for the growth of
plasmids carrying blue/white colour selection.
Make stock at 100mM. Store protected from light at -20°C.
Use at final concentration of 0.5mM.
Hoqness Solution
3.6mM K2HP04, 1.3mM KH2P04, 2mM Na3Ci.2H20, 1mM MgSO4.7H20, 4.4%
glycerol.
Make stock at 10x concentration. Filter sterilise.
GTE
50mM glucose, 10mM EDTA, 25mM Tris.HCI (pH 8)
Use autoclaved Tris and EDTA. Sterile filter the glucose.
2.2.2 Growing bacterial cells on agar plates
The desired volume (up to ~200gl) of bacterial cells is pipetted onto the surface of
the L-agar, and is then spread by a sterile bent glass rod until the liquid has
thoroughly soaked into the agar. (If more cells than are contained in 200pl are
required, the cells may be concentrated by 1min centrifugation in a microfuge
followed by resuspension of the pellet in a smaller volume.) The plates are then
inverted and incubated for 12-16 hours at 37°C. Cells were viable from plates stored
at 4°C for several weeks.
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2.2.3 Frozen stocks of bacterial colonies
The selected colony was re-streaked on a fresh L-agar plus ampicillin plate, then a
single colony from the new plate was used to inoculate 5ml of Terrific broth plus
ampicillin. After incubation at 37°C for approximately 16hrs, a 1/10 volume of 10x
Hogness solution was added to 1ml of the culture in a standard 1.5ml eppendorf
tube (Treff). This was then frozen and stored at -70°C.
To reactivate cells from frozen stocks, a plastic loop was passed across the surface
of the frozen culture and sufficient cells would be picked up to spread on an L-agar
plate and grow at 37°C.
2.2.4 Use of colony picker
A colony picking robot (Hybaid) was used according to the manufacturer's
instructions to spot the CSC product library colonies onto filters and in the
preparation of their frozen stocks.
2.2.5 Extraction of plasmid DNA (small scale)
The method used was a modification of the alkaline lysis method of Jones and
Schofield (1990).
The desired colony on an agar plate was used to inoculate 6ml of Terrific broth plus
ampicillin and was grown at 37°C overnight with continuous shaking at 250rpm. The
culture was then centrifuged for 1min in a standard 1.5ml eppendorf tube, adding
I.5ml of the culture at a time and retaining the pellet. The pellet was then
resuspended in 200pl GTE (50mM glucose, 10mM EDTA, 25mM Tris.HCI (pH 8)
and left on ice for 5mins. Next, to lyse the bacterial cell wall and denature the DNA,
500pl of freshly prepared 0.2M NaOH/1% SDS was added, mixed thoroughly by
vortexing and left on ice for 5mins. To neutralise, 250gl of 3M KAc (pH 4.8) was
then added, mixed thoroughly as before and left on ice for 10 mins.
To remove the cellular debris, the tube was centrifuged twice for 10 mins at RT at
II,000rpm and in each case the supernatant was retained. RNase A (Sigma) was
then added at a final concentration of 20|ag/ml and left at 37°C for 10mins. The
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supernatant was extracted twice with 200pl chloroform (Fisons), mixing the layers
thoroughly by vortexing and then separating them by centrifugation for 1min.
The DNA was then precipitated by adding an equivalent volume of 100%
isopropanol (Fisons) and immediately centrifuging for 10 mins at room temperature.
The supernatant was discarded and the pellet then washed briefly in 500pl 70%
ethanol and dried under vacuum.
2.2.6 Precipitation with polyethylene glycol (PEG)
The DNA prepared for ABI sequencing was subjected to a further precipitation. The
pellet was resuspended in 33.6pl dH20, then 6.4pl NaCI and 40pl autoclaved 13%
PEG80oo were added. After thorough mixing, the tube was incubated for 20 mins on
ice and then the DNA was precipitated by centrifugation for 15 mins at 4°C. The
supernatant was then removed and the pellet dried under vacuum. The pellet was
then resuspended in 20pl of dH20. To check the concentration of plasmid DNA
recovered, 1pl of the 20|iil was run on a 0.8% agarose gel, and the intensity of the
bands compared with standards.
2.2.7 Extraction of plasmid DNA (large scale)
The selected bacterial colony was grown overnight at 37°C, with shaking at 250rpm,
in 4ml Terrific broth plus ampicillin. This 4ml was then used to inoculate a further
400ml of Terrific broth for an overnight culture. This culture was then centrifuged in
50ml volumes at 4000rpm for 20mins at 4°C. The pellet was then resuspended in
16ml GTE and left for 5mins on ice. Next, 32ml of freshly prepared 0.2M NaOH/1%
SDS was added, mixed thoroughly by vortexing and left for 5mins on ice, before
adding 16ml 3M KAc (pH 4.8), again mixing and leaving for 10 mins on ice.
The tubes were then centrifuged at 4000rpm for 20 mins at 4°C and the supernatant
retained. This supernatant was filtered under gravity through 4 layers of gauze into
fresh centrifuge bottles. 36ml of isopropanol was then added and the bottles spun
immediately at 4000rpm for 10 mins at 4°C. The supernatant was discarded and the
pellet was washed with 20ml of 70% ethanol and centrifuged at 4000rpm for 10
mins at 4°C. The supernatant was once again discarded and the bottles drained.
The pellet was resuspended in 2.5ml TE (pH 8) and transferred to a Universal tube.
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3.55g CsCI and 200gl of EtBr (5mg/ml stock) (Boehringer Mannheim) were added
and the solution transferred to a 'quickseal' tube (Beckmann). A balance tube was
made up if necessary with TE, CsCI and EtBr. The tube was then spun for 20hrs at
80,000rpm at 20°C in a fixed angle rotor. The plasmid band was then carefully
extracted through the side of the tube with a needle and syringe and placed in a
15ml tube. The plasmid DNA was then extracted three times with a 0.25x volume of
CsCI-saturated isopropanol. Water was then added to increase the volume
approximately twice, and then the DNA was ethanol precipitated. The resulting
pellet was resuspended in 1ml water and the concentration of plasmid DNA
checked by running 1 pi on a 1% agarose gel and comparing the band intensities
with standards.
2.3 Extraction of cosmid and PAC DNA
Cosmid and PAC DNA was extracted as described above (2.2.7) large scale
plasmid preparation.
2.4 Extraction of genomic DNA from Cultured Cells
Frozen cell pellets were allowed to thaw before being resuspended in TNE (10mM
Tris, pH 8.0; 1mM ethylenediaminetetra-acetic acid (EDTA); 150mM NaCI). The
cells were then lysed by the addition of 2.5ml lysis buffer (0.5% sodium dodececyl
sulphate (SDS);150mM NaCI; 100mM Tris.HCI, pH 8; 100mM EDTA). RNA was
digested by the addition of 300pg RNase A (Sigma) and incubated at 37°C for 15
minutes. Proteins were then digested by the addition of Proteinase K (Boehringer
Mannheim) at 0.5mg/ml with incubation overnight at 50°C. An equal volume of water
saturated phenol was then added to the extracts and mixed thoroughly before being
centrifuged at 3000rpm for 5 minutes. The aqueous layer was removed and
extracted with an equal volume of 1:1 Phenol/chloroform in the same way as
described above. The aqueous layer was removed and then extracted with an equal
volume of chloroform. The DNA was then precipitated from the aqueous layer with
0.5 volumes of 7.5M ammonium acetate and two volumes of ethanol. The DNA was
spooled out of the solution onto a glass rod and allowed to air dry. The DNA was
then washed in 70% ethanol and again allowed to air dry. The DNA was then
dissolved in 200pl TE (10mM Tris.HCI pH 7.5; 1mM EDTA).
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2.5 Cloning of DNA Molecules into Plasmid Vectors
2.5.1 Plasmid vector
The plasmid vector used was pBluescribe (pBS; Stratagene) which is a 2746bp
plasmid derived from pUC19 (Yanisch-Perron et al, 1985). It contains an ampicillin
resistance gene and a multiple cloning site flanked by T3 and T7 promoters.
All the DNA molecules cloned possessed cohesive termini, which were compatible
with a restriction enzyme site in the multiple cloning site of pBS. The digested insert
molecules were therefore directly ligated into pBS linearised with the appropriate
enzyme. So as to prevent recircularisation of the plasmid during ligation the 5'-
phosphate groups from the vector were firstly removed by phosphatase treatment.
The circular plasmid containing an insert of DNA was then used to transform
competent cells.
2.5.2 Strain of bacteria used
The competent cells were made from E.coli, strain XL1-Blue (Stratagene). The
genotype of XL1-Blue cells is: recA1 endA1 gyrA96 thi-1 hsdR17 supE4 relA1 lac
[F' proAB laclq ZAM15 Tn10 (Tetr)j
2.5.3 Preparation of competent cells for electro-transformation
XL1-Blue bacterial cells were taken from a frozen stock using a sterile loop and
streaked out onto a fresh L-agar plate and grown at 37°C overnight. One of the
resulting colonies was then used to inoculate 10mls of Terrific broth plus
tetracycline, which was left at 37°C in a shaking incubator overnight. This whole
culture was then used to inoculate 11 of Terrific broth, and this was grown shaking at
37°C. The absorbance at 600nm of the culture was continually checked on a
spectrophotometer.
The cells were harvested when the Abs6oo was between 0.5 and 1.0, which is still in
the log phase of growth. The flask containing the culture was then chilled on ice for
15-30 mins then the contents were centrifuged 50ml Falcon tubes (which had been
left on ice) for 15 mins at 4000rpm at 4°C. The supernatant was discarded and the
pellets resuspended in a total of 11 of sterile water before centrifugation as before.
The pellets were resuspended in a total of 500ml sterile water and re-centrifuged.
Pellets were then resuspended in 20ml of 10% glycerol and centrifuged again. The
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final resuspension was in 2-3ml of 10% glycerol. This cell suspension was then
aliquoted into 40gl volumes in 1.5ml eppendorf tubes and snap frozen on dry ice
plus methanol (Fisons). The aliquots were stored at -70°C.
2.5.4 Test transformation of competent cells
In order to quantify the competence of the cells prepared as above, they were
subjected to a test transformation using 1ng of pBS vector alone as the
transforming DNA. Cells transformed with pBS contain an ampicillin resistance gene
and can therefore be selected for on L-agar plus ampicillin plates. The competence
of the cells is measured in colony forming units (cfu's) per ,ug of transformed DNA.
Values of 107 to 5x108 cfu's/gg pBS were routinely achieved.
2.5.5 Electro-transformation of competent cells
An aliquot of competent cells was thawed on ice, and the transforming DNA (usually
1gl of the ligation reaction) was added, mixed with the cells and left on ice for 1min.
This mixture was then transferred to an ice-cold cuvette (Flowgen) and subjected to
a pulse of 2.5kV in a BioRad Gene Pulser. The cells were swiftly mixed with 1ml of
Terrific broth, transferred to an eppendorf tube and left at 37°C for 1 hr to enable the
cells to begin to express the ampicillin resistance gene conferred by the
transformed plasmid. Aliquots of several different volumes were then spread onto L-
agar plus ampicillin plates and incubated overnight at 37°C.
2.5.6 Selection for colonies that contain recombinant plasmids
Selection of colonies containing recombinant plasmids was achieved using
blue/white colour selection. The polylinker of the vector pBS interrupts the (3-
galactosidase producing gene, lac Z. This disruption is in-frame and results in a
harmless insertion of a few amino acids into the [3-galactosidase gene. Expression
of this gene within bacterial cells can result in the production of a blue colour if the
medium on which the cells are grown contains the chromogenic substance X-Gal
and the derepressor of the Lac operon, IPTG. If however the polylinker site in the
plasmid is interrupted by an insert of foreign DNA, a functional (3-galactosidase
enzyme cannot be transcribed and hence the resultant colonies are white.
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2.6 Electrophoretic analysis of DNA
2.6.1 Electrophoresis solutions
Materials and Methods
Stock solutions of electrophoresis buffers were made:
20x TAE
0.8M Tris.HCI, pH 8.0; 20mM EDTA; 0.4M acetic acid.
20x TBE
1M Tris.HCI, pH8.0; 20mM EDTA; 1M boric acid, pH8.3.
Electrophoresis gels were run in 1X electrophoresis buffer.
10x DNA Loading Buffer
20% Ficoll (Pharmacia), 100mM EDTA, orange G (Sigma).
6% Polyacrylamide Gel (for ALF automated qenotypinq)
Gels were made up with 6% Hydrolink (Long Ranger™, AT Biochemicals Ltd) in
0.6X TBE (0.06 M Tris base, 0.05M boric acid, 0.6mM EDTA)containing 7 M urea.
2.6.2 Size markers used in Gel Electrophoresis
250-500ng of the appropriate size marker was used per gel. Size markers used
were:
a) 7 DNA digested with HindiII (Boehringer Mannheim)
b) pX174 digested with Haelll (Boehringer Mannheim)
c) 1kb ladder (Gibco BRL)
The sizes of the bands in A.Hind III, pX Hae III and the 1 kb ladder are listed in Table
2.1.
Table 2.1: Band sizes of markers X Hind III, pX Hae III and 1 kb ladder.



























2.6.3 Agarose gel electrophoresis
DNA molecules were separated according to their size on horizontal agarose
medium EEO (Sigma) gels. The percentage of agarose used to make the gel
depended on the size range of the DNA molecules to be resolved. Digested
genomic DNA or plasmid DNA was commonly run on 0.8-1% agarose gels, whereas
smaller fragments, such as most PCR products, were run on 1-2% agarose gels. All
agarose gels were made with and run in either 1XTAE or 1XTBE. To stain the DNA,
ethidium bromide was added to all agarose gels and to the running buffer at a
concentration of 250pg/ml of buffer. 1X loading buffer was added to the DNA prior
to loading the sample on the gel. Gels were run at 25-80V depending on resolution
and run-time required.
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DNA fragments were visualised on a mid range UV transilluminator and
photographed using a video copy processor (Mitsubishi).
2.6.4 Polyacrylamide Gel Electrophoresis on Automated Laser
Fluorescent (ALF) Sequencing gels for allele genotyping
Electrophoresis was carried out on a 40-lane automated laser fluorescence (ALF)
sequencer (Pharmacia) using 6% polyacrylamide gels in 0.6X TBE (0.06 M Tris
base, 0.05M boric acid, 0.6mM EDTA) and run in the same buffer at constant power
(55W) and constant temperature (50°C).
After the PCR reaction the products from both reactions (D11S931 and D1S1621),
for the same patient, were run in the same lane on the ALF sequencer (since the
products are of different size) with appropriate size markers and gold standards.
Automated genotyping was carried out using 'ALF' manager and 'ALP' software.(Fie
et al 1995, Mansfield et al 1994 ). All gel results were also checked manually.
2.7 Purification and Concentration of DNA
2.7.1 Ethanol precipitation
To concentrate DNA and remove salts, a 1/10 volume of 2M NaAc, pH 5.5 was
added to the DNA solution, followed by 2-3 volumes of 100% ethanol at -20°C. The
contents of the tube were mixed and then chilled at -70°C for 1hour to overnight.
The tube was then centrifuged at 11,000rpm for 15 mins at 4°C. The supernatant
was poured off, and the pellet dried under vacuum. The pellet was then
resuspended in the desired volume of dH20.
2.7.2 Phenol/chloroform based extraction
To remove proteins from DNA samples, the DNA was extracted with organic
solutions. Two methods were used:
PPhenol/ chloroform extraction:
DNA was extracted twice with a phenol/water/chloroform mixture (Applied
Biosystems). A 1/10 volume of this organic mixture was added to the DNA solution
to be extracted, vortexed vigorously and then centrifugation at 11,000rpm for 2
mins. The upper, aqueous layer was then removed carefully, avoiding the
80
Chapter Two Materials and Methods
precipitated protein at the interface between the two layers. The DNA was then
recovered by ethanol precipitation.
2) Chloroform/isoamylalcohol/ether:
DNA was extracted first with a 1/10 volume mixture of chloroform
(Fisons)/isoamylalcohol (Sigma) in a 24:1 ratio. A second extraction was then
performed with an equal volume of water-saturated ether (Fisons). After separation
of the aqueous layer from the ether, the tube was left open to the air for 10 mins to
allow evaporation of any residual ether, and then DNA was ethanol precipitated.
2.7.3 Drop dialysis
DNA solutions were drop dialysed to remove salts. A 0.025pm drop dialysis filter
(Millipore) was placed on the surface of a pool of sterile water in a Petri dish. After 5
mins, the DNA solution (maximum 20pl) was placed as a drop onto the surface of
the filter and left for 30 mins, during which the concentration of salts in the sample
equilibrates with the water. The drop was then 'sucked back up' into a clean tube.
2.7.4 Purification of DNA from agarose gels
DNA fragments were run in low melting point agarose (Ultrapure LMP agarose,
Gibco BRL) in 1x TAE. Gels were viewed on a mid range UV transilluminator and
the required fragment was excised using a sterile scalpel blade as quickly as
possible to minimise nicking of the DNA. Care was taken to ensure that a minimum
of agarose was excised with the required DNA band.
Isolation of DNA from gel slices was by agarase treatment. The gel slice was diluted
with water to decrease the percentage agarose, then 1/25 volume of 25x agarase
buffer (Boehringer Mannheim) was added. Large gel slices were split into aliquots of
~100pl each. The gel slices were then melted at 70°C for 10 mins, during which
they were vortexed and spun down several times to ensure they were properly
melted. The slices was left to cool to 37°C, then 1gl (0.5-1 unit) agarase (Boehringer
Mannheim) per 10Opil was added. The reaction was left to proceed for 2hrs at 37°C,
then the DNA was ethanol precipitated at -70°C from 1 hr to overnight.
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2.7.5 Geneclean (Bio 101 Ltd)
The Geneclean Kit was used to purify DNA from agarose gel slices in accordance
with manufacturers instructions.
2.8 Transfer of DNA to membranes
2.8.1 Southern Blot transfer
DNA was transferred from gels to nylon membranes by capillary blotting. This
method was adapted from Southern (1975).
Gels were photographed next to a ruler to allow for future sizing of DNA fragments.
Firstly the DNA was denatured by gently shaking the gel in denaturing solution
(0.5M NaOH, 1.5M NaCI) for 30-45 minutes. The gel was then neutralised by gently
shaking in neutralising solution (1M Tris.HCI, 2M NaCI, pH 5.5) for 45 minutes and
then rinsed. A large strip of 3MM filter paper (Whatman) was soaked in 20 X SSC
(3M NaCI, 0.3M Na3C6H507.2H2O, pH7.0) and placed on a glass plate so that the
ends of the paper were in a reservoir of 20x SSC, forming a wick. The gel was
placed on top of the wet filter paper, then a correctly sized piece of nylon membrane
(Hybond-N, Amersham), was placed directly onto the gel. Two pieces of 3MM
blotting paper, pre-soaked in 20x SSC, were placed on top of the membrane. Air
bubbles were removed carefully. Any exposed wick was screened off with Saran
wrap (Dow Chemical Company), then a weighted stack of paper towels was placed
on top.
Gels were blotted for were blotted for 5 hours to overnight. After blotting, the
membranes were left to air dry, and then DNA was bound to the filter by exposing it
to 1200|iJoules of UV irradiation in a Stratalinker (Stratagene) or baked at 80°C for
1hour. Nylon membranes were stored in Saran wrap or between two sheets of 3MM
paper at room temperature.
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2.8.2 Transfer of bacterial colonies and phage plaques to filters and
replication of filters
Plates containing phage plaques had to be placed at 4°C for at least 15 minutes
prior to lifts being taken to ensure that the top agar was not removed during the
procedure. Nitrocellulose (Schleicher and Schuell) or nylon (Hybond-N, Amersham)
circular filters were marked with an asymmetric pattern of dots and placed carefully
on the surface of the agar plate, avoiding air bubbles. The filter was left on the
surface for approximately 10 sees while the pattern of orientation dots from the filter
was transferred onto the bottom of the Petri dish. The filter was then removed
carefully, avoiding smearing the colonies/plaques, and placed face up. The bacterial
colonies on the agar plates were left at 37°C for several hours to 'recover'. A
second lift could be taken from the phage plates if required after a further 15
minutes at 4°C.
2.8.3 Fixation of the bacterial colonies / phage plaques to filters by lysis
One sheet of 3MM paper was soaked in 10% SDS and the filters were placed face
up and left for 5 minutes. The filters were then removed and placed on 3MM paper
which had been soaked in denature solution (1.5M NaCI, 0.5M NaOH) and again
left for 5 minutes before being transferred to neutraliser solution (1.5M NaCI, 0.5M
Tris.HCI (pH 7.5))again on 3MM paper for 5 minutes. The final stages was to soak
the filters in 2X SSC for 5-10 minutes. The filters were left to air dry and were then
baked at 80°C in a vacuum for 20 mins (nitrocellulose) or UV irradiated as in section
(nylon).
2.9 Radiolabelling of DNA
2.9.1 Preparation of DNA for probes
Probe DNA was in two forms, either in solution or contained within a gel slice. 25-
50ng was labelled for a single hybridisation. DNA for gel slice hybridisation probes
was excised from an Low Melting Point (LMP) gei after electrophoresis and diluted
with 1-3 times (depending on concentration) its volume of water. The gel slice was
melted at 65°C and vortexed, before storage at -20°C. Before use in a labelling
reaction, the gel slice was remelted at 70°C.
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2.9.2 Random Priming of DNA probes
This method is adapted from Feinberg and Vogelstein (1983 and 1984).
A labelling reaction with [a-32P]-dCTP involves random priming from
hexanucleotides and then polymerisation along the DNA strand catalysed by the
Klenow fragment of E.Coli polymerase 1. A radiolabeled base is incorporated at
every C nucleotide.
The DNA strands were firstly denatured by heating to 100°C for 5-10 mins. DNA in
solution was then kept on ice to prevent reannealing of the strands. DNA in a gel
slice form was allowed to cool slightly before the labelling reaction. The labelling
reaction was carried out using either a Random Prime kit (Boehringer Mannheim) or
a Hi-Prime kit (Boehringer Mannheim). For the random prime kit, 11 pi total of DNA
plus water was mixed with 3pl 10pCi/pl [a-32P]-dCTP (Amersham), 1 pi (2 units)
Klenow enzyme, 1 pi each of dATP, dTTP and dGTP and 2pl reaction buffer. For the
Hi-Prime kit, 13pl of DNA plus water was mixed with 3pl 10pCi/pl [a-32P]-dCTP and
4pl Hi-Prime (which contains the enzyme, nucleotides and buffer). The reactions
were then incubated at 37°C for 1 hour (Random Prime or Hi-prime with a gel slice)
or 10 mins (Hi-Prime with DNA in solution).
The percentage incorporation of the radiolabeled nucleotide was checked by TCA
precipitation of ~0.5pl of the reaction mix on a GF/B circular filter (Whatman). If the
incorporation was 50% or above, the unincorporated nucleotides were removed by
running the probe through a Sephadex G-50 Nick column (Pharmacia Biotech). The
storage buffer was removed and then the column was washed by running through
~500pl TE. The probe (~20pl) was then added to the top of the column, followed by
380pl TE. The probe was then eluted with a further 400pl TE, and collected in a
tube containing 500pg sonicated salmon sperm DNA (Sigma). The probe was
denatured by heating to 100°C for 10 mins and added to the prehybridisation
solution in the bottle.
Hybridisation probes were "stripped" in order to minimise hybridisation occurring
due to high copy number repetitive elements in the probe. The probe was denatured
at 100°C for 10 mins in the presence of 500pg sonicated salmon sperm DNA and
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250gg sonicated total human genomic DNA. It was then left to reanneal for 40




5x SSC, 10% dextran sulphate, 0.1% sodium pyrophosphate, 0.1% SDS and 5x
Denhardt's solution. 5x Denhardt's solution contains 0.1% ficoll, 0.1% PVP and
0.1% BSA (Sigma). Filter before use.
2.10.2 Prehybridisation of filters
Under a solution of 2x SSC, the filter was placed between two slightly larger sheets
of gauze. For hybridisation to multiple filters with a single probe, up to 3 layers of
filters could be placed in the same bottle, with layers of gauze separating them. Air
bubbles trapped between the filter and the gauze were removed. The filter and
gauzes were then rolled up together, transferred to a glass hybridisation bottle
(Hybaid) and unrolled onto the surface of the bottle.
Denatured sonicated salmon sperm DNA was added to the prehybridisation solution
at a concentration of 100|ig/ml. 12ml of prehybridisation solution was added to a
small bottle and 18ml to a large bottle, and the bottle rotated in an hybridisation
oven (Hybaid) at 68°C for a minimum of 1 hour before adding the probe.
2.10.3 Hybridisation conditions
For random-primed probes, hybridisations were carried out at 68°C overnight.
2.10.4 Washing conditions
Following hybridisation, the filters were removed from the bottle and separated from
the layers of gauze. In a plastic tray, the filters were washed with 3 changes of
~500ml washing solution (0.1-2X SSC, 0.1% SDS) using gentle agitation. The
temperature of the wash and the concentration of SSC depended on the washing
stringency required. For random-primed probes, a high stringency wash (3x 15 mins
in 0.1 x SSC, 0.1% SDS at 68°C) was commonly used.
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The filters were then wrapped in Saran wrap (Dow Chemical Company), avoiding
creases.
2.10.5 Detection of hybridisation signal
Autoradiography :
The filters were placed in a light-tight cassette with a signal enhancing screen. They
were then exposed to X-OMAT x-ray film (Kodak) for a length of time dependent on
the amount of radiolabeled probe left bound to the filter (several minutes to several
days). Filters hybridised to 32P-labelled probes were exposed at -70°C. Stratagene
Glogos II luminescent markers were used for alignment. The film was developed on
an automatic x-ray film processor RGII (Fuji).
Phosphorimaqinq Alternatively, the filters were exposed to a phosphor screen
(Molecular Dynamics) for hours to several days. The screen was then scanned on a
Phosphorlmager (Molecular Dynamics), where a laser beam converts the
radioactive signal into a digital image, with variations in the pixel value proportional
to the amount of radioactive signal present. The grey-scale image was adjusted as
desired and was then printed on a laser printer.
2.10.6 Removal of radioactive probe from filters
Since hybridisation filters can be used several times with different hybridisation
probes, removal of radioactive probes from the filters is often required. This can be
achieved in one of two ways. Firstly, the filters could be washed in 0.4M NaOFI at
50°C for 30 mins, to denature the probe DNA strand from the surface of the filter.
The neutral pH was then restored by a 30 min wash in 0.1x SSC, 0.1% SDS, 0.2M
Tris.HCI, pH 7.5, also at 50°C. Alternatively the filters could be subjected to one
very stringent wash, in 0.1 % SDS or in distilled water at 100°C for 5 mins.
The filters were then exposed to x-ray film overnight to check that all the probe had
been removed.
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2.11 Enzymatic Manipulation of DNA
2.11.1 Restriction enzyme digestion of DNA
Digestions of DNA with restriction endonucleases were carried out in the
appropriate buffer at the temperature recommended by the manufacturer.
Restriction enzymes were supplied by Boehringer Mannheim, NEB and Gibco BRL.
1-1 Opg of DNA was digested in 10-40pl containing 1/20 volume 0.1 M spermidine
(Sigma), using 1 unit of enzyme per pg of DNA cut. The reaction was left at the
appropriate temperature for 11/2 hours to overnight. Somatic cell hybrid, total human
genomic and YAC DNA was always digested overnight. If two different enzymes
were used, both of which required the same buffer, the digests were carried out
simultaneously. Otherwise, after digestion with one enzyme, the sample was drop
dialysed for 30 mins or ethanol precipitated. The appropriate buffer was then added
and the second digestion carried out. When necessary, reactions were terminated
by heating to 68°C or 80QC for 15 minutes, according to the heat sensitivity of the
enzyme (NEB Catalogue, 1992). Restriction digests which were to be run on gels
were terminated by the addition of 1/10th of their volume of "stop mix" (100mM
EDTA, pH8.0; 20% Ficoll and Orange G).
2.11.2 Dephosphorylation of 5' termini
Calf intestinal phosphatase (CIP) was used to dephosphorylate the 5' ends of the
vector molecules before cloning. This prevents recircularisation of vector molecules
during the ligation step.
7gg DNA was dephosphorylated with 0.1 unit CIP (Boehringer Mannheim) in 50pl 1x
CIP buffer (10mM Tris.HCI, pH 8.3, 1mM ZnCI2, 1mM MgCI2) at 37°C for 30 mins.
The reaction was stopped by the addition of 1 ptl of 0.5M EDTA. The
dephoshorylated DNA was then chloroform/isoamyl alcohol then ether extracted
and ethanol precipitated. The pellet was resuspended in 10pl TE.
2.11.3 Phosphorylation of 5' termini
Addition of a phosphate group to a DNA strand ('kinasing') is by transfer of the
terminal phosphate of yATP. It is necessary to kinase oligonucleotides before they
can be ligated to restriction enzyme digested DNA.
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4|ig oligonucleotide DNA was mixed with 1pl (10 units) polynucleotide kinase (PNK;
Boehringer Mannheim) and 0.5-1mM ATP (Boehringer Mannheim) in 1/10 volume
10x PNK buffer (50mM Tris.HCI, pH 7.5, 10mM MgCI2, 5mM DTT) in a total volume
of 50pl. The reaction was incubated at 37°C for 30 mins. The sample was then
chloroform/isoamylalcohol then ether extracted and ethanol precipitated. A recovery
of 25% was assumed.
2.11.4 Ligation of cohesive termini
The insert DNA and the vector DNA were mixed on ice, typically in a ratio of 5:1
vector to insert. 10-100ng of vector DNA was normally used. The reaction was
carried out in 10-50pl using 0.1 unit of bacteriophage T4 DNA ligase (Boehringer
Mannheim), in 1x ligase buffer (66mM Tris.HCI, pH 7.5, 5mM MgCI2, 1mM DTT,
1mM ATP). The ligation mixture was then incubated at 16°C overnight. The enzyme
was then inactivated by heating to 65°C for 15 mins.
For a trial ligation, 100ng of bacteriophage X digested with Hind III was religated
under the same conditions. The extent of ligation could be visualised by running the
religated product on a 1% agarose gel.
2.12 Oligonucleotides
2.12.1 Oligonucleotide Synthesis
Oligonucleotides were either synthesised (by Agnes Gallagher) as ammonium
stocks on an Applied Biosystems 381A oligonucleotide synthesiser or were
purchased from Genseis. Oligonucleotides for magnetic bead capture were
synthesised incorporating a 5' biotin moiety. Oligonucleotides for use in the allelic
association study were fluorescently labelled.
Oligonucleotides were precipitated from ammonium stocks by ethanol precipitation
of 350pl of the stock. The precipitated DNA was resuspended in 500pl water and
the concentration assessed by measuring the Abs26o- An absorbance of 1
corresponds to a concentration of 25pg/ml for single stranded DNA.
The oligonucleotides that were obtained from Genesis Ltd were in lyophilised form.
88
Chapter Two Materials and Methods
2.12.2 Oligonucleotide primer Design
The recombinant DNA inserts in the plasmid pBS were amplified using two
published primers; 291 and 292 ('forward' and 'reverse' primers from Stratagene
catalogue, see Table 2.2 for sequences).
Other primers were designed using the programme Oligo4 (Hybaid). Primers were
between 18 and 46 nucleotides in length depending on the DNA source on which
they would be used. They were chosen to be stable oligonucleotides with a Tm
between 50°C and 70°C. A maximum hairpin structure or potential dimerism of 3
nucleotides (preferably less) was permissible, but only a 2 nucleotide internal match
if it involved the 3' end. If possible the A+T : C+G ratio was near 50%.
In one instance, it was necessary to synthesise slightly degenerate primers due to
unresolved sequence ambiguities.
2.12.3 Duplexing oligonucleotides
In certain cases it was necessary to form a duplex between two complementary (or
partially complementary) oligonucleotides. The two oligonucleotides (150pg/ml
each) were mixed together in 10jal 1x TM (10mM Tris.HCI, pH 7.5, 5mM MgCI2) and
the tubes were placed in a small volume of water at 90°C. The water was then left
to cool to below 30°C over a period of 15 minutes to 1 hour.
2.13 Amplification of DNA by the Polymerase Chain Reaction (PCR)
PCR is a technique used for the amplification of a specific DNA sequence (Saiki et
al, 1988; Mullis and Faloona, 1987). The specificity is provided by oligonucleotide
primers complementary to the 5' ends of the two strands of the sequence to be
amplified. These primers anneal to the template DNA strand and direct amplification
by a thermostable polymerase. The PCR reaction is a series of cycles, each
consisting of three steps. The first is a short high temperature step (92-94°C) to
denature the template. This is followed by a reduction in temperature to allow the
primers to anneal to the template (~50-65°C depending on the primers used), then
finally the temperature is increased to 72°C (or 68°C for long PCR) to permit
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extension from the primers by the polymerase. Multiple cycles of these three steps
result in exponential amplification of the desired sequence.
2.13.1 PCR conditions
Commonly 100-200ng of template genomic DNA was amplified in 50gl in 0.5ml
microcentrifuge tubes (Robbins Scientific), with 0.2pl (1 unit) Amplitaq (Perkin Elmer
Cetus) in 1x reaction buffer (10mM Tris.HCI, pH 8.3, 50mM KCI, 1.5mM MgCI2,
0.01% (w/v) gelatin) and 0.1% Triton X-100 (Sigma). The reaction employed 300ng
of each primer and 200pM each dNTP (Advanced Biotechnologies). The reaction
was overlaid with 40pl mineral oil (Sigma).
PCR programmes were run on an Hybaid Omnigene machine or Perkin Elmer
Cetus DNA thermal cycler. The basic programme was 30 cycles of denaturation
annealing and extension steps
The denaturation step was usually short and at a temperature of 93-94°C. Usually
1-2mins in the first cycle and 15-30 sees thereafter. The annealing step temperature
is critical in determining the success of the PCR reaction, and is dependent on the
structure of the primer. Primer Tm's were determined using the Oligo 4 programme
(Hybaid) and annealing temperatures of ~5°C lower than the Tm was used.
Annealing steps were 30 sees to 1 min long.
The extension step is carried out at 72°C. The extension time is also critical in
determining the success of the PCR, since longer products need longer extension
times (approximately 1 min per kb of sequence). The length of the extension time
was generally the time estimated for effective elongation of the fragment required
with a longer final extension time to ensure fragments were complete.
After the reaction, 10pil of the PCR reaction was visualised by electrophoresis on
0.8-2% agarose gels.
'Hot Start' PCR (Chou et al, 1992) was commonly used if increased specificity in the
PCR reaction was required. The PCR reaction was set up as 2 separate mixes, one
containing the DNA and primers, the other containing the enzyme, buffer and
nucleotides. The mixes were heated to 90°C for several minutes, before combining
them. Addition of the enzyme to the DNA at a temperature at which the DNA is
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denatured helps to prevent mispriming before the initial denaturing temperature is
reached.
Touch Down' PCR (Don et al, 1991) was also used to increase specificity of the
PCR reaction and involves decreasing the annealing temperature by 2°C per cycle
until the final annealing temperature is reached. This means that during the first few
critical cycles, only highly specific primer-template interactions can occur, which
selects for amplification of the correct product during the rest of the reaction. An
annealing temperature 10°C above the calculated value was used in the first cycle,
which decreased by 2°C each cycle until the final annealing temperature was
reached.
2.13.2 PCR amplification of vector inserts from bacterial colonies
This method was adapted from Taylor (1991).
A toothpick stab of a bacterial colony was transferred to a tube containing 50pl of
water. This tube was then heated to 96°C for 4 mins. 1pl of this was then used as
the template for a PCR reaction. Primers used were Universal primers designed to
the polylinker sequence of pBS, 291 and 292 (see table 2.2).
The PCR reaction mix was exactly as in section 2.13.1
The PCR programme used was:
Denaturing: 93°C for 30 sees in first cycle and 15 sees thereafter.
Annealing: 55°C for 30secs.
Extension: 72°C, 10 cycles of 1 min, 10 cycles of 2 mins, 10 cycles of 3 mins.
2.14 Sequencing of DNA
2.14.1 Cycle sequencing of DNA
Sequencing of DNA was done on an ABI automated sequencing machine (Applied
Biosystems). Thermal cycling of sequencing reactions increases signal intensity and
decreases sensitivity to reaction conditions. Dye terminator chemistry was used,
that is dideoxy-nucleotides terminated the sequencing reaction at each base to
generate the ladder of fragments. Each of the four dideoxy-nucleotides is labelled
with a different dye, such that the attached computer can recognise the peak of dye
corresponding to a particular base at each position.
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Plasmid DNA for sequencing was prepared by alkaline lysis followed by PEG
precipitation according to the protocols in sections 2.2.5 and 2.2.6. All other DNA
was also prepared in this way where possible or was sequenced using this method
from PCR products (see next section). The sequencing reactions were performed
using a Taq DyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems)
according to the manufacturer's instructions. Ideally, approximately 200ng plasmid
DNA was used in the reaction, although results were produced with as little as
~20ng. 10ng of either primer 291 or 292 was used per reaction, depending on the
orientation of the sequence required.
The cycle sequencing reaction was performed on a Perkin Elmer Cetus DNA
thermal cycler. The programme was as follows: Place tubes in rack preheated to
96°C. Perform 25 cycles of 96°C for 30 sees, 50°C for 15 sees and 60°C for 4 mins.
Rapid thermal ramp to 4°C and hold.
As much as possible of the mineral oil was removed with a pipette, then the product
was ethanol precipitated, using Applied Biosytems NaAc and 3 volumes of cold 95%
ethanol. The tubes were then placed on ice for 15-30mins, before centrifugation for
15-20 mins at 11,000rpm. The supernatant was then removed, and the pellet
washed with 70% ethanol and spun at 11,000rpm for a further 10 minutes. The
pellet was then vacuum dried for 3 minutes. Immediately before loading onto a
sequencing gel, each pellet was resuspended in 4gl stop mix (1gl of 50mM EDTA,
pH 8, 30mg/ml Blue Dextran to 5pil deionised formamide) and heated to 90°C for 2
minutes to allow the DNA to denature.
The samples were loaded onto a 6% acrylamide gel (prepared by Agnes
Gallagher), which was run in 1x TBE at 2500V, 45mA for 12 hours. The sequence
data was gathered by the computer and displayed as a visual output of differently




2.14.2 Sequencing of PCR products
This method has been modified from Winship, 1989.
Materials and Methods
The PCR product was first purified from a gel in order to separate it from primer
dimers and any spurious products. A large amount of DNA is required in the
reaction itself, so in some cases the product of several PCR reactions was pooled
and concentrated into a smaller volume by ethanol precipitation. The resulting
product was then gel purified by running it on a 1% (typically) LMP agarose gel and
excising the required band. The DNA was recovered from the gel slice by agarase
treatment and ethanol precipitation. The precipitate was resuspended in 10-40jnl
and the DNA concentration checked by running 1pl on a gel next to a known
amount of size marker. Approximately 200ng DNA was used per sequencing
reaction.
Alternatively, the PCR product was purified by excising the band from a 1% agarose
gel. This gel slice was then placed at the top end of a 200pl filter tip (Rainin
Instrument Company Inc.) placed in an epindorff tube and spun at 11,000rpm for 15
minutes at room temperature. The resulting solution was then drop dialysed as in
section 2.7.3 for 45 minutes. A small aliquot of the product was then run on a gel in
order to determine the concentration of the DNA and up to 1pg was used in the
sequencing reaction depending on the size of the product.
Reactions were stored at -20°C until loading on a gel. Prior to loading they were
heated to 80°C for 2 mins to denature the DNA.
2.14.3 Analysis of sequence data
The sequences obtained were edited and manipulated using GCG (Genetics
Computer Group) programmes available through the HGMP Computing service
(Devereux et al, 1984). Database searches were performed using the GCG Blast
(Altschul et al, 1990) and Fasta (Pearson and Lipman, 1988) programmes.
2.15 Coincident Sequence Cloning
Coincident Sequence Cloning (CSC) is a method for isolating the sequences shared
between two DNA resources (see section 6.1). This is achieved by denaturing the
two DNA sources, mixing them ('integration') and then recovering the duplexes
which are formed between the two resources (inter-resource duplexes, IRDs). In
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this context, the two resources used were a pooled resource of PAC DJ4B9/3 and
cosmids B01519 and 10142 from chromosome 1 and a pooled cDNA resource
consisting of three ages of foetal brain cDNA, so that the product should be
transcribed sequences from the PAC and cosmids.
At all times during the preparation of the Source DNAs, their integration and
cloning, great care was taken so that the samples would not become contaminated.
All materials used were dedicated solely to CSC, fresh solutions were made up and
autoclaved, and all labware was washed with water and then ethanol or autoclaved
where possible.
2.15.1 Preparation and digestion of the Genomic DNA resource
PAC and cosmid DNA was isolated using the same method as described for large
scale preparation of plasmid DNA (i.e. CsCI equilibrium density gradient; see
section 2.1.7). The PAC and cosmid DNA were then run out on a 1% LMP gel to
assess the concentration of the DNA. The PAC and cosmid DNA was pooled in the
ration of 4:1:1 . 50ng of the pooled DNA was ethanol precipitated and air dried.
The resulting pellet was resuspended in 5pl 1x restriction enzyme buffer A
(Boehringer Mannheim) and digested with Sau3AI at 37°C for 1 hr. The enzyme
was heat killed by heating at 70°C for 15 mins. The sample was then placed on ice.
2.15.2 Preparation and digestion of the cDNA resource
Oligo-dT primed poly A selected cDNA was prepared from three ages of foetal brain
tissue using an Invitrogen Fasttrack mRNA isolation kit according to manufacturers
instructions. Briefly the technique involved mechanical homogenization of the frozen
tissue in lysis buffer which also inactivates any RNases released as the cells lyses.
After homogenisation the cell lysate was left at 45°C for 15-60 minutes to allow the
cells to fully lyse and complete digestion of proteins and ribonucleases to occur.
950i.il of 5M NaCI was added and mixed by inversion. Any remaining DNA was
sheared by passing the lysate 3-4 times through a sterile plastic syringe fitted with
a 19 gauge needle. Oligo dT cellulose was then added to the lysate and the mixture
incubated for 15-60 minutes to allow the mRNA to bind to the cellulose. ( A typical
mammalian cell contains about 10-11 g of RNA of which only 1-5% is poly A RNA.
The rest is made up of rRNA (80-85%) and tRNA (15-20%). To separate the
94
Chapter Two Materials and Methods
heterogeneous population of mRNA from the other RNA in the cell, affinity binding
to oligo dT cellulose is used exploiting the major characteristic of mRNA,
polyadenylation, to obtain pure intact mRNA).
Once the mRNA has bound the oligo dT cellulose is pelleted by centrifugation at
3000Xg and the supernatant discarded. The cellulose then undergoes a series of
washing stages to remove unwanted cell debris before elution of the mRNA from
the cellulose oligo dT resin. The mRNA is then precipitated with 0.15 volumes of 2M
sodium acetate and 2.5 volumes of ethanol by freezing on dry ice until solid and
then centrifuging at 16000Xg for 15 minutes at 4°C. The pelleted mRNA then used
for cDNA synthesis.
The Invitrogen copykit cDNA synthesis kit was used to convert single stranded
mRNA into double stranded cDNA (based on a modified version of Gubler-Hoffman
(1983) method of cDNA synthesis) according to manufacturers instructions. Briefly
this involved denaturing the RNA at 65°C for 10 minutes and then in rapid
succession adding placental RNase Inhibitor, reverse transcriptase buffer, 100mM
dNTP 80mM sodium pyrophosphate and reverse transcriptase and incubating at
42°C for 60 minutes to allow the first strand cDNA to be synthesised (see
manufacturers handbook for further details) this reaction was then put on ice before
second strand cDNA synthesis was carried out by the addition of second strand
buffer, 1mg/ml BSA, 10mM (3-NAD, 1M DTT, RNase H, E.coli DNA ligase and DNA
polymerase. This was then incubated at 15°C for 90 minutes and then a further 30
minutes at room temperature. The reaction was then stopped by heating to 70°C for
15 minutes prior to the addition of T4 DNA polymerase. This was incubated at room
temperature for 10 minutes (to blunt end the cDNA) and 2pl of 0.5M EDTA was
added to stop the reaction. The cDNA was then cleaned by phenol/chloroform
precipitation and then the addition of 4M ammonium acetate and 3 volumes of
ethanol. After 15 minutes on dry ice this was spun at 3,000Xg for 15 minutes at 4°C
and the pellet retained and dried.
The three ages of foetal cDNA used were 15.3 weeks, 12.2 weeks and 10.5 weeks
of gestation. These cDNA were separately extracted and an aliquot run out on a
1% agarose gel in order to determine their concentration. The cDNA s were then
pooled in equal molar proportions. 100ng of this pooled resource was then ethanol
precipitated and air dried. The pellet was resusupended in 5pl 1x restriction enzyme
buffer A (Boehringer Mannheim) and digested with Sau3AI at 37°C for 1 hr. The
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enzyme was heat killed by heating at 70°C for 15 minutes. The sample was then
placed on ice.
2.16 'Catch Linkering' of Genomic and cDNA resources for CSC
Catch linkering is a method for amplifying DNA, for instance a whole PAC, into a
simplified resource. It is an alternative to Alu-PCR (Nelson et al, 1989), yet is not
dependent on the presence of any specific sequence elements other than frequent
restriction enzyme sites. DNA is digested with Sau3AI, and then a short double
stranded 'catch linker' is ligated onto each cohesive end. The intervening DNA can
then be amplified by PCR using primers designed to the catch linkers. Catch
linkered material can be used as a substrate for Coincident Sequence Cloning.
2.16.1 Preparation of catch linkers
Catch linker oligonucleotides were 477 / 479 for genomic DNA resource and 727 /
731 for cDNA resource (see Table 2.2 for sequences of these primers).
Oligonucleotide 477 was synthesised with and without biotin at the 5' end.
Oligonucleotides 479 and 731 were phosphorylated at the 5' end to enable them to
be ligated to the restriction enzyme digested DNA. 1pg of each oligonucleotide was
duplexed in 10pl TM (10mM Tris.HCI; 5mM MgCI2 pH 7.4) to form the double
stranded linker.
2.16.2 Ligation of catch linkers
For the genomic resource, 200ng linker DNA was ligated onto ~50ng digested
genomic or cDNA, in 20jul volume at 16°C overnight. For the cDNA resource 500ng
of catch linker was ligated to 100ng cDNA in a 50pl volume at 16°C overnight. The
sample was then briefly spun and placed on ice.
2.16.3 PCR amplification
1 pil of the ligated material was then amplified by PCR, using 600ng oligonucleotide
477 or 727 as the primer. Biotinylated 479 was used if labelled product was desired
(see Table 2.2).
The PCR programme used was:
Denaturation: 94°C for 15 sees
Annealing: 54°C for 30 sees
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Extension: 72°C for 1 min (cycles 1-10), 2 mins (11 -20) and 4 mins (21 -35).
10|_il of the PCR product was examined on a 1% agarose gel. The remainder was
ethanol precipitated and resuspended as appropriate to future use.
2.17 Preparation of Genomic DNA
The genomic resource was catch linkered (section 2.13) using biotinylated 477 as
the PCR primer.
Before use in the CSC experiments it was necessary to purify the catch linkered
product from a gel, to remove primer dimers. It is preferable to do this without
staining the DNA with ethidium bromide or exposing it to UV irradiation.
The catch linker PCR product was ethanol precipitated and resuspended in 10ptl
dH20. 9pl of the sample was then run on a 1.5% LMP agarose gel in a midi-gel
apparatus, without ethidium bromide staining. The remaining 1pl was run in a
parallel, test track next to a pX Haelll marker track. When the loading dye had
reached the bottom of the gel, this test and marker tracks was sliced away from the
gel and stained with ethidium bromide. The DNA in these tracks was then viewed on
a UV transilluminator. The top and bottom positions of the catch linker product with
respect to the marker were noted, and the gel was nicked where it should be cut to
remove the primer dimers. This test track was then aligned alongside the rest of the
gel, and the gel sliced across at the position of the nick.
In order to concentrate the product DNA into a smaller volume of gel, the orientation
of the gel was reversed and the product run back up towards the wells. Loading dye
placed in a hole at the bottom of the gel before turning it round was used to judge
when the run was complete. A second pX Haelll marker track was sliced off and
stained, and nicks made at the positions corresponding to the top and bottom of the
catch linker product smear. This track was then aligned with the track containing the
product, and the product was excised from the gel, guided by the nicks in the
marker track.
The DNA was purified from the gel slice by agarase treatment and then was ethanol
precipitated overnight. The resulting pellet was resuspended in 5pJ dH20. The
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concentration was estimated by running 0.5pl on a 1% agarose gel. The remaining
4.5gl (~800ng) was used in the HF-CSC experiment.
2.17.2 Preparation of cDNA
20|ag cDNA which had been catch linkered using 727 as the PCR primer was
digested to completion with Sau3A restriction enzyme. The Sau3A digestion is
never entirely complete with 1-5% of the linker sequences being retained (most
likely due to some of the cDNA being single stranded and therefore impossible to
restriction enzyme digest). This allows both the end ligation CSC method to be
performed using primers specific to the capture oligonucleotide sequences
(789/596) and hybrid fishing CSC to be carried out using primer (727) designed to
the catch linkers which have not been entirely removed from the cDNA resource.
2.17.3 Preparation of 'blocking' DNA
Human Cot1 DNA was used to pre-anneal to the denatured genomic and cDNA
resources, to prevent inter-resource hybridisation due to high copy repeat elements.
Two 10gg aliquots of Cot1 human genomic DNA were ethanol precipitated and
vacuum dried.
2.17.4 Integration of the YAC and cDNA
200ng genomic DNA and 10gg cDNA were made up separately to 8.4pl in water.
The 10gg Cot 1 DNA which was ethanol precipitated was resuspended in this 8.4gl
for both the cDNA and genomic resource. 1.8gl 1M NaOH was added to each of
these resources (with an appropriate time delay) and the tubes placed at 37°C for 5
mins to ensure the denaturation is complete. The tubes were then warmed to 50°C
and 9.8,ul FNET/HCI (6gl formamide, 2gl NET (400mM Tris. HCI, pH7.8, 2.5M NaCI,
50mM EDTA), 1.8gl 1M HCI) at 50°C was added to each to neutralise the alkali.
The neutral pH of each was confirmed by spotting 0.5g.l of each onto Indicator
paper. The tubes were then placed at 45°C for 0.5 hours (genomic resource) and 3
hours(cDNA resource) for pre-annealing with the blocking DNA. After this, the two
DNA resources were combined and left submerged at 45°C overnight to permit the
formation of the IRDs.
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The integration and subsequent steps were also performed using controls of 'cDNA
only' and 'no DNA'. 25pl M280 streptavidin coated magnetic beads (Dynal) were
washed in phosphate buffered saline/BSA according to the manufacturer's
instructions and then incubated for 15 mins at RT in 10Optl TEN-S/P (0.1% SDS,
0.5mg/ml PVP in TEN buffer (TEN buffer: 10mM Tris.HCI, pH7.4, 1mM EDTA,
100mM NaCI)). This buffer was then replaced with 10Opil TEN-S/P containing 10pg
sonicated salmon sperm DNA and incubated for a further 15 mins. This buffer was
then removed and the beads resuspended in 25pl TEN-S/P.
The duplexed DNA was made to 0.1% SDS, 0.5mg/ml PVP and then this solution
was used to replace the bead solution. The DNA/bead mixture was incubated for 30
mins at room temperature with occasional mixing.
Washes were performed with 6 changes of 150pl TEN at room temperature, then 8
changes of 150pl 0.1x SSC at 68°C. The beads were resuspended in 20pl of TEN
and heated to 60°C before adding in 250ng of 732 and 735 (kinased) capture
oligonucleotides (see Table2.2 for sequences). Then the solution was allowed to
cool to room temperature over a 1hour period. The beads were washed with 4
changes of 10Opil of TEN and the beads resuspended in 20pl Taq ligase buffer
(Cambio). A 5 minute ligation was then performed at 45°C using 10 units of Taq
DNA Ligase. The reaction was stopped by adding 1 pil of 500mM EDTA.
The beads were then further washed with 3 changes of 100pl of TEN at 45°C and 5
changes of 10Ojul 0.1 X SSC at 65°C.
The products were then eluted from the beads by heating to 90°C for 4 mins in 10pil
dH20 before immobilisation of the beads and recovery of the buffer/eluate DNA. The
eluate was then passed through a further magnetic separation to remove all traces
of beads.
2.17.7 PCR amplification of the products
1pl of the eluate and controls were amplified in duplicate with 600ng of the cDNA
linker primer 727 (HF-CSC) or 789 and 596 (EL-CSC) (Table 2.2). The programme
used was:
Denaturation: 94°C for 30 sees in the 1st cycle and 15 sees thereafter.
Annealing: 54°C for 30 sees
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Extension: 72°C for 11/2 mins (cycles 1-10), 2V2 mins (cycles 11-20), 4 mins (cycles
21-29) then 8 mins (cycle 30)
The PCR reactions were then visualised on a 2% agarose gel.
2.17.8 Cloning of the product DNA
A library was made from the end ligation product DNA by cloning the PCR product
into pBS vector.
20pl of the product DNA was chloroform/isoamyl alcohol then ether extracted and
ethanol precipitated. The pellet was resuspended in 5pil. The DNA was then heat
shocked at 65°C for 5 mins and cooled to RT, to disentangle the molecules. The
concentration was checked by running 1pl on a 2% agarose gel, and then the
remainder was digested with EcoRI in a total of 10gl. The enzyme was heat killed at
70°C for 10 mins, and then the sample was ethanol precipitated. The pellet was
resuspended in 10pil and subjected to heat shock as above.
20ng of the digested product DNA was ligated to 20ng pBS DNA (digested with
EcoRI and phosphatased), in a total of 20pl at 16°C overnight. The ligation mix was
then drop dialysed and 1 jul was used for electro-transfomation of competent cells.
2.18 Screening a full length foetal brain library
The full length foetal brain library which was screened was obtained from Clontech.
Library details:
Human full length foetal brain 5'-STRETCH PLUS cDNA library
Titre: >108 pfu/ml
Vector: A.gt10
Host Strain: C600 Hfl
Cloning site: EcoRI
Priming method: oligo dT and random primed
mRNA source: pooled from 7 Caucasian foetuses 20-26 weeks
Average insert size: 0.4-2.5Kb
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The library was plated out according to manufacturers instructions onto L-agar
plates. Briefly the library stock is diluted and combined with the host E.coli strain
(C600) which has been grown in the presence of maltose and magnesium sulphate
at 37°C until confluent. This solution, after 15 minutes of further incubation at 37°C
with agitation, was mixed with LB soft top agar and poured on the surface of a plate
which already had set L-agar in it. This was then incubated at 37°C overnight. The
plates were then removed and placed a 4°C for at least 15 minutes to prevent the
top agar from being removed during transfer of the plaques to membranes. The
plaques were then transferred to nitrocellulose membrane filters and fixed as in
section 2.8.2 and 2.8.3. These filters were then hybridised with probes derived from
the CSC product library as in section 2.8. Once positive plaques were identified
plugs were taken. This was achieved using a large 1ml tip to remove the region
which had a positive plaque in it as assessed by lining up the autoradiogram and
original agar plate. These plugs were then allowed to soak in lambda dilution buffer
(10X dilution buffer: 58.3g 1M NaCI 24.65g 0.1 M MgSo4.7H20 350ml 1M Tris.HCI
(pH 7.5), 50ml 2% gelatin make up to 1L with water and autoclave) overnight and
replated as above in order to obtain single positive plaques. Once a single plaque
has been obtained in plug form this is again allowed to soak overnight in dilution
buffer and then the solution is diluted 1/1000 and this is heated to 90°C for 5
minutes. 2gl of this solution can then be used in a PCR reaction with Primers 391
and 392 which are designed to the A,gt10 vector sequence and amplify up the cDNA
insert. Several PCR products can then be pooled together and used in sequencing
reactions as described in 2.14.
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Table 2.2 Sequences of oligonucleotides used for PCR amplification and DNA
sequencing
Name Oligonucleotide sequence 5'-> 3' Function/comments
Actinin PCR and sequencing
J101 GCT TCT GTA ATC ACT CAT ccc ACTN 2 PCR
J102 AGG ATA CTG GTT TCT GAC TTG ACTN 2 PCR
J103 GAG ACT GAC ACG ACT GAG CAA ACTN 3 PCR
J104 TGG CTG GCT TTT CTC TTA GGC ACTN 3 PCR
Plasmid vector primers
291 CAG GAA ACA GCT ATG AC pBS primer reverse
292 GTA AAA CGA CGG CCA GT pBS primer forward
M13 TGT AAA ACG ACG GCC AGT forward
M13 CAG GAA ACA GCT ATG ACC AT reverse
EST Mapping and sequencing
"K290 GCA CAG AGA ATG AAT GAT AAG Z39242 sequencing
K97 TGA CAG GGG TGA TTC TCC Z39242 sequencing
K229 CAC CTG GAA GCA TCT GTT Z39242 sequencing
*K872 CTT TTA GAT TGT GGG TAT TAT Z39242 sequencing
K204 CTC AGA AAT CAC CAC TAA Z39242 sequencing
K301 CTG CCA TAC TTG TTT TCC Z39242 sequencing
K568 ATG GGA ATG GAA ATG GTG Z39242 sequencing
K85 TAG CGG GTG TGA AGT GGT ATC Z39242 sequencing
K289 ACT TCA TAA GTA TGC AAA ACA Z39242 sequencing
Primer pairs for EST PCR
Z19327 AGG CAC AAG TTT AAG CAG CAT
TGC CAG TCT GTA TTG AGG GGT
Z28525 AGT CTC CAC AAA TGG TCT GCT
AAT GCC GTA TGT TGT AGG GGT
Z28611 GTC TGT CTC TGC GGC TTC TGT
CCT TCA AGT TCC AAG CGT CT
Z28653 TTG AAA ACA CTG AAA ACC TCT
TGA ACT GAA CCT TGG ACT GAT
F00203 AGT GGT CGC CAA GTA AGA GG
CTT GGC ATG TGA GGG CTA TT
F00755 GTG GAG CAC ATT ATA GAC AG
AAT GAG TTG TTG TTG TTG AT
F00845 GTG GTT ACA TCT ATT CTT GCT
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tgt ccc gta aag
cac cag cag tag
ttt tca gcg gtc
ggt tgt aaa agg
att tcc aca ttc
aga tga ctg tga
acc tct ttc ttt
ata ctc aag gtt
Allelic association study primers
ttt ctc acc ttt aaa tgt cat ca Forward
cca gta cgc aga tgg tcc ta reverse
agt ttg gta ggt att ct Forward
gag aaa tag tat gtg ttt gcc reverse
Coincident Sequence Cloning
ccg aat tct aga gtc gac c
gat cgg tcg act cta gaa ttc gg
gcg aat tct aga ctg cag g
aat tcc tgc agt cta gaa ttc gc
gga cgg gtc gac acg cga gga ccg
aat tct aga gtc gac c
gat cgg tcg act cta gaa ttc acc
cgt gct acc gga acg
gga cgg gtc gac acg cga gg
cgt tcc ggt agc acg gg
CSC clone sequencing primers
cca gaa gtt tgt cac cag
tga ggc agg aga atc gct
ttg tct gcc tga aaa tgt
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M306 cca ggg aca aag TTW wca csc c|one 3a6
sequencing primer
N164 taa caa cta acc tcc cct CSC clone 3A6
sequencing primer
1184 ctt tcc acc ttc tgc cat CSC clone 3A6
sequencing primer
N811 cca ggg aag cag gag aaa CSC Clone 1 1B6
internal primer
N812 tcc cag aaa aca ata ccc CSC Clone 1 1B6
internal primer
Vector Primer for EST clone 299277
T3 aat taa ccc tca cta aag gg Vector pT3T7
T7 cat tat gct gag tga tat ccc g Vector pT3T7
Vector Primers for phage cDNA clones
391 agc aag ttc agc ctg gtt aag t Vector A.GT10
392 tta tga gta ttt ctt cca ggg Vector AGT10
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High Resolution Mapping of The Actinin Genes
ACTN 2 and ACTN 3
Results Chapter Three
3.1 Introduction
a-actinin is part of the spectrin gene super family, a diverse group of cytoskeletal
proteins, which also include the a and (3-spectrins and dystrophin. These family
members are characterised structurally by a central rod domain which is composed
of 4 (a-actinin) to 24 (dystrophin) repeat units and EF-hand (helix-loop-helix motif)
calcium binding domain that may or may not be functional. There is also a highly
conserved amino terminal actin binding domain in spectrin, a-actinin and dystrophin
and a carboxyl terminal domain which appears to be unique to dystrophin. The
spectrins and dystrophins are thought to play a role in maintaining cellular integrity
and flexibility as components of the membrane cytoskeleton. The a-actinins have
more diverse functions but all serve as actin binding and crosslinking proteins in
both muscle and non muscle cells, a-actinin is rod shaped and dimerizes in an anti-
parallel fashion. In skeletal muscle, a-actinin is a major component of the Z-discs. In
non muscle cells a-actinin is found along microfilament bundles where it may
mediate membrane attachment at adherns-type junctions in a dynamic manner,
regulated by the calcium binding EF hands. In smooth muscle a-actinin is found at
dense bodies and dense plaques and has similar anchoring functions (Blanchard et
al 1989, Matsudaira 1991, Beggs et al 1992).
A number of different isoforms of a-actinin have been identified by biochemical
studies such as isoelectric focusing but many of these are thought to result from
post translational modifications of the protein. Brain isoforms of a-actinin and
spectrin exist, the latter being known as fodrin.
a-actinin genes have been described in the invertebrate Dictyostelium discoideum,
Caenorhabditis elegans and Drosophila melanogaster and in the vertebrates
chicken, mouse and rat. Three human a-actinin genes have been described, a-
actinin 1(ACTN1) maps to chromosome 14q22-24 and is a non-muscle cytoskeletal
isoform whereas ACTN 2 (1q42-q43) and ACTN 3 (11 q13-q14) are expressed in
skeletal muscle (Beggs et al 1992). Amino acid sequence comparison demonstrates
that these genes are highly homologous to each other and are also conserved
across species.
Defects in the actin crosslinking proteins have been associated with several human
diseases. Mutations in the spectrin gene which result in a quantitative deficiency of
spectrin affecting membrane binding properties and oligomerisation, can cause
some forms of haemolytic anaemia. Becker and Duchenne muscular dystrophy are
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genetically inherited wasting diseases of skeletal muscle which are caused by
deletions in the muscular dystrophy gene resulting in truncation of the protein
product, dystrophin.
a-actinin has not been associated with any human diseases as yet, although it was
a candidate gene for Nemaline Myopathy which is a neuromuscular disorder
characterised by the presence in skeletal muscle of nemaline rods composed, in
part, of a-actinin. a-actinin has since been excluded as being involved in this
disorder (Tahvanainen et al 1994). North and Beggs (1996) found a deficiency of
ACTN 3 in merosin positive congenital muscular dystrophy (a subset of patients with
congenital muscular dystrophy who are deficient for the extracellular matrix protein
merosin). It is likely that this may be a marker of the condition and it is
undetermined as to whether this deficiency reflects a gene mutation or is a
secondary effect.
Other structural proteins which have been described as being involved in disease
processes include myosin in which a defect in the myosin VIIA gene is responsible
for Usher syndrome type 1B (Weil et al 1995). Usher syndrome is the most frequent
cause of deaf-blindness in humans. Interestingly the gene responsible for this
disorder (USH1B) maps to 11 q 13.5 and there has been a report of schizophrenia
co-morbid with Usher syndrome (St Clair 1994). Another gene for Usher syndrome
has also been mapped to chromosome 1q41. Abnormal expression of the
microtubule associated proteins (MAPs) MAP2 and MAP5 in specific sub-fields of
the hippocampus of schizophrenics has been reported and it has been suggested
that this could underlie some of the cytoarchitectural abnormalities described in
schizophrenia as well as possibly impairing signal transduction in the affected
dendrites (Arnold et al 1991). Microtubule associated proteins have also been
implicated in temporal lobe abnormalities in schizophrenics due to faulty assembly
of these proteins resulting from a deficiency of trophic forms of non NMDA
receptors (Kerwin 1993).
Brain a-actinin has been studied previously in chick brain to elucidate any possible
involvement it may have in neurotransmission (Zheng and Babitch 1995). Chemical
neurotransmitters are stored within the nerve terminals in synaptic vesicles that are
often associated with cytoskeletal components and the presynaptic plasma
membrane. When nerve stimulation causes influx of calcium, neurotransmitter is
released and vesicles are recruited for release by rearrangements of the nerve
ending cytoskeleton of which actin is a component. However, studies by Zheng and
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Babitch (1995) indicated that chick brain a-actinin was localised in the cytoplasm
and the level in nerve endings was minimal. They concluded that a-actinin was not
likely to be involved in neurotransmission.
Recently Wyszynski et al (1997) identified a-actinin 2 as being a brain postsynaptic
density protein that co-localises in dendritic spines with NMDA receptors and the
putative NMDA receptor clustering molecule PSD-95 in the rat brain. NMDA
receptors exist in vivo as heteromultimeric complexes consisting of the essential
NR1 subunit which is co-assembled with various units of the NR2 subfamily which in
turn are associated with PDS-95 synaptic proteins, a-actinin 2 binds to the
cytoplasmic tail of both NR1 and NR2B by its central rod domain. NR1 a-actinin
binding is directly antagonised by calcium / calmodulin. The authors speculate that
calcium / calmodulin may displace a-actinin 2 from NR1 subunits, to which it may
bind at resting intracellular calcium levels, in response to postsynaptic calcium
influx. This mechanism may contribute to calcium dependent inactivation and run
down of NMDA receptors and may also lead to receptor detachment from the actin
cytoskeleton and their redistribution during synaptic activity. Hence a-actinin may
play a role in both the localisation of NMDA receptors and their modulation by
calcium.
a-actinin is also involved in the organisation of networks and bundles of actin
filaments in neural growth cones (the growing tips of axons or dendrites). During
development growth cones guide growing neurites to their appropriate target site
and are the direct precursors to synaptic and neurosecretory terminals, undergoing
dramatic structural changes upon target recognition (actin-based motility of lamellae
ceases and specialised neurosecretory release sites are organised) (Forscher and
Smith 1988). a-actinin may be involved in the organisation of actin at the growth
cone margin and in its dynamic protrusions (Letourneau and Shattuck 1989). a-
actinin may also be a linker protein between receptors for the extracellular matrix,
integrins and actin filaments and be involved in the adhesion process of growth
cones to the substratum (Sobue 1993). a-actinin-actin interactions may therefore
cause bundling of actin filaments within filopodia or anchorage to the filopodia
membrane and may induce retraction of growth cones or encourage reorganisation
of actin microfilaments during growth cone movement. Hence, it is possible that
abnormalities in a-actinin may have an effect on neuronal migration and navigation.
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The a-actinin genes, ACTN 2 and ACTN 3, have been described by Beggs et al
(1992) as mapping to chromosome 1q42-q43 and 11 q 13-q 14 respectively. The
translocation breakpoint described in the K26 pedigree which co-segregates with
schizophrenia and associated disorders resides at t(1:11 )(q43,q 14.2). Primarily due
to both the location of these two closely related genes on both the translocation
chromosomes, in the vicinity of the breakpoint which might explain the mechanism
of chromosomal rearrangement through illegitimate recombination between
paralogs, and because of their biological functions, ACTN 2 and 3 were considered
to be of interest as potential candidate genes. The aim of these experiments was to
further determine the candidacy of these genes by first determining their precise
location with respect to the translocation breakpoint by high resolution mapping,
utilising available somatic cell hybrids and YACs from the contigs which had been
produced around the breakpoint on chromosome 1 and 11.
3.2 High Resolution mapping of the ACTN 2 and ACTN 3 actinin genes
3.2.1 Production of YAC and Somatic cell hybrid panels;
YAC contiguous clone maps have been assembled which extend over the region
disrupted by the translocation on chromosomes 1 and 11 (see section 1.16). These
contigs span a 3Mb region in the case of chromosome 11 and 2Mb in the case of
chromosome 1. Restriction enzyme mapping panels were constructed for both
chromosome 1 and 11 using DNA from the YACs in these respective contigs
(Figure 3.1 and 3.2). 5gg of YAC DNA was cut with restriction enzymes EcoFH or
Hindi11 and then run out on a 1% agarose gel and Southern blotted using standard
procedures (see section 2.8). These filters were then used in hybridisation reactions
with probes made from the actinin genes, ACTN 2 and ACTN 3.
Several somatic cell hybrids were available containing fragments from human
chromosome 11 including the translocation derived 11 chromosome, the human
chromosome 11 only hybrid J1CI4 and the series of 4 WJX hybrids derived from
J1CI4 by X-irradiation (Fletcher et al 1993). A derived 1 translocation chromosome
carrying somatic cell hybrid was also available as was a human chromosome 1 only
carrying hybrid A9. A full list of these hybrids is described in Table 3.1. These
hybrids have been thoroughly characterised using a large number of chromosome
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The somatic cell hybrid panels were made in a similar fashion to that of the YAC
hybridisation panels, being cut with restriction enzymes EcoR1 or Hindlll, run on 1%
agarose gels and Southern blotted (see section 2.8). On each somatic cell hybrid
panel a total human genomic DNA control was included along with mouse only and
hamster only cell lines in order that human specific bands could be identified.
3.2.2 Hybridisation Probe Production
The cDNA sequence for ACTN 2 and ACTN 3 has been published (Beggs et al
1992) and is available in the GENBANK database (HGMP Resource centre, Hinxton
Hall, Cambridge: accession numbers: M86406 and M86407) However, little
information was available on intron/exon boundaries in these two genes. Two
intron/exon boundaries had been described in ACTN 2 as a result of the
identification of a CA dinucleotide repeat polymorphism, described by Beggs et al
(1992) and were available in the GENBANK database (accession number:
M86804). No such information was available for ACTN 3.
Oligonucleotide primers were designed to the 3' untranslated regions (3' UTR) of
the two a-actinin genes ACTN 2 and ACTN 3. 3' UTRs are usually more divergent
between genes than coding regions and BLAST (Altschul 1990, Pearson and
Lipman 1988) database searches indicated that these regions were less conserved
in both the actinin genes which are 90% similar in cDNA sequence (Beggs et al
1992). By designing primers from the 3'UTR region, problems of cross hybridisation
between the two actinin probes and between other members of the spectrin gene
super family, which are highly homologous, were minimised.
PCR was done using 100ng of total human genomic DNA as template (see section
2.13 for description of PCR procedure). The oligonucleotide primers designed for
ACTN 2 were; J101; 5'-GCTTCTGTAATCACTCATCCC-3' and J102; 5'-
AGGATACTGGTTTCTGACTTG-3'. Those designed for ACTN 3 were J103; 5'-
GAGACTGACACGACTGAGCAA-3' and J014; 5'-TGGCTGGCTTTTCTCTTAGGC-
3'. Conditions used in the PCR reaction are detailed in Table 3.2. As the published
3'UTR sequence for ACTN 3 is only 133bp long, one of the oligonucleotide primers




Table 3.2 PCR conditions for amplification of ACTN 2 and ACTN 3 probes (PCRs
were carried out on Hybaid Omnigene PCR machines).
;
Denature Annealing Extension
Cycle 1 94°C/2mins 55°C/30secs 72°C/1 min
Cycle 2-29 94°C/30secs 55°C/30secs 72°C/1 min
Cycle 30 94°C/30secs 55°C/30secs 72°C/2mins
The expected product sizes for ACTN 2 and ACTN 3 were 913bp and 316bp
respectively. The ACTN 2 product was of the expected size but the ACTN 3 probe
was slightly larger than expected at approximately 400bp (Figure 3.3). Both the
PCR products were sequenced by single pass automated fluorescent sequencing
(see section 2.14). The results showed the ACTN 2 probe to be as predicted from
the published 3' untranslated region sequence. The ACTN 3 probe however was
found to have an additional 80bp inserted into the probe sequence (Figure 3.4) at
position 2565 of the published cDNA sequence. Analysis of this sequence showed
that it is flanked by splice consensus sequences (Mount et al 1982) and therefore
these primers span a small intron in genomic DNA.
Comparison of the ACTN 2 and 3 probe sequences showed that the two probes are
not homologous and should not cross react (data not shown).
Several PCR products for ACTN 2 and ACTN 3 were pooled together and run out
on a low melting point agarose gel. Bands of the appropriate size were then cut out
and the DNA purified using a Geneclean II kit (see section 2.7.5). This DNA was









Figure 3.3: ACTN 2 and ACTN 3 PCR probes from 3'untranslated region of the genes.
Expected product sizes were ACTN 2 - 913bp and ACTN 3-316bp.
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Figure 3.4a: Location of ACTN 3 intron within the cDNA sequence. The position of
the start of the 3'UTR is marked with an arrow. Primers used to amplify the probe
from genomic DNA are identified (J 103 and J104). The position of the intron is
marked in red.
2451 CGCAGCTGGG GTGGTGACCT TCCAGGCCTT CATAGACTTC ATGACCCGAG
2501 AGACAGCCGA GACTGACACG ACTGAGCAAG TTGTAGCTTC CTTCAAGATC
2551 TTGGCAGGAG AC AACTA CATCACCCCC GAGGAGCTGC GGCGCGAGCT
INTRON
2601 CCCTGCCAAG CAGGCCGAGT ACTGCATCCG CCGTATGGTG CCCTACAAGG
2651 CATCCGGGGC CCCGGCTGGA GCCCTGGACT ACGTGGCCTT CTCCAGTGCC
3'UTR
2701 CTCTATGGGG AGAGCGACCT TTGA :CAA CCACTGAGGT TCTCTATGCA
2751 AGATGGAGAG AGGATGCACC CTGTGGCTGA TCCCATCCGT CCCTCGGAGC
2801 AAGGGCCTAA GAGAAAAGCC AGCCAAGTGC TTCTGAATAA AGATCCCTCT
2851 CTGGGTCA
Figure 3.4b: Sequence of the ACTN 3 PCR probe, indicating the intron sequence.
The intron sequence is underlined with dotted lines indicating the splice consensus
sequences.
1 CTyCCTTCAA GATCTTGGCA GGAGAC 5
51 GGCTGGTGGG CTAGGGCAGG GCACGGGACC TGTGGGTCCT CAACGCCTCT
101 A ACTACATCAC CCCCGAGGAG CTGCGGCGCG AGCTCCCTGC
151 CAAGCAGGCC GAGTACTGCA TCCGCCGTAT GGTGCCCTAC AAGGGATCCG
201 GGGCCCCGGC TGGAGCCCTG GACTACGTGG CCTTCTCCAG TGCCCTCTAT
251 GGGGAGAGCG ACCTTTGACC CCAACCACTG AGGTTCTCTA TGCAAGATGG





3.2.3 Southern Blot Hybridisations to Chromosome 1 and 11 YAC and
Somatic Cell Hybrid Panels
The ACTN 2 3'UTR probe was hybridised to a filter containing YAC DNA from the
chromosome 1 contig and the somatic cell hybrids all of which had been cut with
Hindlll restriction enzyme (see section 3.2.1). The results from this hybridisation
(Figure 3.5) showed a band corresponding to approximately 1Kb in size in the A9
(human chromosome 1 only), MIS39.8 and MAR1 (derived chromosome
11 containing hybrids) somatic cell hybrids and in total human genomic DNA (THG).
This band does appear to be slightly larger in size in the two hybrids MIS39 and
MAR1 than in A9 and total human genomic DNA. This is most likely due to the
greater amount of DNA loaded on the Southern blot for MIS39.8 and MAR1 in
comparison to A9 and total human DNA lanes (see gel picture Figure 3.5). The
large amount of DNA is likely to cause slight retardation of the DNA as it runs
through the gel resulting in the slight band size difference. There is also a difference
in the intensity of the bands seen with the MIS39.8 and MAR1 hybrids being less
strong than expected given the difference in the amount of DNA loaded on the blot.
This is a reflection of the low copy number in the hybrids in comparison to total
human genomic DNA. A slightly smaller band at approximately 500bp was seen in
total human genomic DNA (THG) and in MAR 1 hybrid but is only very faintly visible
in MIS39.8 and A9 hybrids. No bands were seen in the derived 1 hybrids MIS7.4
and MAR12 or in the chromosome 11 only hybrid J1CL4 (indicating that this probe
does not cross hybridise with ACTN 3 on chromosome 11)(See Figure 3.5).
Similarly, no bands were seen in the hamster or mouse only cell lines, indicating
that this probe does not hybridise across these species. To confirm that the ACTN 2
probe is contained in these hybrids PCR analysis was done using 200ng of DNA in
the same PCR reaction that was used to amplify the ACTN 2 probe (see Table 3.2).
The PCR results are displayed in Figure 3.6. The results confirm those found in the
Southern blot analysis.
None of the YACs contained a band of 1Kb in size (refer to right hand side of figure
3.5) but YAC 36DH11 did contain a band which was slightly smaller than this, at
approximately 800bp. This band was not seen in any of the other YACs in the contig
which are known to overlap with 36DH11(31 AH8, 757F9, 851G8) indicating that, if
this band is real, this YAC may be chimaeric. A band of the same size to that seen
in YAC 36DH11was also present in the two lanes which contained size marker DNA
indicating that this band may be a result of plasmid contamination in the positive
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Figure 3.5: Southern blot hybridisation analysis of ACTN 2 3'UTR probe hybridised to
the chromosome 1 YAC and somatic cell hybrid panel cut with restriction enzyme Hindlll
(THG = total human genomic DNA)
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Figure 3.6: PCR analysis showing amplification of ACTN 2 3'UTR from
the somatic cell hybrids.
THG=total human genomic DNA.
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YAC since size markers contain plasmid DNA. To determine if this band in YAC
36DH11 was real or not PCR was done on the YAC DNA to try to amplify a band
corresponding to the ACTN 2 probe. PCR conditions were the same as for ACTN 2
probe production and 200ng of YAC DNA was used in the PCR reaction. Total
human genomic DNA and the human chromosome 1 only hybrid, A9, were included
as positive control samples. Results from the PCR (Figure 3.7) showed that
36DH11 did not contain a band corresponding to the ACTN 2 gene. A band was
seen in the positive control samples A9 and total genomic human DNA but in none
of the chromosome 1 YACs (Figure 3.7). It is probable that the band seen on
hybridisation in YAC 36DH11 is the result of plasmid contamination of this YAC
DNA and does not represent the ACTN 2 gene. It is likely therefore that the ACTN 2
gene is not contained in any of the chromosome 1 YACs. Since the chromosome 1
YAC contig spans approximately 2Mb around the breakpoint the ACTN 2 gene most
probably lies out-with this region.
The ACTN 3 3'UTR probe was hybridised to chromosome 11 YAC filters which had
been cut with restriction enzyme EcoR1. The results (not shown) demonstrated that
the ACTN 3 probe was not contained in any of the YACs in the chromosome
11 contig. Only 1 YAC, D0485, crosses the translocation breakpoint and therefore
extends proximal to the breakpoint, all the other YACs in the contig are distal to the
breakpoint. Since YAC D0485 only extends 500Kb proximal to the breakpoint it is
possible that the ACTN 3 gene could lie just beyond this YAC, still being within a
reasonable distance of the breakpoint. To exclude this possibility high resolution
mapping employing somatic cell hybrids was carried out.
The ACTN 3 probe Southern blot analysis to an EcoR1 somatic cell hybrid panel
showed that several EcoR1 fragments hybridised with the ACTN 3 probe in total
human genomic DNA and that hamster and mouse fragments also hybridised with
this probe (Figure 3.8). The total human genomic DNA appears to contain three
major bands on a background smear. The smear is likely to be due to the greater
complexity of the genomic DNA and also possibly due to repetitive elements. The
largest of these bands (approximately 23Kb) also appears in the chromosome 11
only hybrid J1CL4 and the derived 11 hybrid MIS39.8 as well as in E67.1 and E67.4
which contain fragments of chromosome 11. Two bands (~10Kb and -4Kb) were














o o ^ « 5 <
z> I cm in to t-
J i- o) 00 co co






Figure 3.7: PCR analysis showing amplification of ACTN 2 3'UTR
from the chromosome 1 YACs
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Figure 3.8: Southern blot hybridisation analysis of ACTN 3 3'UTR probe hybridised to
the chromosome 11YAC and the somatic cell hybrid panel cut with restriction enzyme
EcoRI. (THG = total human genomic DNA).
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hybrid C127, indicating that the ACTN 3 probe cross hybridises to homologous
genes in the mouse. Two bands of slightly different size to those seen in the mouse
were also seen in J1CL4 and the hamster background hybrid WG3H (~10Kb and
~1.8Kb). The only band which was seen in the chromosome 11 hybrids and total
human genomic DNA which didn't correspond to either a mouse or hamster band
was the ~23Kb band and was therefore deemed the human ACTN 3 band. A slightly
smaller band to that designated as the human ACTN 3 band is seen in the hybrid
MAR12. This hybrid contains other chromosomes as well as the derived 1
translocation chromosome (although it does not contain normal chromosomes 1 or
11). It is therefore possible that this band represents a related family member which
resides on a different chromosome.
A PCR assay using primers J103 and J104 was done in order to confirm the
Southern blot analysis (Figure 3.9). 200ng of DNA was used in the reaction which
was carried out as described in Table 3.2. Strong bands of the correct size were
seen in J1CL4, total human genomic DNA, MIS39.8, E67.1, E67.4, WJX3.4 and
MAFLI (translocation patient total genomic DNA). No other bands were seen in any
of the other hybrids confirming the results obtained from the Southern blot analysis.
Since the somatic cell hybrids have already been characterised in terms of
chromosome 11 markers (Evans et al 1995) it was possible to map the ACTN 3
gene to a defined interval on chromosome 11 (See Table 3.3 ). This interval was at
the GST PI Locus corresponding to a map position at 11 q 13. The GST PI locus is
the only locus in which E67.1, E67.4, MIS39.8 and WJX 3.4 are all positive and the
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Figure 3.9: PCR analysis showing amplification of ACTN 3 3'UTFt from the somatic cell
hybrids. (THG = total human genomic DNA).
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Table 3.3: Chromosome 11 marker analysis of somatic cell hybrids (reproduced
from Evans 1994). + indicates the presence of a marker in the cell line, - indicates
its absence and ND indicates not determined. The GST PI locus where the ACTN 3
gene is predicted to map from the Southern Blot analysis is in bold typeface and
underlined.
SOMATIC CELL HYBRIDS
LOCUS MIS MIS CF52 WJX WJX WJX WJX E67.1 E67.4
7.4 39.8 3.4 5.4 7.4 11.2
HBB - + ND - + - - + -
D11S87 - + ND - - - - ND ND
TYR LI + - + + - - - +
PGA - + - + - + - + -
ROM1 - + - + - + - - -
MDU 1 - + - + - + - - -
GST PI + - + - - - + +
ADROA2 - + ND + - - - + -
FGF 4 - + - + - - - - -
D11S527 - + + + - - - - -
D11S533 - + + + - + - - +
OMP - + + + - + - - +
TYR - + + - - + + - +
CLG + - + - + - + - +
STMY1 + - + - + - + - +
D11S385 + - + - + - + - +
NCAM + - + - - + + - +
DRD2 + - + - - + + - -
D11S351 + - + - + - + - -





The Southern blot hybridisations and PCR analysis have shown that both ACTN 2
and ACTN 3 lie out-with the region of the YAC contigs spanning the translocation
breakpoints on chromosome 1 and 11. The chromosome 1 contig spans
approximately 1Mb on either side of the breakpoint and since ACTN 2 has been
shown to most probably lie out-with these YACs, it can be deemed to be greater
than 1Mb away from the translocation breakpoint on chromosome 1. Since there
are several other identified cDNAs which are closer to the breakpoint, ACTN 2 was
considered to be too far from the breakpoint to be further analysed as a candidate
gene involved in the psychiatric diagnosis in the K26 t(1:11) translocation family.
Southern blot hybridisation of ACTN 2 with somatic cell hybrids confirmed that
ACTN 2 map position is distal to the translocation breakpoint as it was located on
the derived 11 chromosome. It is not possible to refine this mapping position further
as characterised chromosome 1 somatic cell hybrids are not available to us. ACTN
2 has however been mapped to the interval D1S439-D1S446 (246-256cM on
radiation hybrid map) in the Human Transcript Map (Schuler et al 1996,
http://www.ncbi.nlm.nih.gov/SCIENCE96/). The chromosome 1 YAC contig is
contained within this region in the interval D1S225-D1S459 (249-251 cM - the
breakpoint being approximately half way between these markers).
Since we know that ACTN 2 is not contained within the YAC contig (i.e. between
markers D1S225-D1S459 - 249-251 cM) and that it maps proximal to the breakpoint,
it probably lies in the region between markers D1S459 and D1S446 (251-256cM).
Southern blot hybridisation analysis and PCR similarly showed that ACTN 3 did not
map to the chromosome 11 YAC contig. This result would place this gene greater
than 2Mb distal to the breakpoint but since only 1 YAC (D0485) spans the
chromosome 11 breakpoint this gene could lie just beyond this, at a distance of
greater than 500Kb or so proximal to the breakpoint. Southern blot analysis using
somatic cell hybrids placed ACTN 3 in the region of the GST PI locus at 11 q 13,
some considerable distance proximal to the chromosome 11 breakpoint.
Quackenbush et al (1995) produced an STS content map of human chromosome
11 in which they localised 910 chromosome 11 specific YAC clones. They mapped
ACTN 3 to chromosome 11 q12-13.1 by STS and radiation hybrid mapping, placing
it between markers D11S913 and D11S916 at position 113 on their radiation hybrid
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map. The translocation breakpoint is flanked by marker TYR on chromosome 11
which is also on the radiation hybrid map produced by Quackenbush residing at
position 11 q 14.2 (position 146 on the radiation hybrid map). From their STS YAC
contig map they estimate the distance between these two markers to be greater
than 15Mb, some considerable distance from the breakpoint (although it must be
emphasised that this distance is by no means accurate but serves to demonstrate
the large intervening distance between the ACTN 3 gene and the breakpoint).
The GST PI marker is also positioned on their radiation hybrid map at approximately
position 113 and therefore lies extremely close to where they have positioned ACTN
3. The Human Transcript map (Schuler et al 1996) has also positioned both GSTP1
and ACTN 3 on their radiation hybrid map at between markers D11S913 and
D11S1314 (70-77cM)(see Figure 3.10). These results therefore confirm the validity
of the somatic cell hybrid mapping approach used to map ACTN 3.
The two a-actinin genes ACTN 2 and ACTN 3 were considered as candidate genes
for involvement in the psychiatric diagnosis in a family in which schizophrenia and
associated disorders cosegregate with a t(1:11) balanced translocation on the basis
of location in close proximity to the breakpoint and biological function. As these two
homologous genes lie in close proximity to the translocation breakpoint they may
also provide a mechanistic explanation of the translocation event by illegitimate
cross over.
High resolution mapping of these two genes using YAC and somatic cell hybrid
panels from the region indicated that these two genes map some considerable
distance from the breakpoint making it highly improbable that they are involved in
the psychiatric diagnosis in this family.
Exclusion of ACTN 2 and 3 from the search for genes involved in the psychiatric
diagnosis in the translocation family will allow more effort to be directed to candidate
genes which map in close vicinity to the breakpoint.
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Figure 3.10 Cytogenetic, genetic and radiation hybrid maps from Evans et al
(1995), the McDermott Centre for human growth and development
(http://mcdermott.swmed.edu/) and the Human Transcript Map
(http://www.ncbi.nlm.nih.gov/SCIENCE96/).





















































RH - Radiation Hybrid Map
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High Resolution Mapping of Expressed Sequence
Tagged Sites on Chromosome 11
Results Chapter Four
Introduction
In 1995 Rosier et al regionally assigned 68 new human gene transcripts (ESTs) to
25 sub-regions of chromosome 11. These transcripts were originally obtained from
a collection of partial cDNA sequences derived from skeletal muscle and infant
brain cDNA libraries established at Genethon by the Genexpress program. These
ESTs had been previously assigned to chromosome 11 using a panel of non-
chromosomic somatic cell hybrids. Using a collection of somatic cell hybrids
containing different deletion fragments of chromosome 11 (which had previously
been characterised by cytogenetic data, reference markers and by their
microsatellite content), assignment of the ESTs to the 25 subintervals of
chromosome 11 was achieved (Rosier et al 1995). Among the somatic cell hybrids
used to regionally assign these EST were the hybrids MARIand MAR12, containing
the derived 11 and derived 1 translocation chromosomes respectively, from the K26
pedigree.
Rosier et al (1995) identified 69 diseases which were genetically linked to
chromosome 11. For 31 of these diseases no responsible gene had been identified
resulting in them being termed "orphan pathologies". The regions of chromosome
11 to which these orphan pathologies had been linked were used to generate a
disease map of chromosome 11 which was integrated with the cytogenetic, genetic
and genie maps. Each of the 25 subintervals defined on chromosome 11 has at
least one EST contained within it so that each orphan pathology has at least one
EST localised to the region close to it, thus providing positional candidate gene(s)
for that disease which could then be investigated. The region of chromosome 11 in
which our translocation, associated with schizophrenia, resides is indicated on this
integrated map and falls into subinterval 21-22 of the 25 subintervals as defined by
their somatic cell hybrids. Region 21 lies above the translocation breakpoint as
determined by the translocation hybrid MAR1 which is represented on the hybrid
panel and extends from11q14.3-q21(D11S1789-D11S1780). This region contains 4
ESTs. Region 22 lies below the translocation breakpoint as defined by MAR12,
extending from 11q21-23.2 (D11S1342-D11S1327) and contains 16 ESTs (see
Figure 4.1).
The position of the translocation breakpoint on chromosome 11 in the Rosier et al
paper, as indicated by the positions of MAR1 and MAR12 hybrids, is 11 q21. The
position of the breakpoint has been further refined since the publication of this
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Results Chapter Four
These newly identified transcripts which flank the chromosome 11 breakpoint are
potential candidate genes for involvement in the psychiatric diagnosis in the K26
pedigree. In order to further determine the candidacy of these gene transcripts it
was necessary to determine their proximity to the breakpoint and to establish if any
of them crossed the translocation breakpoint. To this end, high resolution mapping
of these ESTs, using chromosome 11 YACs and somatic cell hybrids was
undertaken.
4.2 Mapping of ESTs to chromosome 11 YACs:
Of the 20 ESTs (See Table 4.1) which were mapped in the region around the
translocation breakpoint by Rosier et al (1995) three ESTs were identified by
sequence database searches as corresponding to known genes, namely
mitochondrial acetoacetyl-CoA thiolase (F00504), small nuclear ribonucleotide
polypeptide C (F05464) and alpha B-crystallin (F00690). The other 17 ESTs were of
unknown sequence identity in the database (Rosier et al 1995). The alpha B-
crystallin gene (F00690) had previously been mapped to 11q22.3-q23.1 and the
mitochondrial acetoacetyl-CoA thiolase gene (F00504) had also been previously
mapped to 11q22.3-q23.1. These two EST were therefore not looked at further due
to their remote location from the breakpoint.
The 18 ESTs which showed no sequence identity in the database and EST F05464
were mapped to the chromosome 11 YAC contig panel. Since no primer pairs were
described in the paper for amplification of the ESTs, the corresponding cDNA
clones (which were listed in the paper) were ordered from the IMAGE consortium
(Lennon et al 1996) clones held at HGMP, Flinxton Flail, Cambridge. Only 10 clones
were available (see Table 4.1) from this source and the cDNA clone insert was used
as a probe in Southern blot hybridisation analysis on the chromosome 11 YACs.
The remaining ESTs for which no cDNA clones were available were mapped to the
chromosome 11 YACs by PCR analysis using unique primers which were designed
to the published EST sequence.
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Table 4.1: Chromosome 11 ESTs residing in subintervals 21 and 22 as










F05464 21 YES Hybridisation small nuclear
ribonucleotide
polypeptide C
F02133 21 YES Hybridisation None
F00203 21 NO PCR None
Z39212 21 YES Hybridisation None
F00504 22 N/D N/D mitochondrial
acetoacetyl-CoA thiolase
F00690 22 N/D N/D Alpha B-crystallin
F04857 22 YES Hybridisation None
F02376 22 YES Hybridisation None
Z38957 22 YES Hybridisation None
Z39242 22 YES Hybridisation None
Z42258 22 YES Hybridisation None
and PCR
Z42924 22 YES Hybridisation None
and PCR
Z46134 22 YES Hybridisation None
and PCR
Z28525 22 NO PCR None
Z28611 22 NO PCR None
Z28653 22 NO PCR None
Z19327 22 NO PCR None
F00755 22 NO PCR None
F00845 22 NO PCR None
Z45606 22 NO PCR None
Sub-interval 21 corresponds to regional classification in the Rosier et al (1995) paper and is
the region just proximal the chromosome 11 breakpoint. Sub-interval 22 corresponds to the
region distal the translocation breakpoint on chromosome 11.
133
Results Chapter Four
4.2.1 High resolution mapping of chromosome 11 ESTs by Southern
Blot hybridisation Analysis
cDNA clones from which the ESTs were derived were obtained for EST's F05464,
F02133, Z38957, F04857, F02376, Z39212, Z39242, Z42258, Z42924 and Z46134
from HGMP Resource Centre, Hinxton, Cambridge.
Probes were made from the cDNA clone insert by boiled colony PCRs (see section
2.13.2), employing primers designed to the Lafmid BA vector sequence (291; 5'-
CAGGAAACAGCTATGAC-3'and 292; 5'-GTAAAACGACGGCCAGT-3'), into which
the cDNA had been cloned. PCR products were run out on a 1% low melting point
agarose gel. The product was cut out and the DNA purified using Geneclean kit
(section 2.7.5). These probes were then used for hybridisation to the chromosome
11 YAC panels, which are described in section 3.2.1. All YAC panels contained
chromosome 11 only hybrid J1CI4 and total human genomic DNA as positive
controls.
The results of these hybridisations indicated that 9 out of the 10 cDNA clones from
which the ESTs were derived, were not contained within any of the YACs in
chromosome 11 YAC contig. Negative results were reported only when positive
bands were seen in total human genomic DNA and J1CL4 with all the YACs being
negative. An example of such a result is shown in Figure 4.2. In the majority of the
cDNA hybridisations a constant band, which differs in size from that seen in the
positive controls, is seen in all of the YACs (see Figure 4.2). This band is
approximately 8Kb (EcoR1) in size and appears on several of the YAC hybridisation
blots with different probes. This band is not consistent with the vector bands of the
Lafmid BA vector or with Yeast specific bands (as indicated by the inclusion of
Lucy2 yeast only cell line in some of the panels). These bands were initially thought
to have resulted from some contamination from the boiled colony at the PCR stage.
However, they also appear when a PCR product from the 3' end of EST Z39242
prepared from Qiagen minipreped DNA was used as a probe (see Figure 4.3) and
therefore may be the result of contamination in the YAC DNA perhaps resulting
from the preparation of the DNA as it does not appear in the human hybrids or
human genomic DNA. Alternatively, these bands could be the result of YAC vector
contamination. These results indicate that these ESTs are not in close proximity to
the translocation breakpoint since they do not reside within the YAC contig. This
would place them at a distance of greater than 2Mb distal, and 800Kb proximal to
the chromosome 11 breakpoint.
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Figure 4.2: An example of Southern blot hybridisation analysis of
the cDNA clone corresponding to EST F02133 onto chromosome 11 YAC panel
cut with restriction enzyme EcoRI. Positive controls THG(total human
genomic DNA) and J1 (chromosome 11 only hybrid) are included in the
panel. A constant band at 8Kb is visible in all the YACs but the positive
controls have a larger band only at approximately 10Kb.
135
Figure 4.3: Southern blot hybridisation analysis of PCR product from 3' end of the
cDNA clone corresponding to the EST Z39242 hybridised onto a chromosome
11 YAC panel cut with EcoRI.
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The cDNA clone, from which the EST Z39242 was derived, appeared to contain
bands in several of the YACs in the chromosome 11 contig, as well as in the
positive controls J1CL4 and total human genomic DNA (Figure 4.4A and 4.4B). This
clone was investigated in more detail.
cDNA clone corresponding to EST Z39242:
The cDNA clone from which the EST Z39242 was derived has an insert size of
1.4Kb. When this clone insert was hybridised to the chromosome 11 YAC panel,
several bands were seen in overlapping YACs in the contig. A band was visible in
the chromosome 11 only hybrid J1CL4 against a background smear and several
bands were visible in total human genomic DNA again against a strong background
smear (Figure 4.4). This initially seemed to indicate that this clone, although
probably containing a repeat element, (as indicated by the background smear seen
in total human DNA) did map to the YAC contig. The pattern of banding in the YACs
suggested that this cDNA clone may represent a large gene, exons of which
extended across much of the YAC contig. (Figure 4.5 indicates where these exons
could lie according to common bands seen in overlapping YACs. Chimaeric YACs
D165 and H515 are ignored). The YAC D0485 which spans the translocation
breakpoint on chromosome 11 also appears to contain a band, implying that this
postulated gene may be in close proximity to the chromosome 11 breakpoint and
perhaps even span it. This band was not in common with any YACs overlapping
with D0485.
Southern blot hybridisation analysis on the somatic cell hybrid panel using the clone
insert as a probe, showed high background smearing despite pre-blocking of the
probe with sonicated total human genomic DNA to compete out any repetitive
sequences. Since this suggested that the probe contained a substantial repetitive
element, primers were designed to the EST sequence of Z39242 in order to
reassess the analysis of the YAC panel with a repeat free probe. The cDNA clone
corresponding to the EST Z39242 was also sequenced in order to determine the
repeat content. The walk primers used to sequence this clone are listed in Table
4.2.
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Figure 4.4 A: Southern blot hybridisation analysis of the whole cDNA
clone corresponding to the EST Z39242 onto the chromosome 11 YAC
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Figure 4.4 B:Southern blot hybridisation analysis of the whole cDNA
clone corresponding to the EST Z39242 onto a full length chromosome














Table 4.2 : Oligonucleotide primers used to sequence cDNA clone corresponding to
the EST Z39242. *Primers used in PCR to produce a repeat free probe.
Primer Name Primer Sequence (5'->3')
Vector Primer M13 (forward) TGT AAA ACG ACG GCC AGT
Vector Primer M13 (reverse) CAG GAA ACA GCT ATG ACC AT
*K290 GCA CAG AGA ATG AAT GAT AAG
K97 TGA CAG GGG TGA TTC TCC
K229 CAC CTG GAA GCA TCT GTT
*K872 CTT TTA GAT TGT GGG TAT TAT
K204 CTC AGA AAT CAC CAC TAA
K301 CTG CCA TAC TTG TTT TCC
K568 ATG GGA ATG GAA ATG GTG
K85 TAG CGG GTG TGA AGT GGT ATC
K289 ACT TCA TAA GTA TGC AAA ACA
The sequence of the cDNA clone is shown in Figure 4.6. There is no open reading
frame in this sequence and the poly A tail is marked indicating that this clone is
derived from the 3' end of the gene.
Repeat database searches (Pythia program Jurka et al 1992) indicated that a
repetitive sequence was present and BLAST database searches indicated that
several regions in the sequence showed homology to members of the LINE 1
repeat family, which are found at high frequency in the human genome at
approximately every 70Kb (Arveiler and Porteous 1992). The fact that there is a
large repetitive element in the sequence and no open reading frame implies that this
1.4Kb clone is all 3' untranslated sequence. Southern Blot hybridisation analysis
using a Line 1 repeat probe was done on selected YACs from the chromosome
Hcontig. The result of this hybridisation is shown in Figure 4.7 (This work was
carried out by John Maule who also kindly provided the Southern blot hybridisation
shown in Figure 4.7). The LINE1 probe ESL1.7 was used to probe the panel of




Figure 4.6: Sequence of cDNA clone from which the EST Z39242 is derived. The
EST sequence is underlined with dotted line and the repetitive element in the
sequence is underlined with bold solid line.
1 GCGGCCGCAG GAAATTTTTT TTTTTTTTTT TTCTATGCAC AGAGAATGAA
51 TGATAAGCCT
Poly A Tail
TAAGCTATCA AAATGGTGGA GATGAGGAGA AGAGATTGAC
101 AATCAATGCA TACAACATAA GATACTACTG TAGTAATGTG GTAAAGCTAT
151 TAGATATGTG AAAGGGGTGA TTCTCCTCTA CATTCTCTTA TGCTGAGTAA
201 CAGCTCCCCA GAATAAAAGG GAAAATTTTC CCCAGTCAAA ATACATAAAT
251 GGAAGACATA AATATTTCCT CTCTCCTAGA AGACCGGCAG AAACAGATGC
301 TTCCAGGTGC TAGGCATTTT CCATTTTGCC AGGAGTAATC TTAGCATGCT
351 CACATTCAAT AGTTCTTTGA GGAATATCCA AATAAAATTA TTTTAGCTAT
401 TCTCATGAAG ATATAATACC CACAATCTAA AAGTTAGTAA GAATTAAGGA
451 TAAATATTAA CAAGTGCTAG GATTAAAATA AACCTTCATA GGGATAAAAG
501 ACTACATATT GGGTATAATG TACACTGCTC CAGTGACAGG TGCACCAAAA
551 TCTCAGAAAT CACCACTAAA GAACTTATCC ATGTAACAAA AAACCACCTG
601 TACCCTCAAA ACTATTGAAA AATAAATAAA TAAACTTTCA TGGTTACAAA
651 AAAACAAACA AACAGCTAAC ACAATTAAGG AGCTCACATT ACTAAAATGC
701 TGAATCAAGG CTCAGCCATG TTGTAGTATG TATCAGTACT GCATTCCTTT
751 TTATTTCCCA ACAATATTTT ATTGTATAAA TATACCACAT TTTTTGGTCC
801 ATTCATCAAT TGATGGAAAT TTAGGTTTTT TCCATTTTTT GACTGTTATT
851 AATAATGTTC CATGAACATT AGTGTACATG TTTTTATACT GACATATCTT
901 TTTACTTCTC TTGGAAGGGC AGAGCTGCTG GTTCACATGG TAACTCTGTT
951 TAAGAACTGC CAGACTkGTT TTCCAAAGAG GCTGCACCAT TTCCATTCCC
1001 ATCAGCAGTG TTTGAGGGTT CCAATTTTCC ACAACATTAT TAATACTTGC
1051 TGTTACCTGT CTTTTTGATT CTAGCCATCC TAGCGGGTGT GAAGTGGTAT
1101 CTCACTGTGG CTTTGATTTA CATTTCCCCT GATGGCTAAT GATGTTGACA
1151 TCTTTTGGCC ATTTGTCCTT ATGGCCCATT TGTGTATGTT AGCTGTGGAT
1201 TTTTCATAGA TGCCCTTTAT CAGGTCAAGG AAGTACTTTC TATTCCTTAT
1251 TTAATGAGTG TTTTCATCCT GAAGGGGTGT CGCATTTTGT CAAGTGTGTT
1301 TTCTGAATTT AAAGGTGATC ATGTGGTGCT TGATACCAGC TGTTTTTGTT
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Figure 4.7: Southern blot hybridisation analysis of LINE 1 repeat probe (ESL 1.7)
hybridised to selected YACs from the chromosome 11 YAC panel. The YACs have
been cut with two restriction enzymes BssH I/ and Eag I.
(Southern blot courtesy of John Maule).
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The results from this hybridisation showed that only a few bands were seen in the
YACs and that this was reminiscent of that seen in the Southern blot hybridisation
analysis of the EST Z39242 cDNA clone, in that only a small number of bands were
seen in the YACs (although the YACs were cut with restriction enzyme Hindlll in this
panel). This implied that perhaps the bands seen in the initial hybridisation analysis
of the EST Z39242 cDNA clone were a result of the LINE 1 repetitive element and
that the non repetitive segment of the clone may in fact not map to the YAC contig.
PCR analysis was carried out on the chromosome 11 YACs using primers K290 and
872 (see Table 4.2), in order determine if the non-repetitive component of the cDNA
clone did map to the YAC contig. PCR was also done on the cDNA clone DNA
(isolated using Qiagen miniprep kit) to prepare a probe for Southern blot
hybridisation analysis on the chromosome 11 YAC and somatic cell hybrid panels.
PCR conditions were as described in Table 4.3 and 200ng of DNA was used in
each reaction. The cDNA clone DNA was used as a positive control along with
J1CL4 and total human genomic DNA.
Table 4.3: PCR conditions for amplification of a repeat free section of cDNA clone
(from which EST Z39242 was derived) from the chromosome 11 YACs and somatic
cell hybrids.
Denature Annealing Extension
Cycle 1 94°C/30sec 55°C/30sec 72°C/25sec
Cycle 2-39 94°C/15sec 55°C/30sec 72°C/25sec
Cycle 40 94°C/15sec 55°C/30sec 72°C/45sec
The results from the PCR indicated that the repeat free segment of the cDNA clone
was not contained in any of the chromosome 11 YACs (Figure 4.8). A band of the
correct size was however seen in total human genomic DNA and the chromosome
11 only hybrid J1CL4 but not in the mouse or hamster cell lines. It is likely therefore
that the bands seen in the original probing using the whole cDNA clone as a probe
in Southern blot hybridisation analysis were the result of the repetitive element in
the cDNA clone and not a result of the clone mapping to within the YAC contig.
Southern blot hybridisation of the PCR product derived from the cDNA clone
confirmed that the clone was not contained in any of the chromosome 11 YACs
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Figure 4.8: PCR analysis showing amplification of the 3' end of the cDNA clone
corresponding to EST Z39242 (using primers K290 and 872) from somatic cell hybrids
and chromosome 11 YACs.
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chromosome 11 only hybrid J1CL4. The band seen in total human genomic DNA
was still contained within a background smear but this is most likely due to the
higher complexity of the DNA in comparison to that of J1CL4. The band in J1CL4 is
much weaker than that seen in total genomic DNA and is a reflection of the lower
copy number in this hybrid. A constant band which appears in all the YACs but
which is of different size to that seen in the total human genomic DNA and
chromosome 11 only hybrid J1CL4 is again seen in this probing although it is very
faint. This band is not seen in the yeast only hybrid LUCY2 and so is unlikely to
represent a yeast specific fragment, neither does it correspond to the size expected
from the Lafmid BA vector sequence (see section 4.2.1).
4.2.2 High resolution mapping of chromosome 11 ESTs by PCR
Analysis
The remaining 8 ESTs, for which no cDNA clone could be obtained, were mapped
to the chromosome 11 YAC panel by PCR analysis. Primers were designed to the
published EST sequences either using the Oligo 4 computer package (Hybaid) or
the Primer design program "Primer" at HGMP Resource Centre, Hinxton,
Cambridge ("Pimer" - version 0.5 Lincoln et al 1991 (unpublished), MIT centre for
genome research and Whitehead institute for biomedical research, Nine Cambridge
centre, Cambridge, Massachusetts). Table 4.4 lists the primers and PCR conditions
used in the PCR assays. PCR analysis was also carried out on 3 of the ESTs which
were originally mapped using cDNA probe hybridisations in order to confirm these
results (Z42258, Z42924 and Z46134).
Results from the PCR indicated that none of the ESTs mapped to within the
chromosome 11 YAC contig (see Figure 4.9 for examples of PCR results), placing
them at a distance greater than 2Mb distal to the breakpoint or greater than 800Kb
proximal to the breakpoint. Positive controls J1CL4, total human genomic DNA and
negative control LUCY2 Yeast only hybrid, were included in each EST PCR. A
negative result in the YACs was only judged to be real if positive bands of the
correct size were seen in the positive controls J1CL4 and total genomic DNA and if
a negative result was obtained in the yeast only hybrid LUCY2. Several
chromosome 11 YACs contained bands in the PCR for EST F00755 but this band
was of greater than expected size and corresponded to the size of band seen in the
LUCY2 yeast only hybrid. A band of the correct size was seen in the positive control

















































































































































































































































from yeast and probably represents a homolog of this EST in yeast (see Figure
4.9b).
PCR analysis was also done on the somatic cell hybrids to confirm the position of
these ESTs as either proximal or distal to the breakpoint and to refine their mapping
positions further. Results from this analysis are summarised in Table 4.5.
Table 4.4: Oligonucleotide primers and conditions used to amplify EST sequences








































































































































































Table 4.5 : Summary of results from PCR analysis of chromosome 11 ESTs on
somatic cell hybrids.
Hybrid EST
Z19327 Z28525 Z28653 F00203 F00755 F00845 Z45606 Z46134
THG + + + + + + + +
J1CL4 + + + +(+>) + + + +
MIS39 + -(+>) N/D + N/D - -
MIS7.4 + + N/D - N/D + + +
MAR1 + N/D - N/D + N/D N/D -
MAR 12 + N/D + N/D + N/D N/D +
WJX3.4 - - - + - - -
WJX5.4 - + + -(+» + + + +
WJX7.4 - - + - - -
E67.1 + - + - + + + -
E67.4 + -(+» + + + + -
RAG + N/D N/D N/D N/D N/D - N/D
CI 27 + -(+» - - + 111 -
WG3H - - - -(+» - - -
A9 + - - - + - -
















THG - Total human genomic DNA
+ - PCR product of expected size present in somatic cell hybrid
- No PCR product of the expected size was seen in somatic cell hybrid
N/D - Hybrid not done
(+>) - Band of greater than expected size present.
? - Map location undetermined.
DER1- derived chromosome 1 indicating that this EST maps to distal the breakpoint
on chromosome 11.
DER11- derived chromosome 11 indicating that this EST maps to proximal the breakpoint
on chromosome 11.
Two of the ESTs (Z19327 and F00755) could not be localised to either above or
below the translocation breakpoint on chromosome 11 as a similar size band to that
expected for the EST was seen in the mouse only hybrid, thus masking the status
of all the hybrids in a mouse background (including the MIS and MAR hybrids). In
EST Z42258 (not shown in Table 4.5) the mouse only hybrid similarly contained a
band of equivalent size to that expected from the EST in human DNA which
prevented it being further mapped.
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It would be possible to map these EST further by determining restriction enzyme
sites which were different between the two homologs (mouse and human).
Restriction enzyme digests could then be carried out on the PCR products, allowing
differentiation between mouse and human bands and those hybrids containing the
human EST to be determined. The PCR on EST Z28525 also showed a band in the
mouse only hybrid but this band was distinguishable from the expected human
product and therefore did not pose any problem. One ESTs, F00203, had a product
present in the hamster only hybrid but this again was of a different size to the
expected human product and was distinguishable from it.
The ESTs Z45606, F00845, Z28653 were unable to be more finely mapped, other
than to lying distal to the translocation breakpoint as determined by the MIS and
MAR hybrids. The inability to more finely map these ESTs was a result of them all
showing the same positive pattern in the hybrids, namely MIS 7.4, WJX5.4, E67.1
and E67.4 for which no corresponding region existed from previous characterisation
of these hybrids with chromosome 11 markers (no region distal to the breakpoint is
positive for both E67.1 and E67.4, see Table 3.3 and 4.5). This is likely to be a
result of either cross contamination of the two hybrids with each other so that they
both appear positive in PCR analysis or undetected positive regions of chromosome
11 in the hybrids due to the large distances between the markers used to
characterise them. It is possible that a region which is positive for both E67.1 and
E67.4 is present distal to the breakpoint but more markers in the intervening
distance would be required to further characterise the hybrids.
The Human Transcript Map which has been produced by Schuler et al (1996) (and
is continually being added to) has mapped many of the ESTs described in the
Rosier et al (1995) paper subsequently to this work being undertaken. The results
of this mapping are shown in Table 4.5.
Since the ESTs, which could not be mapped due to mouse or hamster homologs
masking the PCR results, have now been mapped on the Human Transcript Map
(Schuler et al 1996) (see Table 4.6) it was unnecessary to repeat the mapping by
restriction enzyme digestion of the somatic cell hybrid PCR products. One EST,
Z28611, was refractory to PCR and could not be amplified despite using several
differing annealing temperatures and magnesium concentrations. A new set of
oligonucleotide primers was designed to the EST sequence but did not improve the
PCR. However, this EST has now been mapped by the Human Transcript Map and
does not lie in the vicinity of the chromosome 11 breakpoint.
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Since none of the ESTs appear to map to the region around the translocation
breakpoint they are deemed to be too far from the breakpoint to be further pursued
as candidate genes involved in the psychiatric diagnosis in the translocation family
K26.
Discussion:
High resolution mapping of Expressed Sequence Tagged Sites (ESTs) derived from
sequencing the ends of cDNA clones is a rapid method by which to identify
candidate gene transcripts from a region which has been genetically linked to a
disease. There are various pitfalls to using these however such as low copy
repetitive elements which may be present in the corresponding cDNA clones which
may give somewhat misleading results as has been demonstrated in the current
study. This is often due to the presence of 3' untranslated regions of the gene being
present in the clones which are more likely to contain repetitive elements than
coding regions. Since the ESTs are often derived from cDNA libraries which have
been oligo dT primed and therefore select the 3' most end of the gene by virtue of
the poly A tail it is likely that many cDNA clones corresponding to ESTs will contain
repetitive elements and this should be borne in mind when using these clones.
Of the 20 ESTs which were mapped to the region around the translocation
breakpoint on chromosome 11 by Rosier et al (1995), high resolution mapping
showed that none resided within the chromosome 11 YAC contiguous clone map.
This placed these ESTs at a distance of greater than 2Mb distal and 800Kb
proximal to the chromosome 11 breakpoint. It is therefore unlikely that any of the
genes corresponding to these ESTs are involved in the psychiatric diagnosis in the
K26 translocation family.
There are many ways that a translocation event may disrupt gene function such as
by affecting the chromatin structure around a gene, by disrupting long range control
elements of gene function or by creating gene fusion products. There are examples
of translocation breakpoints having an effect on a gene some distance away and
causing disease. One such example is seen in the case of the PAX6 gene,
mutations in which cause the eye disorder Aniridia. Several families have been
described where the chromosomal breakpoints have been up to 85Kb distal to the
PAX6 gene and caused Aniridia. Since no mutations in the PAX6 gene were seen
this was thought likely to be because a chromosomal rearrangement which caused
an inappropriate chromatin environment which does not allow normal expression of
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the gene (Fantes et al 1995). Another example occurs in Campomelic dysplasia,
which is a skeletal malformation syndrome. This disease is caused by mutations in
the SOX9 gene on chromosome 17q and translocation families have been
described in which the breakpoint is 130Kb from the SOX9 gene (Wirth et al 1996).
Translocations events in Burkitt's Lymphoma have shown that when the gene
responsible for the condition, c-myc, is brought under the influence of B-cell control
elements on chromosomes 2, 14 or 22 the breakpoints can be up to 340Kb away
from the c-myc gene and still lead to constitutive up-regulation expression of the
gene (Joos et al 1992). Although it may be possible that longer range effects which
could act at up to 800Kb from the breakpoint may exist, none have been
demonstrated to date. It is therefore unlikely that any of the genes corresponding to
these ESTs are involved in the psychiatric diagnosis in the K26 translocation family.
Several genes which reside within 800Kb proximal to the translocation breakpoint
on chromosome 11 have been identified (Devon et al 1997) as a result of the
positional cloning strategy being undertaken to elucidate the genes involved in the
psychiatric diagnosis in this translocation family and are currently being persued.
The Human Transcript Map (Schuler et al 1996, World Wide Web site location:
http://www.ncbi.nlm.nih.gov/SCIENCE96/. Site hosted by National Centre for
Biotechnology Information, National Institute of Health, Bethesda. MD 20894 USA)
has recently localised many of the ESTs from around the breakpoint region to an
integrated chromosome 11 radiation hybrid, cytogenetic and genetic map. This data
has confirmed the location of the ESTs as either above or below the breakpoint.
The ESTs whose map positions were able to be determined by the chromosome 11
somatic cell hybrids are slightly different from those of the Human Transcript Map.
However, these positions are at the same general location. For example, those
ESTs mapping to the interval D11S351 to THY1 (corresponding to 110-112cM on
Human Transcript Map, cytogenetic location approximately 11q22.3 refer to figure
4.1) such as Z28525 and Z46134 are mapped in the Human Transcript map to
region D11S1325-D11S1778 (105-106cM) respectively. This corresponds to a
cytogenetic position of 11q21-q22. EST F00203 was mapped to the region between
D11S533 and OMP, corresponding to cytogenetic region 11 q 13.5-q 14.1, by somatic
cell hybrid PCR analysis. The marker D11S533 is in very close proximity to the
marker D11S911 in the Eugene McDermott Centre for Human Growth and
Development integrated chromosome 11 map (World Wide Web Site location:
http://mcdermott.swmed.edu/. Site hosted by University of Texas South Western
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Medical Centre, Dallas, Texas, USA). The Human Transcript Map places this EST
at interval D11S916-D11S911 at approximately cytogenetic location 11 q 13. This
EST's map position is very similar to that seen in the Transcript map. As a result of
a greater number of STS markers on the Human Transcript map and very detailed
characterisation of the radiation hybrids used to localise ESTs it is quite possible
that the mapping positions on this map will differ slightly from those of the
chromosome 11 somatic cell hybrids. The latter were characterised with far less
markers and therefore the cytogenetic location inferred by these results is less
specific than that of the Transcript Map. However, given that the ESTs which were
mapped by the somatic cell hybrid method correspond reasonably well to the map
positions in the Transcript Map the viability of using this method for high resolution
mapping is again demonstrated.
The ESTs which have been investigated in this study for involvement in the
psychiatric diagnosis in the translocation family have been considered as candidate
genes solely on the basis of their position in close proximity to the translocation
breakpoint.
None of the ESTs will be considered further at the present time as candidate genes
due to their distant location from the translocation breakpoint. However, until the
whole gene has been mapped we cannot exclude the possibility that the 5' end is in
the region of the breakpoint (since the ESTs are usually designed to the 3' end of
the gene and some genes can be extremely large). It is possible that if further
biological information becomes available on the genes that these ESTs represent
which is of interest, such as further mapping or functional and expression data
which may indicate their possible involvement in the psychiatric diagnosis of the
K26 pedigree, these genes may be further considered as candidate genes in the
absence of any stronger candidate gene residing in closer proximity to the
breakpoint. Information on these ESTs, available through various databases and
World Wide Web sites, will therefore be monitored.
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Table 4.6: ESTs described in Rosier et al (1995) mapping positions in Human
Transcript Map (Schuler et al 1996 and on WWW at the National centre for
biological information, National Institute of Health website location
http://www.ncbi.nlm.nih.gov/SCIENCE96/)










F00690 YES D11S1893-D 11S938
(109-1 lOcM)
Ilq21-q22
Alpha Crystallin B chain










































Z28611 NO* D11 SI 333-D 11S917
(98-100cM)


































This EST was not mapped in the Human Transcript map but shows strong homology to the
KIAA0092 protein which has been mapped to the region indicated.
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An allelic association study of two polymorphic
markers in close proximity to a balanced
translocation t(1:11) breakpoint which




One of the most popular strategies for finding genes involved in psychiatric
disorders and many other complex disorders, has been to carry out genetic linkage
analysis on large families with many affected members. However, such studies
have failed to identify unequivocally the gene(s) involved in schizophrenia, most
likely due to the complex nature of the disorder (polygenic non-Mendelian
inheritance, probable aetiologic heterogeneity and difficulties with precise
phenotype definition). Recent world-wide collaborations and methodological
refinements have enabled large numbers of families to be studied, thus improving
the power of the technique and several candidate regions have been identified,
most notably chromosome 6p (Wang et al, 1995, Straub et al 1995) and 22q (Pulver
et al, 1994; Coon et al, 1994). Further replication and refinement of these regions is
needed. Population based association studies, in which the frequency of an allele at
the marker locus in disease population is compared to that of an ethnically matched
control population, provide an alternative approach to family based linkage analysis
and have been widely used in psychiatric genetics.
Association studies have considerable appeal since they can detect genes that
contribute to only a relatively small proportion of the overall liability to developing a
disorder. It is likely that most psychiatric disorders result from the combined effects
of several genes of moderate or small effect and therefore association studies may
be a particularly good way of identifying these genes. Association studies are non-
parametric and therefore do not rely on any prior assumptions, other than the
disorder having a genetic component, unlike conventional genetic linkage studies in
which mode of inheritance, penetrance levels etc. must be correctly specified.
Another distinct advantage of association studies is that large affected families,
which are often difficult to obtain, are not required.
Association studies have been successfully performed in a number of complex
disorders such as late onset Alzheimer's disease with apolipoprotein E 4 allele
(Corder et al 1994) and myocardial infarction with angiotensin converting enzyme
(Cambien et al 1992). A recent and impressive demonstration of the power of
association studies to detect the subtle effects of genes on multifactorial
quantitative traits, is the association between a dopamine D4 receptor gene
polymorphism and the personality trait of novelty seeking behaviour (Ebstein et al
1996). The initial report of association in a group of 124 Israeli subjects whose
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personality scores were based on tridimensional personality questionnaire (TPQ)
has been replicated using a different personality questionnaire in an ethnically
different population (Benjamin et al 1996) and family studies have demonstrated
that the effect is genetic and not due to population stratification. Association studies
are being widely used in attempts to detect quantitative trait loci involved in
personality as they provide the necessary statistical power to detect relatively small
gene effects that contribute to complex behavioural traits.
The positional cloning strategy which is currently being employed on the K26
translocation family to elucidate the relationship between the translocation event
and the psychiatric diagnosis in this family is based on the hypothesis that a gene or
genes involved in mental illness in this family reside at or near the translocation
breakpoint on chromosome 1 and/or 11. The regions around the chromosome 1
and 11 breakpoints have been cloned as described in sections 1.16 and 7.2. Two
polymorphic markers have been identified as lying in close proximity to the
translocation breakpoint, as a result of this positional cloning strategy. A 2.7Kb
derived chromosome 1 fragment was isolated from hybridisation of a genomic
library made from a translocation patient DNA using a 2.15Kb cosmid derived probe
which spanned the wild-type chromosome 11 breakpoint. This derived chromosome
1 probe was used as a probe back onto the genomic translocation patient library
and identified a 7Kb wild-type chromosome 1 fragment. This wild type chromosome
I fragment was sequenced in order to determine differences between the wild-type
and derived chromosomes in this region (see section 7.2). As a result of this
sequencing and subsequent database searching, a polymorphic triplet repeat,
which showed strong homology to the STS marker D1S1621, was identified. This
triplet repeat was approximately 300bp distal to the chromosome 1 breakpoint.
The dinucleotide repeat marker, D11S931, is in close proximity to the chromosome
II breakpoint and resides at approximately 85Kb proximal to the translocation
breakpoint.
The evidence of linkage between chromosome 1 and 11 and mental illness is
sparse with few independent reported genetic linkage results from around the
region of the translocation breakpoint. Genetic linkage studies by our group using
chromosome 1 and 11 markers in close proximity to the breakpoint have provided
no further evidence of linkage (Muir et al in preparation). However, given that
association studies are a sensitive method for detecting genes of moderate to weak
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effect, markers D1S1621 and D11S931 provide an opportunity to investigate an
association between the translocation breakpoint region and a postulated
schizophrenia susceptibility gene residing in close proximity to the breakpoint, in a
random population of affected subjects versus normal controls. These subjects
were selected from the same geographical region as that of the translocation family.
5.2 Pilot study to assess the polymorphism of marker D1S1621
A pilot study was carried out using the marker D1S1621 in order to determine how
polymorphic this marker was and if it would be sufficiently informative, in terms of its
polymorphism, to be used in the association study. Several members of the
translocation family were genotyped as described above for marker D1S1621. It
was apparent that five alleles were present, with an excess of one of these alleles
being seen in most of the family members (allele 261 bp). When a larger population
was studied (in the association study described below) a sixth rarer allele was also
identified (267bp). The marker D1S1621 was deemed polymorphic enough to be
used in the study based on the fact that it had six alleles which seemed to all (with
the exception of allele 6, 267bp) appear frequently in the population studied.
Based on the information obtained from the allelic association study on the control
sample (described below), the heterozygosity of the marker D1S1621 was
assessed.
Heterozygosity can be determined by the equation:
n
HET = 1-1 Pi2
i=i
n = number of alleles
Pi = population relative frequency of the ith allele
HET - Probability that a random individual is heterozygous for any two alleles at a
gene locus.
For marker D1S1621 the heterozygosity value is 0.77 as determined by the
UNILINK computer program (Terwilliger and Ott 1994).
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5.3 An allelic association study of D1S1621 and D11S931 in
schizophrenia subjects, unipolar depressed subjects compared to
control subjects.
The frequencies of the alleles of D11S1621 and D11S931 were studied in a random
population of subjects with schizophrenia and also in a random population of
unipolar depression subjects (a diagnosis also prominent in the t(1:11) family) and
compared to ethnically matched control subjects in order to determine if there was a
difference in allele frequencies between the affected populations and the control
population.
5.3.1 Subjects:
The schizophrenia subjects (n=105) and the unipolar depressed subjects (n=84)
were all either in-patients or out-patients at the Royal Edinburgh Hospital,
Morningside Park, Edinburgh. All patients were interviewed by psychiatrists using
the Schedule for Affective Disorder and Schizophrenia-lifetime version (SADS-L)
(Endicott and Spitzer 1978). Diagnoses were based on RDC and DSM IV criteria
(Spitzer et al 1978 and American Psychiatric Association 1994). Control subjects
were obtained from the general population and were excluded from the study if they
had a personal or family history of psychiatric illness. All subjects originated from
the south east of Scotland and gave informed consent to take part in this study.
Standard procedures were used to extract DNA from peripheral blood samples.
Subjects were genotyped for markers D11S931 and D1S1621 by the polymerase
chain reaction (PCR) using a fluorescent primer and electrophoretic analysis was
carried out using a 40-lane automated laser fluorescence (ALF) sequencer.
5.3.2 Genotyping subjects for markers D11S931 and D1S1621
Amplification of D1S1621 marker was achieved using primers
5'-TTTCTCACCTTTAAATGTCATCA-3' and 5'-CCAGTACGCAGATGGTCCTA-3'.
The first of these primers was used as described from information obtained from the
GENBANK database and Whitehead institute/MIT centre for genome research
databases (http://www.genome.wi.mit.edu/)(Hudson et al 1995). The second of
these primers was designed to the sequence extending just beyond the marker
D1S1621 corresponding to the sequence obtained from the 7Kb wild-type
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chromosome 1 sequence around the breakpoint as the primer described in the
database for this marker was refractory to PCR. This PCR produced a product of
between 252bp and 267bp. D11S931 was amplified with oligonucleotide primers 5'-
ATGTTGGTAGGTATTCT- 3' and 5'-GAGAAATAGTATGTGTTTGCC -3' which
were designed to the EST sequence described in the database in order to obtain a
product which was of a different size to that for D1S1621, since the primers
described in the database would have produced a product of approximately 250bp.
The difference in PCR product size was desirable to allow both the PCR products,
from the same patient DNA, to be run in the same lane of the polyacrylamide gel,
thus reducing the number of gels required for the genotyping.
Tables 5.1 and 5.2 show the PCR conditions for markers D1S1621 and D11931
respectively.
Table 5.1 PCR conditions for marker D1S1621:
Denaturation Annealing Extension
Cycle 1 -27 94°C/30sec 55 °C/75sec 72°C/15sec
Cycle 28 94°C/30sec 55°C/75sec 72°C/6mins
Table 5.2 PCR conditions for marker D11S931:
Denaturation Annealing Extension
Cyclel 94°C/5min 47°C /30sec 72°C/1min
Cycle 2-29 94°C/1 min 47°C /30sec 72°C /1min
Cycle 30 94°C/1min 47°C /30sec 72°C /2min
Electrophoresis was carried out on a 40-lane automated laser fluorescence (ALF)
sequencer (Pharmacia).
After the PCR reaction, the products from both reactions (D11S931 and D1S1621),
for the same patient, were run in the same lane on the ALF sequencer (since the
products are of different size) with appropriate size markers and gold standards
(kindly provided by Stewart Morris). Automated genotyping was carried out using
'ALF' manager and 'ALP' software (He et a/ 1995, Mansfield et al 1994 ). All gel




For marker D1S1621, 142 control subjects, 105 schizophrenia subjects and 84
unipolar depressed subjects were genotyped. The PCR detected 6 alleles of sizes
252bp, 255bp, 258bp, 261 bp, 264bp and 267bp. The allele 258bp was the most
frequently seen allele in the control population, occurring in approximately 33% of
the controls tested. The 267bp allele was seen more rarely than the other alleles
occurring in only 2% of the control population. The most common genotype seen in
the control population was 3/3 (258bp) (14%) with 2/3 (255bp/258bp) (13%) also
being seen at high frequency. No genotype 6/6 (267bp) was seen in any of the
groups tested.
D11S931:
In the case of marker D11S931, 143 control subjects, 100 schizophrenia subjects
and 84 unipolar depressed subjects were genotyped. The marker D11S931 has 4
alleles of sizes 149bp, 159bp, 163bp, 165bp. The 165bp allele was the most
commonly seen in the control population (37%) and the 159bp allele is the least
common (10%). The most common genotype for marker D11S931was 1/4
(149bp/165bp) (24%) and the least common 2/2 (159bp/159bp) (1%).
Figures 5.1 And 5.2 are graphical representations from the ALF automated
sequencing gel which shows the alleles of markers D1S1621 (Figure 5.1) and
D11S931 (Figure 5.2).
Figures 5.3 to 5.6 are graphical representations of either percentage allele




Figure 5.1: Graphical representation of ALF sequencing gel showing the six alleles
(1=252bp, 2=255bp, 3= 258bp, 4=261 bp, 5=264bp and 6=267bp) for marker
D11S931 along side a size marker (229bp). The peak height is representative of
the intensity of the fluorescent band seen on the sequencing gel and the X axis
denotes the time scale (minutes). Each colour represents a different patient DNA
so that the genotype of the patient represented in blue is homozygous 3/3




Figure 5.2: Graphical representation of ALF sequencing gel showing the four
alleles (1=149bp, 2=159bp, 3=163bp and 4=165bp) for marker D11S931 along
side a size marker (194bp). The peak height is representative of the intensity of the
fluorescent band seen on the sequencing gel and the X axis denotes the time
scale (minutes) over which the gel was run. Each colour represents a different
patient DNA so that the genotype of the patient represented in blue is
heterozygous 1/3 (corresponding to alleles at 149bp and 163bp).
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Allele Frequencies at Marker D1S1621
□ Controls (n=143)
□ Schizophrenics (n=100)
□ Unipolar Depression (n=84)
252 255 258 261
Allele Size (bp)
264 267
Figure 5.3 Graphical representation of percentage allele frequencies at marker








Figure 5.4 Graphical representation of percentage allele frequencies at marker
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5.3.3 Statistical Analysis.
The presence of an allelic association was sought by using the computer program
CLUMP (Sham and Curtis 1995).
This program is based on chi-squared analysis of the data. CLUMP is designed to
assess the significance of the departure of observed values in a contingency table,
from the expected values, conditional on the marginal totals. The program works on
2XN tables and was designed for use in genetic case-control association studies.
The chi-squared value associated with the contingency table is defined in the usual
way as the sum over all cells of the squared difference between the observed and
expected value divided by the expected value. The significance is assessed using a
Monte Carlo approach, by performing repeated simulations to generate tables
having the same marginal totals as the one under consideration, and counting the
number of times that a chi-squared value associated with the real table is achieved
by the randomly simulated data (Sham and Curtis 1995). The chi-squared statistic
supplied from the original 2XN table input into the program is termed T1.
CLUMP also provides a novel chi-squared value produced by "clumping" columns
together in a new 2X2 table in a way designed to maximise the chi-squared value.
The significance is again tested by the Monte Carlo simulations and the output chi-
squared statistic is termed T4.
Statistical analysis on the association study data is shown in Tables 5.3 and 5.4.
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Table 5.3: Statistical analysis of allele frequency data using the CLUMP computer
package. T1 indicates normal chi-squared values and T4 indicates maximised chi-
squared values after "Clumping" of data (see text). All values calculated from 1000
simulations.
Chi-squared (%2) P Value
D1S1621 T1 T4 T1 T4
Schizophrenia subjects versus
Control subjects 3.44 1.65 0.65 0.81
Unipolar Depressed subjects




Control subjects 1.59 1.30 0.66 0.69
Unipolar Depressed subjects




Table 5.4: Statistical analysis of genotype frequency data using the CLUMP
computer package. T1 indicates normal chi-squared values and T4 indicates
maximised chi-squared values after "Clumping" of data (see text). All values
calculated from 1000 simulations.
Chi-squared (x2) P Value
D1S1621 T1 T4 T1 T4
Schizophrenia subjects versus
Control subjects 11.10 6.94 0.70 0.69
Unipolar Depressed subjects




Control subjects 5.78 5.10 0.77 0.56
Unipolar Depressed subjects
Versus 4.8 4.4 0.85 0.67
Control subjects
No significant statistical differences in allele or genotype frequency were found for
markers D1S1621 or D11S931 in either the schizophrenia subjects or unipolar
depressed subjects as compared to the control subjects.
The number of subjects used in this study was relatively small and some of the
genotype groups were removed from the analysis or merged with other groups as
their numbers were less than 5 thereby nullifying the chi-squared statistic. Further
analysis of the data has been somewhat inhibited by the small numbers seen in the
allele groups. Division of the data into sub-groups (such as age of onset or those
subjects with a first degree relative with schizophrenia and those without) to look for
an effect of association was not feasible due to the small number of subjects used
in the study.
The D11S931 sample had 99% power to detect a 30% difference in allele




The D1S1621 sample has 97% power to detect 30% difference in allele frequency,
68% power to a detect 20% difference and 19% power to detect a 10% difference
(Cohen 1988).
Discussion:
Association studies which compare allelic frequency among unrelated affected and
unaffected individuals from a population, are currently being widely used in the hunt
for genes involved in psychiatric disorders.
There are essentially three possible explanations for demonstrating a significantly
different distribution of allelic variants in affected versus unaffected individuals. The
first of these is that the disease allele is in very tight linkage disequilibrium with the
marker, the second is that the marker allele is actually involved in causing
susceptibility to the disorder under study (pleiotropy) and the third and most
disturbing is that the result is artefactual arising from population stratification.
Population stratification occurs in a mixed population where any trait present at a
higher frequency in a component of the population will show positive association
with any allele which also happens to be more common in that group. To combat
this problem homogeneous populations should be used where the control and
affected group are closely matched for ethnicity. Alternatively, Falk and Rubinsteins
(1987) Haplotype Relative Risk method in which the parental alleles that are not
inherited by the proband, are used as the control sample provides an elegant
solution to the problem of population stratification.
We observed no significant differences in the allele frequencies of markers
D1S1621 or D11S931 in our population of schizophrenic subjects and unipolar
depressed subjects in comparison to the control population.
This lack of association may indicate that the two markers investigated are not in
linkage disequilibrium with a major gene of high prevalence in the population tested.
This raises two issues the first of which relates to the linkage disequilibrium. The
physical distance over which allelic association may be detected is dependent on
several factors including recombination frequency and the number of generations
from the founder. Data published using highly polymorphic markers suggests that
associations may be detectable at distances of 1Mb or more (Peterson et al 1995).
The hypothesis on which the current work is based is that a gene or gene(s) near
the translocation breakpoint on chromosome 1 and/or 11 is disrupted in some way
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by the translocation event and thereby causes the psychiatric diagnosis in the K26
pedigree. Several mechanisms may be responsible for the effect on the
susceptibility gene. For example a gene which spans the translocation could be
directly disrupted by the translocation event, making it non-functional or causing
inappropriate splicing of two gene products resulting in a protein product which
assumes a new function, or gene control elements may be removed or repositioned
by the translocation event. Since the two markers used in the current study also lie
in close proximity to the breakpoint, especially so in the case of marker D1S1621, it
is likely that they will be in close proximity to the postulated schizophrenia
susceptibility gene in accordance with our hypothesis. Thus, the chance of the
postulated gene and the marker being in linkage disequilibrium and showing an
allelic association is increased by choosing markers in close proximity to the
breakpoint on chromosome 1 and 11. The negative result from the association
study may reflect the lack of linkage disequilibrium between the markers and the
postulated gene or indicate that the gene may not lie in close proximity to the
breakpoint and is not in linkage disequilibrium with either of the markers.
Alternatively, it may be that this postulated gene in close proximity to the
translocation breakpoint, is of major effect in the translocation family but is
prominent in only a minority of the affected population studied and is therefore not
of strong enough effect to be picked up in the association study. The lack of genetic
linkage data published in the regions of the breakpoint perhaps reflects this
hypothesis.
The number of subjects used in the current study has been relatively small and as a
consequence the power of the association study to detect a gene of small effect will
have been reduced. Ideally far larger numbers of subjects should be used in order
to improve the statistical power of the technique to determine the presence of small
gene effects. Given the absence of positive linkage on chromosome 1 it is likely that
any gene in this region will have a small effect size. The sample size used in this
study gives approximately 20% power to detect a 10% difference in allele
frequency. Allelic association may be present but not have been detected due to too
small a sample size.
It is unlikely that we have failed to demonstrate an association due to population
stratification as the control and affected populations have been selected from the
same geographical region as far as possible. Family based controls should however
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be considered wherever possible to lessen this problem (Rubinstein et a/1981, Falk
and Rubinstein 1987).
In conclusion, the present study does not reveal an association between the
markers D1S1621 and D11S931 with either schizophrenia or unipolar depression in
this Scottish population, evidence against a nearby gene of major effect.
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Isolation of genes around the chromosome 1
breakpoint by
Coincident Sequence Cloning (CSC)
Results Chapter Six
6 Introduction
From positional cloning on chromosome 1, it had been established that two cosmids
(B01519 and 10142) and a PAC (DJ4B9/3) either spanned or resided in close
proximity to the translocation breakpoint (work carried out by Kirsty Millar, Susan
Anderson and Sheila Christie) (see Figure 6.1). In order to try to explain the
significance of the translocation event in relation to the psychiatric illness in the K26
pedigree it was important to search for genes in this region. A direct cDNA selection
technique, coincident sequence cloning (CSC)(Brookes et al 1994), was employed
to achieve this aim.
Coincident sequence cloning is a technique which allows the selective isolation of
DNA which is shared between two sources of DNA. If one of the sources of DNA is
genomic DNA and the other cDNA then the coincident DNA between these two
resources should be genes transcribed from the region of genomic DNA. There are
two kinds of CSC. In the following experiments hybrid fishing (HF) and end ligation
(EL) CSC have both been employed using a "one tube" procedure which is
described below.
A schematic diagram of the coincident sequence cloning (CSC) method end ligation
and hybrid fishing techniques and a one tube procedure combining these two
techniques is shown in Figures, 6.2A and 6.2B and 6.2C.
The two types of CSC employed in this experiment, hybrid fishing CSC and End
ligation CSC, differ in their stringency with the latter being a more stringent method
due to end sequence specificity. Initially both methods are the same requiring two
resources, one genomic and the other cDNA from the region which you wish to
identify genes (e.g. cosmid DNA and foetal brain cDNA to identify brain expressed
sequences from the cosmid). These two resources are cut with restriction enzymes
and have catch linkers (synthetic oligonucleotide sequences represented in Figure
6.2 in pink and black) ligated to the ends to allow PCR amplification. In the case of
the genomic resource, a biotin moiety (black circle) is added to allow physical
isolation of this DNA using streptavidin coated magnetic beads at a later stage in
the procedure.
In the hybrid fishing experiment (Figure 6.2A), the two resources are denatured and
allowed to reanneal, forming homo- and heteroduplexes. Stringent washing stages
remove the vast majority of non-coincident DNA before isolation of the DNA using
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template in a PCR reaction utilising primers complementary to the catch linkers.
This is represented in the diagram as PCR 2.
In end ligation CSC, the catch linkers originally used to amplify the cDNA resource
are removed by restriction enzyme digestion before heteroduplex formation. Once
the complementary DNA sequences align, capture oligonucleotides (represented in
Figure 6.2B and C as thin black lines (see key in diagram)), which are
complementary in sequence to the initial catch linker sequence (thick black lines),
used to amplify the genomic resource, are allowed to anneal. These capture
oligonucleotides must be perfectly base paired and end matched before they can be
ligated to cDNA sequences by a high temperature ligation step. This requirement
for perfect base pairing and end matching makes end ligation CSC a more stringent
procedure than hybrid fishing. The coincident DNA can be recovered as previously
described and PCR reactions carried out after elution of the cDNA from the
streptavidin coated magnetic beads, using primers which are complementary to the
capture oligonucleotide sequences (PCR 1). Coincident products can then be
cloned and analysed.
The technique which allows the combination of these two techniques in one
experiment is represented in Figure 6.2Cand relies on the modified cDNA resource
being present both with and without catch linker sequence (pink lines). The
procedure followed is that of the end ligation technique but the hybrid fishing
products can be amplified from the end product by primers complementary to the
catch linker sequence. Separate product libraries can then be made from both the
end ligation and hybrid fishing techniques and can be analysed.
The genomic resource in the current study was a pool consisting of cosmids 10142
and B0159 and PAC DJ4B9/3. Cosmid 10142 and PAC DJ4B9/3 had been identified
as spanning the translocation breakpoint on chromosome 1 and B0159 had been
shown to reside in close proximity to the breakpoint by DNA marker analysis. These
two cosmids and PAC provide good coverage of the breakpoint region. The cDNA
resource consisted of foetal brain cDNA which had been made from three ages of
foetal brain tissue which were pooled (see section 2.15-2.17 for further details).
The CSC technique is capable of handling highly complex DNA resources and can
enrich for coincident elements by up to 105 fold in the case of the hybrid fishing
technique and 107 fold in the End Ligation technique (Brookes 1994). CSC is
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PCR 1 PCR 2
Biotin moiety \ Catch linker , Capture oligonucleotide RS - restriction
site
Figure 6.2C Schema of Coincident Sequence Cloning technique. End Ligation
(EL) and Hybrid Fishing (HF) technique combined in one stage method. Left
hand side represents End Ligation technique and right hand side represents
hybrid fishing technique. See text and Figures 6.2A and B for further explanation.
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6.1 Amplification of the product cDNA
The two input DNA resources were integrated as described in section 2.17.4 and
the cDNA product eluted after stringent washing stages. This cDNA product was
amplified using the conditions described in Table 6.1 using primer 727 (5'-
GCGGAATTCTAGACTGCAGG -3') to obtain cDNA products from the hybrid fishing
experiment and with primers 789 (5'- CGTTCCGGTAGCACGGG -3') and 596 (5'-
GGACGGGTCGACACGCGAGG -3') and conditions described in Table 6.2 to
obtain the End Ligation products. Two negative controls which had been through
the streptavidin bead separation and washing stages were also amplified. The first
of these negative controls was a "cDNA only" control in which a small aliquot of
cDNA alone was put through the bead separation/washing stages to ensure that
these stages were adequate and no unbound cDNA was left on the beads after the
washing stages. The second control was a "no DNA" control, in which water was
substituted for the DNA in order to determine if any contamination had occurred
during the procedure.
















Cycle 21-29 94°C/15sec 54°C/30sec
Cycle 30 94 C/15sec 54°C/30sec








Cycle 11-20 94°C/15sec 55°C/30sec 72°C/2min30sec
Cycle 21-34 94°C/15sec 55°C/30sec 72°C/4min
Cycle 35 94°C/15sec 55°C/30sec 72°C/8min
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PCR products were run out on a 2% agarose gel along with negative controls
(Figure 6.3 and 6.4).
Hybrid Fishing Experiment:
Figure 6.3 shows the hybrid fishing cDNA PCR products obtained using primer 727.
Although the "no DNA" control is negative, the "cDNA only" control has a strong
smear in it similar to that seen in the positive integrated genomic and cDNA lane.
Since the cDNA resource has no biotin moiety (as this is on the genomic resource
only) it should not stick to the beads but should be washed off before the bound
DNA is eluted. The presence of a smear in the negative "cDNA only" control
indicated that either the washing stage was not adequate or that the cDNA was
binding non specifically to the streptavidin coated magnetic beads. In order to try to
combat this problem, the experiment was repeated using a more vigorous washing
technique and also pre-blocking the beads with more sonicated salmon sperm and
PVP (see 2.17.4) to try to ensure that all the non-specific sites on the beads were
occupied. This however made little difference to the result, which still showed a
smear in the cDNA only control (data not shown). The product in the positive
integrated genomic/cDNA lane was not cloned due to difficulties in differentiating
between the cDNA population which had come through from the beads due to
inappropriate binding/washing and the truly coincident cDNA population from the
experiment.
End Ligation Experiment:
Figure 6.4 shows the PCR results for the end ligation experiment using primers 596
and 789. The negative controls included in the PCR reaction are both negative and
a smear is visible in the lane of integrated genomic and cDNA (refer to figure 6.4).
Primers 596 and 789 are specific to the capture oligonucleotide sequence and
therefore would not be expected to amplify the cDNA only negative control. The
cDNA resource is catch linkered with 727/731. This means that only a very small
amount of non specific cDNA should be present in the positive integrated
genomic/cDNA PCR product and the majority of the cDNA amplified should be true
end ligation products as it must have successfully ligated to capture
oligonucleotides in order to be amplified in the PCR reaction. This product was
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Figure 6.3: PCR products obtained from the Hybrid Fishing CSC experiment
using primer 727. Negative controls - water only, cDNA only and a PCR negative
control are shown as well as the integrated genomic and cDNA final PCR product.
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Figure 6.4: PCR product obtained from the End Ligation CSC experiment using
primers 596 and 789. Negative controls - water only, cDNA only and a PCR negative
control are shown as well as the integrated genomic and cDNA final PCR product.
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6.2 Cloning of the End Ligation PCR product:
The capture oligonucleotide ligated to the cDNA in the CSC end ligation experiment
incorporates an EcoRI site (GAATTC) which greatly facilitates the cloning step as
cohesive end cloning can be employed. The amplified product was digested with
EcoRI and cloned into pBS vector which had been digested with EcoRI and
dephosphorylated. This vector was transformed into XL blue bacterial strain. The
cells were plated at an optimum density so that individual colonies could be
recognised and accurately picked by a colony picking robot (Hybaid). 1200 clones
were picked and spotted onto five nitrocellulose filters in duplicate spotted format.
Approximately 10% of the colonies contained no insert as determined by blue/white
colour selection. Picking 1200 clones provided approximately two fold coverage of
the region under study (~140kb).
6.3 Analysis of the End Ligation product library:
6.3.1 Strategy for analysis of End Ligation product library:
Initial analysis of the library included identification of clones containing high copy
repetitive elements in order that these could be excluded from further analysis
(section 6.3.2). Since there was no major band seen in the CSC product smear, 200
representative clones were picked and their inserts amplified by PCR in order to
determine the average insert size of the clones. This was with a view to sequencing
those clones with a reasonable insert size (over 100bp) by single pass automated
cycle sequencing. The sequences from the ends of all clones were checked in order
to ensure that the capture oligonucleotide and vector sequence were present.
These clones were then analysed by computer database searches to see if they
matched any previously identified products in the GENBANK and dbEST databases
(HGMP resource centre, Hinxton Hall, Cambridge) or constituted novel cDNAs.
Products with database matches to known human DNA sequences or novel clones
were hybridised back onto the product library in order to determine how well they
were represented in the library and to prevent repeated analysis of the same
sequences. In order to prove that the clones were derived from the original input
genomic resource, products were hybridised onto restriction enzyme digest panels
of the cosmid and PAC genomic resource in Southern blot hybridisation analysis.
To show that the clone was derived from the foetal brain cDNA either the clone was
amplified from the original cDNA resource (which was very limited in supply) and/or
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the clone was used to screen a full length foetal brain cDNA library (Clontech) which
also served a secondary purpose of trying to extend the CSC clone sequence.
The CSC end ligation library was also screened with sequences which had been
identified from positional cloning around the chromosome 1 breakpoint. A 7Kb wild
type chromosome 1 fragment, which spans the breakpoint, had been identified by
screening a genomic library made from a translocation patient DNA with a cosmid
restriction fragment which had been shown to cross the breakpoint on chromosome
11. This hybridisation isolated a derived chromosome 1 fragment which was then
used as a probe back onto the genomic library allowing the 7Kb wild-type
chromosome 1 fragment to be obtained (see section 7.2). Another probe used to
screen the CSC library was obtained by random sequencing and database
searching of cloned restriction enzyme fragments (Eag1 or Not1) of the PAC
DJ4B9/3 (work carried out by Kirsty Millar and Susan Anderson). One of the
restriction enzyme clones identified by this procedure matched an EST in the
database (GENBANK accession number N49833) and was used as a probe onto
the CSC library. This clone resided within 30Kb of the breakpoint, as determined by
restriction enzyme mapping, and resided outwith the 7Kb which the wild-type 1
sequence covered (Kirsty Millar and Susan Anderson).
The library was also screened with the PAC and cosmid inserts from the original
genomic resources (see section 6.3.4).
6.3.2 Assessment of high copy repetitive elements in the library:
Repetitive elements are found in high frequency in genomic DNA (Alu elements
comprise 5% of the human genome; Shen et al 1991) and in cDNA (3-5% of cDNA
clones contain Alu elements; Crampton et al 1981). It is therefore likely that
repetitive elements will be genuinely coincident products recovered from the
experiment. Products which contain repetitive elements are problematic since the
repetitive element can mask the effect of the non repetitive clone insert. The library
was initially screened for repetitive elements by hybridisation analysis of gridded
filters with Human Cot1 DNA, which is comprised almost entirely of high copy
repetitive elements, primarily Alu elements. Prior to integration in the CSC
experiment, the genomic and cDNA resources had been allowed to anneal to an
excess of Cot1 DNA in order to quench most of the Alu elements to reduce the
amount occurring in the product DNA.
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The result of the Southern blot hybridisation analysis with human Cot1 DNA showed
that approximately 2% of the library clones contained repetitive elements.
6.3.3 Analysis of End Ligation product library with probes residing in
the vicinity of the chromosome 1 breakpoint:
The end ligation CSC product library was screened by hybridisation with the wild-
type chromosome 1 7Kb fragment (which spans the chromosome 1 breakpoint) as
well as with a DJ4B9/3 PAC restriction enzyme clone identified as an EST by
sequencing and database searching (N49833)(see section 6.3.1). Results of the
hybridisation analysis on the CSC library showed that for the 7Kb wild-type 1
fragment no positive clones were identified indicating that none of the products in
the library resided within this 7Kb region around the breakpoint. Similarly for the
PAC restriction enzyme clone, no positive results were obtained by hybridisation
analysis suggesting that the EST matching clone (N49833) was also not
represented within the CSC product library. (See discussion section for further
explanation of these results).
6.3.4 Random sequencing of clones from the End Ligation CSC library
Boiled colony PCRs using primers designed to the pBS vector sequence (291;
5'CAGGAAACAGCTATGAC-3' and 292; 5'-GTAAAACGACGGCCAGT-3') were
carried out on 200 clones from the End Ligation library in order to determine the
average insert size and to identify clones with reasonably sized inserts (>100bp) for
random sequencing. Table 6.3 lists the insert sizes found in these clones.
Table 6.3 Insert size of End Ligation CSC product library clones





Twenty clones with variously sized inserts were sequenced using primers 291 and
292. One of these clones (3A6) was very large ~2.3Kb. The sequence obtained was
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checked against the GENBANK and dbEST databases and was found to have no
database matches. This clone was therefore investigated further (see next section
6.3.5). One other clone had a very small insert composed of tandemly repeated
capture oligonucleotide sequences only.
The remaining eighteen clones showed very strong identity to E.coli sequences
(see Figure 6.5 for an example of the E.coli matches). These clones were however
properly linkered with the capture oligonucleotide sequence being identifiable at one
or both ends of the clone (it is possible that if the clone has an internal EcoRI site
that the capture oligonucleotide sequence will be seen just at one site, the other end
of the clone being ligated to the vector by virtue of the internal EcoRI site). This
would indicate that the E.coli contamination has been present early on in the CSC
procedure. The contamination has most probably originated from the PAC genomic
DNA resource since it is unlikely that an artefactual product would be correctly
linkered due to the stringency of the end ligation technique. PAC DNA is present in
very low copy number in bacterial cells as the result of the vector origin of
replication which only allows one copy of the PAC per cell. When the PAC DNA is
purified the ratio of PAC DNA to E.coli background DNA is low in comparison with
for example a plasmid DNA prep where there is a high copy number per cell.
Consequently, problematic contamination from E.coli is more prominent when
working with low copy PACs compared to higher copy plasmids or cosmids.
An explanation of how this E.coli contamination could have arisen from the genomic
resource is given below.
The genomic resource is catch linkered in the initial stages of the CSC experiment
with the following sequences; 477; 5'-CCGAATTCTAGAGTCGACC-3' and 479; 5'-
GATCGGTCGACTCTAGAATTCGG-3' (bold lettering indicates the EcoRI restriction
enzyme cutting site). The capture oligonucleotide sequences, which are ligated to
the cDNA resource, are extended versions of these primers (5'-
GATCGGTCGACTCTAGAATTCACCCGTGCTACCGGAACG- 3' and
5'-GGACGGGTCGACACGCGAGGACCGAATTCTAGAGTCGATC-3' sequence in
bold indicate the sequence identity to the catch linker sequences). Prior to ligation
of the PCR amplified end ligation product (which has capture oligonucleotide
sequences ligated to it) into pBS vector, the PCR product is cut with EcoR\
restriction enzyme. Once this has been done the remaining sequence of the capture
oligonucleotide and that of the catch linker sequence is identical. It is therefore not
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possible to tell from this sequence being present in the final CSC product clone,
whether this clone is a genuinely coincident product or is the result of contamination
from the genomic resource. Southern blot hybridisation onto restriction enzyme
digests of the cosmids PACs and original cDNA (or PCR analysis) is the only way to
prove coincidence to both the DNA resources.
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Figure 6.5A: CSC clone 100a sequence comparison with E.coli ada gene promoter
region (M13155) as identified by GENBANK database searching.
100a: 78 GATCACCAAAGAAGGCGATAGCTTTAAAACCTGGATGTC 116
I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II I I
E.coli: 29 GATCACCAAAGAAGGCGATAGCTTTAAAACCTGGATGTC 67
100a: ACCACAGTTTAAAAGCTTCCTTGTCAGCGAAAAAAATTAAAGCGCAA 163
I I I I I I I I I II I I I II II I I I I I I I I I I I II I II I I I I I I I I I I I II
E.coli: ACCACAGTTTAAAAGCTTCCTTGTCAGCGAAAAAAATTAAAGCGCAA 114
100a: GATTGTTGGTTTTTGCGTGATGGTGACCGGGCAGCCTAAAGGCNATC 210
I I I I I I I I I I I I I I I I I I I I I II I I I I I I 1 I I I I I I I I II I I I III
E.coli: GATTGTTGGTTTTTGCGTGATGGTGACCGGGCAGCCTAAAGGCTATC 161
100a: CCTAACCAGGGAGCTGATTATGAAAAAAGCCACATGCTTAACTGACG 257
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I
E.coli CTTAACCAGGGAGCTGATTATGAAAAAAGCCACATGCTTAACTGACG 208
100a: ATCAACGCTGGCAATCTGTCTTAKCCCGCGACCCGAATGCCGACGGG 304
I I I I I I I I I I I I I I I I I I I I I I I + I I I I II I I I I I I I I I I I I I I I I
E.coli ATCAACGCTGGCAATCTGTCTTAGCCCGCGACCCGAATGCCGACGGC 255
100a GAATTCGATATC 316




Figure 6.5B CSC Clone 15312 (247bp insert) sequence compared to the E.coli
genome.




I I I I i I III I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Ecoli GTGGTACGCACGGCGAAAACGAATTCGCCGTCGGCATTCGGGTCGCGGGCTAA 2308149
15312 GACAGATTGCCAGCGTTGATCGTCAGTTAAGCATGTGGCTTTTTTCATAA 171
I I II I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I II I I II I I I
Ecoli: GACAGATTGCCAGCGTTGATCGTCAGTTAAGCATGTGGCTTTTTTCATAA 2308199
15312 TCAGCTCCCTGGTTAAGGATAGCCTTTAGGCTGCCCGGTCACCATCACGC 221
II I I I I I I I I I I I I I I I I I I II II I I I I I I I I I I I I I I I I I I I I I I I I I I
Ecoli: TCAGCTCCCTGGTTAAGGATAGCCTTTAGGCTGCCCGGTCACCATCACGC 2308249
15312: AAAAACCAACAATCTTGCGCTTTAATTTTTTTCGCTGACAAGGAAGCTTT 271
I I I I I I I II I I I I I I I I I I I I I I I I I I I I I II I I I II I I I I I I I I II I I I
Ecoli: AAAAACCAACAATCTTGCGCTTTAATTTTTTTCGCTGACAAGGAAGCTTT 2308299
15312: TAAACTGTGGTGACATCCAGGTTTTAAAGCTATCGCCTTCTTTGGTGATC 321
I I II I I I I I I I II I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I
Ecoli TAAACTGTGGTGACATCCAGGTTTTAAAGCTATCGCCTTCTTTGGTGATC 2308349




If the E.coli contamination has been derived from the genomic resource then it must
have been present in the initial stages of the CSC experiment. In order for the E.coli
sequences, obtained from the CSC experiment, to have linker sequences present
they must have been cut in the initial Sau3AI digest (to have compatible sticky ends
onto which the linker sequence are ligated). The catch linker sequences would
therefore have been added to both the genuine genomic DNA resource (i.e. the
cosmids and PAC DNA) as well as to the E.coli DNA. This contaminating DNA
would therefore be present throughout the CSC procedure. If these E.coli
sequences constituted a large proportion of the "genomic resource," it is possible
that when the genomic resource (with or without coincident product) was eluted off
the streptavidin coated magnetic beads, only a small proportion of the DNA
contained coincident cDNA. The PCR reaction would only amplify sequences which
had the capture oligonucleotide ligated to them and not those with the catch linker
sequences (since the PCR primers are designed to a unique segment of the
capture oligonucleotide). When the end ligation PCR product was run out on a gel
with the negative control samples (cDNA only and water only), a smear was only
seen in the "integrated genomic and cDNA" lane of the gel and the "negative
controls" were negative. However, a "genomic DNA only" control was not done so it
is impossible to tell if a percentage of the smear in the positive lane is due to
genomic only DNA which has come through the experiment. If this contamination
was significant then it would also have been cloned and resulted in clones
containing E.coli sequence inserts. It is therefore highly probable that the E.coli
contamination has come from the PAC genomic resource.
From this preliminary sequencing data, it appeared that the end ligation CSC library
was heavily contaminated with E.coli {90%; 18/20 clones) and was therefore going
to be of limited use in identifying transcribed sequences. A further 30 clones were
sequenced in order to see if the E.coli contamination was as prevalent as the initial
data suggested and to see if any other novel human clones could be identified. Of
these 30 clones only one (11B6) proved not to be E.coli by database searching,
thus confirming the high level of contamination in the library. The clone 11B6 was
further investigated (see section 6.3.5).
In order to try to find any truly coincident products amongst the plethora of E.coli
containing clones the library was screened with the inserts from the B01519 and
10142 cosmids in order to try to identify any clones which were derived from these
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resources. Since the cosmid vector (Lawrist 16) and the CSC clone vector (pBS) do
not show any homology to each other (as demonstrated by sequence alignment
analysis and database searches) the whole cosmids were used to probe the CSC
library in Southern blot hybridisation analysis. This analysis resulted in a high
background on the CSC library filters which may have been due to a small amount
of E.coli contamination in the cosmid DNA preparation. Only one clone was
identified as being positive in this hybridisation analysis. This clone (11G11) was
sequenced and database searches showed that this clone insert matched lawrist 16
with 96% identity (see Figure 6.6). No linker sequences were present in the lawrist
16 sequence and it was probably ligated into the pBS CSC vector directly by virtue
of the presence of EcoRI sites in its sequence. This sequence was therefore
present at the EcoRI digestion step prior to ligation and represents an artefactual
product and as such was not considered further.
6.4 Further analysis of the clones 3A6 and 11B6.
Clone 3A6:
Clone 3A6 has an insert size of 2.3Kb which is much larger than would be expected
to result from a Sau3AI digested fragment (average size 300bp) and probably
represents a partially digested Sau3AI clone. Sequence analysis of the ends of this
clone insert, obtained using pBS vector primers 291/292, showed no matches to
sequences in the GENBANK or dbEST databases.
• Is the CSC clone derived from the genomic resource?:
In parallel with the whole clone being sequenced, it was also important to show that
the clone was truly coincident to both the starting resources. In order to
demonstrate that the clone was derived from the genomic resource Southern blot
analysis was carried out on restriction enzyme digests of the two cosmids 10142 and
B01519 and the PAC DJ4B9/3 which constituted the original genomic resource. The
whole cDNA clone was used as a probe and repetitive elements were blocked with
sonicated total human genomic DNA. The result of this Southern blot analysis is
displayed in Figure 6.7. Three restriction enzyme digests of the PAC and cosmids
are present on the filter (BamHI, Hind III and EcoRI). In each digest of the PAC a




Figure 6.6: Sequence comparison of CSC clone 11G11, isolated by Southern blot





I I I I I I I I I I I I I I I I I I II I I I I I I I I I
46995 GAATTCTGGCGAATCCTCTGACCAGCCAGA 47025
11G11: AAACGACCTTTCTGTGGTGAAACCGGATGCTGCAATTCAGAGCGG 143
I I I I I I I I I I I I I I I I I I I E I I I I I I I I I I I I I I I I I I I I I I I I I
Lawrist: AAACGACCTTTCTGTGGTGAAACCGGATGCTGCAATTCAGAGCGG 47070
11G11: CAGCAAGTGGGGGACAGCATAANACCTGACCGCCGCAGAGTGGAT 188






I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Lawrist TTTTGCTGGGTGGGCTAACGATATCCGCCTGATGCGTGAACGTGA 47205
11G11: CGGACGTAACCACCGCGACATGTGTGTGCTGTTCCGCTGGGCATGC 323
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Lawrist: CGGACGTAACCACCGCGACATGTGTGTGCTGTTCCGCTGGGCATGC 47251
11G11: CAGGAAAACTTCTGGTCCGGTAACGTGCTGAGCCCSGCCAAACTCC 369
I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I + 1 I I I I I I I I I
Lawrist: CAGGACAACTTCTGGTCCGGTAACGTGCTGAGCCCGGCCAAACTCC 47297
11G11: GCGATAAGTGGACCCAACTCCAAATCAACCGTTAACAAKCAACAGG 415
I I I I I I I I I I I I I I I II I I I I I I I I I I II I I I + II I I I I I
Lawrist: GCGATAAGTGGACCCAACTCGAAATNCAACCGTAACAAGCAACAGG 47342
K= T or G
M= A or C
R= G or A
S = c or G
W= A or T
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Figure 6.7: Southern blot hybridisation analysis of CSC clone 3A6 (whole clone insert)




clone is contained within the PAC only. This would place clone 3A6 distal to the
chromosome 1 breakpoint. The 3A6 clone must also lie outwith the immediate
vicinity of the breakpoint since it is not contained in the 10142 cosmid (refer to
Figure 6.1). This cosmid spans the breakpoint and overlaps with PAC DJ4B9/3 in
the region immediately proximal and distal to the breakpoint. If the clone mapped in
this region it would therefore be expected to be seen in cosmid 10142 as well as the
PAC. Similarly, the clone cannot map proximal to the breakpoint as the PAC
overlaps with either cosmid 10142 and/or B01519 in this region. The bands seen in
the PAC digests are contained within a background smear. It had previously been
established, by hybridisation with Cot1 human cDNA, that this CSC clone contained
repetitive elements. The background smear is present as a result of these repetitive
elements not being completely quenched by the blocking procedure with sonicated
total human genomic DNA.
• Is the CSC clone derived from original cDNA starting resource?:
Once it had been established that the clone had been derived from the original
genomic resource it was also important to show that it had also come from the
cDNA resource. In order to establish this, a PCR reaction was carried out on the
original pooled cDNA resource using several primer pairs extending across the
clone sequence. These primers were used in the sequencing of the whole CSC
clone (see next section) and are described in Table 6.5 (M306/I184 —» 598bp
product, M188/M187 -> 1865bp product, M305/M187 -» 1501 bp product and
I184/M187 -> 946bp product. See Figure 6.10 for the 3A6 clone sequence and the
position of these primers). A positive and negative control were also included in the
PCR reactions the positive control being the 3A6 clone DNA and the negative
control being a water only control to show any contamination present. The PCR
reaction using these primer sets failed to amplify a single band from the original
starting cDNA although a band was seen in the 3A6 clone DNA positive control
(Figure 6.8). This may indicate that the CSC clone was not derived from the initial
cDNA and represents a genomic artefact or alternatively it may be that this clone is
very low copy in the original cDNA and has not amplified well enough to be visible in
the PCR product. A secondary PCR reaction was carried out using 1pl of the
primary PCR product as template in the reaction. This PCR similarly failed to
demonstrate a band of the correct size (not shown).
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A foetal brain cDNA library (Clontech) was also screened with a probe produced by
PCR with primers M306 and 1184 on 3A6 clone DNA. The primary screening of this
library was done at high stringency (68°C) and several positives clones were
identified. These positives were weak, taking several days of exposure to film to be
visible. These clones were purified to single plaques which were then subjected to
boiled plaque PCR using primers designed to the vector sequences (391: 5'-
AGCAAGTTCAGCCTGGTTAAGT-3' and 392: 5'- TTATGAGTATTTCTTCCAGGG -
3'). The conditions for the PCR are described in Table 6.4. The PCR products were
then sequenced and compared to the sequence of the clone 3A6 to see if these
cDNA clones further extended the sequence of the CSC clone. This procedure
served two purposes, the first of which was to try to demonstrate that this DNA
fragment corresponded to a gene fragment expressed in foetal brain tissue from
which the original starting cDNA resource was derived. Secondly, the screening of
the full length cDNA library provided an opportunity to further extend the sequence
of the CSC clone. Extending this sequence would allow further information about
the structure of this gene to be gleaned and to permit further database searches.
Table 6.4: PCR conditions for the amplification of cDNA clones from the foetal brain
cDNA library.
Denaturation Annealing Extension
Cycles 1-20 94°C/30secs 56°C/45secs 72°C/2mins
Cycles20-30 94°C/30secs 56°C/45secs 72°C/3mins
The sequences of a cDNA clones from the Clontech foetal brain cDNA library can
be seen in Figure 6.9. These sequences did not extended the 3A6 clone sequence.
When the sequences of the two clones, were compared to the consensus sequence
for the 3A6 clone only between 60 and 70% identity was observed. The probe which
was used to screen the foetal brain library was 598bp in length and contained
200bp of MALR repeat sequence (see Figure 6.10). When the sequence of the
cDNA clones from the library screen were studied, they were shown to contain large
repeat elements as demonstrated by "repeat masker" (Jurka et al 1992) repeat
database. Homology between the repeat elements in the probe and in the cDNA
clone were probably responsible for the clone being identified as positive. Since the




Figure 6.8: PCR analysis showing amplification of CSC clone 3A6 from original




library with CSC clone
of cDNA clone 721 obtained by
3A6.
A) Sequence of cDNA clone 721
Chapter Si.x
screening a foetal brain cDNA
M R
a E
1 TCCGGTTTTT TTTTCACTCA CCCCTCAATC CAGAGAGGGC ATTAATTTAT
51 TCATGAGGGA TCTTCCACCA TGACCCAAAC ACCTTCCATT AGGCCCCACC
101 TCCAACACTG AGATCAAACT TCAACATGAG ATTTGGAGGG ACAAATATCC
151 AAACTATAGC AACATATCAC TTTTGTACCA TCATAAAGCT GAGAAATTGT
201 TAGTTGACAT TGTTGGGGAC CATCTCTATA ACAGTTCATT GGAACAAGTC^
251 TGTTAAAAAT CATGTTCATA CTGATACACA AAACATGTAA TTATCATACA
301 TCTAGTATCA TGTCACACTC AAAAGATAAA TGGTTATAAA TTTTACAAAA
351 GGAGGCTGCA GTTAGGAATG TTTAATTTAC AGTTCTTTCT CACCTACTAT







r = A or G
N= not determined
B) Sequence comparison of CSC clone 3A6 and cDNA clone 721. Sequence
identity was 67.1% identity in 170 bp overlap.
721 TCCGGTTTTTTTTTCACTCACCCCTCAATCCAGA
II I I I I I I I I I I I III
3A6 AAGAGAAAGCAAGCAAGGGGGGGCCAAGTTGTCCTTTTCTAATGAACCCCCTCCCACAGT
1220 1230 1240 1250 1260 1270
40 50 60 70 80 90
721 GAGGGCATTAATTTATTCATGAGGGATCTTCCACCATGACCCAAACACCTTCCATTAGGC
I III I I I II I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I II
3A6 AACGGCGTTAATCCATTCTAGAGGGTGGTGCCCCCATGACCCAAACACTTCCCATTAGGC
1280 1290 1300 1310 1320 1330
100 110 120 130 140
721 CCCACCTCC -AACACT GAGATCAAACTTC AACATGAGATTTGGAGGGA
I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I
3A6 CCCACCTCCTAACACTGCCACATTGGGGATCAGATTTCCAACACATTAACTTTG—GGGA
1340 1350 1360 1370 1380 1390
150 160 170 180 190 200
721 CAAATATCCAAACTATAGCAACATATCACTTTTGTACCATCATAAAGCTGAGAAATTGTT
I III I I I I I I I I I I
3A6 C--ACATTGAAACCATAGCACTCCCCTATAGCAATGAGTAATATCCGCATAGTGATTTTA
1400 1410 1420 1430 1440 1450
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Figure 6.10: Sequence of CSC clone 3A6. Capture oligonucleotide sequences are
marked in bold italics at the beginning and end of the sequence and sequencing
oligonucleotides are also in bold. Repeat elements are also marked on the
sequence.
1 GAATTCTAGA GTCGACCGAT CCGGTTTTAC AGGAGGAATT AACCTGGGAT
51 GGGGGAAAGA ATGCATTTAG TGCTGGAATA TATAAGGAGA GGCTTTCCTT
101 TGTCCCCTCC TCTCTTCTCT CTCCCCCAGG ATTTTTTGTC CTTCCGTGTT
151 CCACCTGATC CATGGCCAAC TGGCTTTAGA AGTTGTTATT AATAGTTCAC
201 CATGCTCATT TTCATGAAAC AGAGGGAAAG GCAGCCTCTT CATTTGATGT
251 CTAGTTAGCA AACCAGARGT TTGTCACCAG CTGGTOATAA
M188
CAGACATTTT
301 TAATAAAACT TACCTCCMAG TTAAAATAAA AATGCTGCCT TAGAGATTTT
351 GTCCTGAAAC ATACGGAAAA ATGACAGGTG GGATCTCTCA TGCAAAACTT
401 CTGCTAGGGC TAAAGGAAAA TATCTGATAA GGTTGTTTGC CCATGGGGGA
451 AGGATTAATT GGATTTTCTG TCTTGCCCCT AGTGTCTGAC CCTCTGTTAT
501 TATGACAGGA CCACAGWAGT TTTGAACGCT GAATCATAGT TTATAGTTTT














701 CAATGAAAGC CTCAGCTGAA GATCATAGGA TTAAATCCAG GCTCCCCTCT
751 TTCAAGTACC TTCTCATGCT ACTGCATTTA TGTGGGTAGT CTGGGATTAT
801 GTCTGTGGTT TGTTTCACTA TTTTCTGGAT CACTTCTGAA CCAGTCCGTG
851 TGTCAGTCCT GTGGATATGC ATTTCATGAA TGAGACTCTG AGGAATTTTC
901 TAATAGTGTC TATGGTGGCA GTGGGAAAAG GGGAGGAGGC AGAGAAAGAG
951 GTGGTAGCAA GAGAAAGAAC TGTGTGGAGC TCGAGCTAAA AGCAGGAGCT
1001 AAGACTGCAA GATCAAATGA TTCCCACTCA GTTGTCCTAG TCTCYGTCYT
1051 TGTTTTCTGT GGCCATAACA GAACACCATA GATTTGGTAA TTTATAAAGA
1101 GCAGAAACAT ATTTCCTCAT CATTCTGGAG ACTGGGAAGT TCAAGATCAA
1151 GGGCTGGCTC AACAGAAGCC TCTTGCTGCA TCATGCCATG GCAGAAGGTG
1201 GAAAGGSAGA GAGGGCAAGA GAAAGCAAGC AAGGGGGGGC CAAGTTGTCC
1251
—► M184
TTTTCTAATG AACCCCCTCC CACAGTAACG GCGTTAATCC ATTCTAGAGG
1301 GTGGTGCCCC CATGACCCAA ACACTTCCCA TTAGGCCCCA CCTCCTAACA
















1401 GAAACCATAG CACTCCCCTA TAGCAATGAG TAATATCCGC ATAGTGATTT
1451 TACTTATTAA ATAATATTGA CATGGCTTCC TCTTTATGGT TTGCTAGTGG
1501 TAAATCTTCA AAACTCTTGG GTAGTTTCTG TGGATATAAA TTCCAGGTGA
1551 GGTTAGTTGT TAAGGAAAGA ATTTCCATGA AAGAAAAACG TGTCTGAGTT
1601 TTGAATAAGG AAAGGCATAC ATTGTGGGTA ACTGAAATGC CATTTTTTCA
1651 CTCCTCCTTC CCCCGGGCTC TAAATACCAT TGCTGAATTG AATCCGTCCA















1851 GGAAGACATT GGGTATGATT TGGAAATAAG CAAAACAGAA CAGACCTGAC4
1901 TTTCTTTCTC TTTCTTCCTT TCTTCCTTCC TTCCTTCCTT TCCTTCCTTC
1951 CTTCCTTCCT TTCCTTCCTT CCTTCCTTTC CTTTCCTTCC TTCCTTCCTT
2001 CTTTCCTTCT TTCTTTTCTT TCTTTTTTTG TTTTGAAAKG GAGTCTTGCT
2051 CTATCACCTA GGCTGGAGTG CAGTGGCGCC ATMTCAGCTC ACKGTAAGGT

























Vector sequence |A |
CGRTCGACTC
K= T or G
M= A or C
R= G or A
S = C or G
W= A or T
Y= T or C
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exact the positives seen on the autoradiogram were weak. Therefore, it appears
that no real positive clones were detected from the foetal brain cDNA library.
As no true positive cDNAs were obtained from this library screening it is possible
that the CSC clone is a genomic clone and not a cDNA clone. In order to further
determine if this CSC clone was a genomic clone, a PCR was carried out which
utilised the primers used to sequence the whole CSC clone. These primers were
designed to amplify consecutively larger fragments of the clone (see Figure 6.10).
By carrying out this PCR on CSC clone DNA as well as on total human genomic
DNA and A9 (hybrid containing only human chromosome 1) DNA, it was possible to
test for regions where the clone DNA, but not the genomic DNA, would be amplified.
Such a result may be indicative of the presence of large intronic sequences across
which the PCR cannot extend in the genomic DNA. Results from this PCR reaction
are shown in Figure 6.11. The region of sequence which constituted the probe used
to screen the cDNA library was amplified from both the genomic resource and from
the clone DNA (M306/M184). However, as the fragments amplified extended further
across the clone sequence a product was still visible in the CSC clone DNA (3A6),
but not in the genomic DNA. This may be the reflection of large intronic sequences
existing between the primers in the genomic, but not the CSC clone DNA, or may
simply reflect the higher complexity of the genomic DNA, compared to that of the
CSC clone DNA. Sequencing the genomic DNA directly to look for points of
divergence and splice sites would distinguish these possibilities.
It is also possible, since this CSC clone is so large and contains several internal
Sau3AI sites, that it is chimaeric, i.e. made up of several different unrelated Sau3AI
fragments which have been spuriously ligated together. This could be another
reason that the genomic PCR did not work as the primer pairs extended further
across the clone sequence and may explain why this clone could not be amplified
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Figure 6.11: PCR analysis showing amplification of fragments across the sequence of the CSC
clone 3A6 from genomic DNA (A9 and THG = total human genomic DNA) and 3A6 clone DNA.
If the clone 3A6 is not a cDNAthen amplification of correctly sized bands across increasingly
large fragments of the clone would be expected to occur in both the clone and the genomic DNA.
If introns are present in the genomic DNA then amplification should occur in the clone 3A6 but
not the genomic DNA.
Expected sizes: M306/M184 - 598bp
M187/1184 - 946bp




• Sequencing the CSC clone 3A6;
The clone 3A6 was completely sequenced using the primers described in Table 6.5.
Table 6.5: Primers used to sequence the 2.3Kb CSC clone 3A6
Primer Name Primer Sequence
Ml 88 5'- CCA GAA GTT TGT CAC CAG -3 '
Ml 87 5'- TGA GGC AGG AGA ATC GCT -3 '
M305 5' - TTG TCT GCC TGA AAA TGT -3 '
M306 5'- CCA GGG ACA AAG TTW WCA -3 '
N164 5'- TAA CAA CTA ACC TCC CCT -3 '
II84 5'- CTT TCC ACC TTC TGC CAT -3 '
W = A or T
Figure 6.10 shows the sequence of CSC clone 3A6 with sequencing primers
highlighted in bold. This sequence contains several Sau3AI restriction enzyme sites
indicating that it is the result of a partial Sau3A\ digestion. Until this clone is proved
to originate from the original cDNA, the possibility that it is a chimaeric clone can not
be excluded.
The clone sequence contains three potential predicted poly A sites which could be
indicative of the 3' end of a gene. These occur at positions 313bp, 335bp and
1846bp and are represented by the sequence AATAAA.
The demonstration of an open reading frame (ORF) (coding sequence containing
no stop or nonsense codons) in a DNA sequence, which can code for a peptide,
provides additional evidence of the genie nature of the sequence. The CSC clone
3A6 was therefore translated in all three reading frames in both directions in order
to try to demonstrate the presence of an open reading frame. However, the
sequence does not maintain a continuous open reading frame throughout its length.
The presence or absence of an open reading frame is critically dependent on the
sequence quality. A single incorrect base pair can destroy the continuity of the ORF
and since there are several ambiguities in the 2.3Kb sequence of this clone this
may offer one explanation for the lack of a continuous ORF. Sequencing and
cloning errors may have occurred during the CSC procedure which could affected
the ORF continuity. The CSC technique is PCR based in which Taq polymerase can
incorrectly copy bases. The DNA has also undergone several rounds of cloning
(since the DNA used in the CSC experiment had already been cloned into either a
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cosmid or PAC) by the time the final CSC DNA clone is sequenced increasing the
likelihood of cloning errors which alter the DNA sequence.
The sequence of clone 3A6 contains a large TC repetitive sequence at the 3' end of
the sequence. Repetitive sequences identified by repeat database searches
("repeat masker", available from at HGMP resource centre, Hinxton Hall,
Cambridge) included a MSTD repeat from the LTR/MaLR family of repeats
extending from 1040bp to 1412bp in the sequence, a simple (GGAA)n repeat
extending from bases 1875-2013 and an AluSc repeat from the SINE/Alu family
extending from 2015bp-2248bp (see Figure 6.10).
The lack of open reading frame and the presence of repetitive elements in the clone
sequence are indicative of the sequence comprising the UTR of the corresponding
gene. Since the original cDNA resource used in the CSC experiment was oligo dT
primed it is likely that 3' sequences of genes will be isolated. However, if the clone
sequence does represent a 3' UTR it would be expected that the PCR with primer
pairs at either end of the sequence (see previous section and Figure 6.11) should
have worked on genomic DNA as well as the cDNA clone DNA, as 3' UTR regions
do not usually contain introns.
• Hybridisation of clone 3A6 onto the CSC library:
The 3A6 clone was hybridised back onto the CSC library in order to determine
whether any other clones containing this sequence were present. One other clone
was positive in this screening. This clone had a very small insert size (41 bp). The
sequence did not further extend that obtained from the 3A6 clone sequence.
• Mapping 3A6 to somatic cell hybrid panel:
The whole CSC 3A6 clone insert was used as a probe in Southern blot hybridisation
analysis of the somatic cell hybrid panel (cut with restriction enzyme EcoR1). The
results from this hybridisation are displayed in Figure 6.12. Although there is a
background smear, present due to the repetitive elements contained in this clone, a
distinct band is visible in the chromosome 1 only hybrid A9, in total human genomic
DNA and in the derived chromosome 11 hybrid MARI. This band is approximately
5Kb in size, which is the same size as that seen in the hybridisation of this probe to
the EcoFH digest of the PAC DJ4B9/3. The band seen in the MAR1 hybrid is
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Figure 6.12: Southern blot hybridisation analysis of 3A6 hybridised
to somatic cell hybrid panel cut with EcoRI
203
Results Chapter Six
chromosome in this hybrid. This result confirms that the clone maps distal to the
chromosome 1 translocation breakpoint.
In conclusion more work on this clone is required to address whether it is truly a
coincident product representing a cDNA derived from foetal brain (See discussion).
It is still possible that this clone is either a chimaeric clone made up of several
unrelated fragments or is a genomic artefact.
Clone 11B6:
• Sequencing clone 11B6:
This clone was identified by random sequencing of 50 CSC clones. The clone insert
was 1076bp in length. It was possible to sequence across the whole of this clone
using the vector primers 291 and 292. The sequence of clone 11B6 is displayed in
Figure 6.13.
Database searching against the GENBANK database showed that this clone
matched two ESTs in the database. The first of these ESTs (and the best match -
96% identity over 546bp)) was a foetal lung EST (GENBANK accession number
W05481). The second EST clone 11B6 matched was derived from foetal heart DNA
(GENBANK accession number AA347756, 92% identity over 436bp). (N.B identity is
assessed by the BLAST program (Pearson and Lipman 1988)). The two EST
matches extended over the same region of the CSC clone as indicated in Figure
6.14a and b. The foetal lung EST extends over the region 248bp to 498bp and the
foetal heart EST extends over the region 231 bp to 433bp. The foetal lung EST was
derived from an I.M.A.G.E consortium clone which was obtained from the HGMP
resource centre, Hinxton Hall, Cambridge. The size of this clone was approximately
600-700bp as determined by a PCR reaction carried out using primers designed to
the vector (pT3T7D) sequence (T3 5'- AATTAACCCTCACTAAAGGG -3' and T7 5'-
CATTATGCTGAGTGATATCCCG -3'). This foetal lung clone, named 299277, was
sequenced using the vector primers. However despite several attempts the clone
was refractory to sequencing.
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Figure 6.13: Sequence of CSC clone 11B6. Capture oligonucleotide sequence is








1 GAATTCAGAC ACTGGTATGC ATCTCTATTA ATGTGTAATA AGTGGCTCCT
51 CAAACTTCAT AGCTTGAAAC AACAAACCTT TATCTCTCAC AGTCTCTGAG
101 AGACAGGAGT CCAGAGTGAC TTAGCTGGGT GGCTCTGACT CAGGGTCTCA
—
151 TAAGGTCGCT GTTAAGACAC ACTTTGGAGC TGCAGTCGTC TAAAGGCTTG









251 CTGCACTGAT TCAGAACAGC AGGGGCTGGC TCTGTACTGG GTGGGTGGGT ^
T
301 GCTCAAGGCC AGACCTACAC AGTGCTCCTG TGTCTGCAGC TGCAGGGAAG
351 CAGGAGAAAC AGTGACGATG GTCCRGGAGA AGCCACCTGA CATATGGCAG
401 AAAAACAAAA TTCAGGGTAC AGACAGTGGS TGGGAVCATC AAYTCAATYG
451 CTTTCTTTCT TTAMTATTTT CCYTCTTTCT AAAAAAGTCT GTGATTTAAA
501 TCAGTGGCTG CAGGARGGAA ACAAGARAMC CAGTAAAGAT GTTTTCAAAG
551 ATGATCCTAT CTGGTGTGAA AAGAAATGAA RAMCTACCCA AAGGGAATAA
601 GCACAAGTAT TATGCAGAGC TTKGTACAGC AAGGGAKTCA GACACCATCA
651 TTTGCAATTT GGCAGAGATT CAAAGGTGGG CAGACGAGTG GGAGAGCTTT
701 ATAGTGGAAA AAGGCGAAGG CTTCAGGTGT GCCCTGATTG GAGGTTATCA
751 ATGCGGGGAA GCTGGAGGCG GCTCACTAGA AGCGAACATC CTGTGTGCTT
801 GGTCAGGGGA CCATATTTGG CTTTCTCTGG TGGGTCCTAA GTTGGAATCG
851 GGGACAAAAA TTAGGGAAGC CATCAGTTAT TAATCCAGTC CTGAACATTT
901 TGAGTCAATT GTTACAGAAG TTATTATTTA GCTTCCTGGA TAGTTACTAG
951 AGAGCAATTT GGCTTCCAGC AGGTCTGATT TAGAGCAGGC CAGCTTCCGG
1001 GGTTGCTTTT TGTGGGTAAG GGTATTGTTT TCTGGGAAAG TTGCTGCACC
1051 TTGTGGATCG GTCGACTCTA GAATTC
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Figure 6.14a: Sequence alignments of CSC clone 11B6 and two ESTs identified as
being of strong identity to this clone by GENBANK database searching.
I: Sequence alignment of CSC clone 11B6 with a foetal lung EST identified from
GENBANK database searching.
GB:W05481 W05481 ZA84F11.R1 SOARES FOETAL LUNG NBHL19W HOMO


































II: Sequence alignment of CSC clone 11B6 with foetal heart EST identified from
GENBANK database searching.
















III I I I I I II II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
GATNGGTCCNGGNGAGGGCCACCTTGACATATTGGCAGAAAAACCAAAATTCAGGGTACA 405
EST
11B6 422 GACAGTGGS-TGGGAVCATCAAYTCAAT 448
I I I I I I I I I I I I I I I I I I I I I I
EST 406 GNCAGTGGCTTGGGNGCATCAACTCAAT 433
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Figure 6.14b: Sequence of CSC clone 11B6 indicating region to which the ESTs
identified by database searching match. Capture oligonucleotide sequence is
highlighted in bold and repetitive elements are marked in the sequence. EST
matches from GENBANK database are also displayed.







1 GAATTCAGAC ACTGGTATGC ATCTCTATTA ATGTGTAATA AGTGGCTCCT
51 CAAACTTCAT AGCTTGAAAC AACAAACCTT TATCTCTCAC AGTCTCTGAG
101 AGACAGGAGT CCAGAGTGAC TTAGCTGGGT GGCTCTGACT CAGGGTCTCA
151 TAAGGTCGCT GTTAAGACAC ACTTTGGAGC TGCAGTCGTC TAAAGGCTTG
201 GCTGGGGCTG AAAGATCACA GAGGCATGGG CACTGTGTTC TAAGTGGTC,
251 CTGCACTGAT TCAGAACAGC AGGGGCTGGC TCTGTACTGG GTGGGTGGGT
301 GCTCAAGGCC AGACCTACAC AGTGCTCCTG TGTCTGCAGC TGCAGGGAAG
351 GAGGAGAAAC AGTGACGATG GTCCRGGAGA AGCCACCTGA CATATGGCAG







451 CTTTCTTTCT TTAMTATTTT CCYTCTTTCT AAAAAAGTCT GTGATTTAAA E
s
501 TCAGTGGCTG CAGGARGGAA ACAAGARAMC CAGTAAAGAT GTTTTCAAAG LJ
551 ATGATCCTAT CTGGTGTGAA AAGAAATGAA RAMCTACCCA AAGGGAATAA
601 GCACAAGTAT TATGCAGAGC TTKGTACAGC AAGGGAKTCA GACACCATCA
651 TTTGCAATTT GGCAGAGATT CAAAGGTGGG CAGACGAGTG GGAGAGCTTT
701 ATAGTGGAAA AAGGCGAAGG CTTCAGGTGT GCCCTGATTG GAGGTTATCA
751 ATGCGGGGAA GCTGGAGGCG GCTCACTAGA AGCGAACATC CTGTGTGCTT
801 GGTCAGGGGA CCATATTTGG CTTTCTCTGG TGGGTCCTAA GTTGGAATCG
851 GGGACAAAAA TTAGGGAAGC CATCAGTTAT TAATCCAGTC CTGAACATTT
901 TGAGTCAATT GTTACAGAAG TTATTATTTA GCTTCCTGGA TAGTTACTAG
951 AGAGCAATTT GGCTTCCAGC AGGTCTGATT TAGAGCAGGC CAGCTTCCGG
1001 GGTTGCTTTT TGTGGGTAAG GGTATTGTTT TCTGGGAAAG TTGCTGCACC
1051 TTGTGGATCG GTCGACTCTA GAATTC









Repeat database searches with the sequence of the clone 11B6 showed that this
clone contained a repetitive element. This repetitive element was a MLT1F repeat
which is a member of the LTR/MaLR family of repeats. The repeat extends from
position 22bp to 217bp, where there is Sau3AI restriction enzyme site. These
repetitive elements are very low copy in the human genome. This clone was not
identified as a repeat containing clone in the initial library screen with Cot1 DNA.
This is likely to be due to under representation of this repeat in the Cot1 DNA which
is largely composed of Alu repeats.
The sequence of 11B6 was checked for the presence of open reading frames which
would help indicate the genie nature of this DNA fragment by translating the
sequence in all three frames in both directions. The sequence does not contain any
sustained open reading frame. This may be for several reasons which have been
mentioned previously for clone 3A6. It may be that errors from the sequencing of
the clone prevent the maintenance of an open reading frame or that the sequence
represents 3' untranslated region of the corresponding gene and no coding
sequence is present in this clone. There are no other distinguishing features in this
sequence (such as a consensus poly A site) which could define its genie nature
further. The fact that the sequence contains a repetitive element may suggest that it
is UTR sequence. It is possible that this clone is chimaeric. The match of this clone
to the two ESTs in the database begins abruptly with a very good match at a
Sau3AI restriction enzyme site (GATC)(refer to figure 6.14b; Sau3AI sites
highlighted in bold). Prior to this Sau3AI site, despite the fact the EST sequence
continues, there is no reasonable match to the sequence possibly indicating that
this clone is chimaeric. The repeat containing section up to the Sau3AI site being
unrelated to the region of the two EST matches and having arisen from an aberrant
ligation reaction.
• Is clone 11B6 derived from the genomic resource?
As previously mentioned for clone 3A6, it is important to determine that the clone
has been derived from both the genomic and cDNA resources that were originally
used in the CSC experiment. The 11B6 clone insert was therefore used as a probe
in Southern blot hybridisation to the same PAC and cosmid digest filters as with
clone 3A6. The results from this hybridisation are displayed in Figure 6.15. It is
apparent from this result that bands can be seen in the cosmid 10142 and in the
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Figure 6.15: Southern blot hybridisation of CSC clone 11B6
hybridised to restriction enzyme digests of the cosmids B01519
and 10142 and PAC DJ4B9/3.
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cosmids two bands are visible in very close proximity to one another at
approximately 12Kb. The Hindlll and EcoRI digests of the cosmids and PAC also
have bands in the PAC and 10142 cosmid lanes but these bands are of different
size (see Figure 6.15). The bands seen in the PAC are of smaller size than those in
the cosmid 10142 in these two digests (EcoRI and Hindlll). This is due to the cosmid
10142 extending beyond the PAC distally in the contig and therefore a smaller
restriction fragment may be expected to be seen in PAC as the clone maps at the
extreme end of the cosmid reducing the size of the restriction fragment. There is a
background smear in the positive lanes (PAC and cosmid 10142) which is
attributable to the presence of the repetitive element which was identified from
sequence analysis of this clone.
• Is the CSC clone 11B6 derived from foetal brain cDNA ?
In order to determine if this clone was derived from foetal brain a PCR on the
original cDNA was carried out using primers designed to the clone sequence (N811:
5'-GCA GGG AAG CAG GAG AAA -3'; N812: 5'- TCC CAG AAA ACA ATA CCC -
3'). The PCR was achieved using A9 DNA (human chromosome 1 only), 11B6
minipreped DNA and original cDNA as template. PCR conditions are described in
Table 6.6. PCR products of the correct size were produced from the chromosome 1
only DNA and from the 11B6 clone DNA but not from the cDNA originally used in
the experiment (see figure 6.16). This may be due to the CSC clone not being
highly represented in this DNA.
Table 6.6 PCR condition for amplification of CSC clone from original cDNA
resource.
Denaturing Annealing Extension
Cycle 1 94°C/30sec 50°C/45sec 72°C/60sec
Cycle 2-34 94°C/15sec 50°C/45sec 72°C/60sec
Cycle 35 94°C/15sec 50°C/45sec 72°C/90sec
In order to demonstrate that the clone was derived from foetal brain cDNA the





Figure 6.16: PCR analysis showing amplification of 11B6 from original foetal brain
cDNA resource, CSC clone DNA and Human chromosome 1 DNA (A9).
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number of positive clones were obtained from this screening. The inserts were
amplified by boiled plaque PCR and sequenced using the vector primers 391 and
392. The sequence obtained from these cDNA clones is presented in Figure 6.17A.
When the sequence of cDNA clone 311 was compared to that of the CSC clone
Figure 6.17: cDNA clone sequences obtained by screening a full length foetal brain
cDNA library with CSC clone 11B6.
A) Sequence of cDNA clone 31. Repetitive elements are highlighted.
1 GAANAGTANA ATCATTTGAA CCTGGGAGTC GGAGGTTGCA GTGAGCCAAG
51 ATCCCAC< 'AC' TCTGTCTt AAA





151 gcttttgatg catgacagat ttcccccaac ttagcaggta gagataacaa
201 |ACATTTATTA TCTTATACCT GAAGTTCAGG AATTGGAGCA GCTCGGCTGG|
251 gtggttctgg ctgagggtct ccagaggttg tagtcagagg ttggtcagag
301 ctgcagtcat cagaargctt gactggggca agaggagctg tgtccaagat
351 ggcgtcctcc catggctgtt ggctggaggc ctcagttcct tgccatgtgg
401 gcctctcaac atagggctgc tcccaacatg scagctggct tgcccctagg







501 Igtggctcaca cctgtaatcc cagaactttg gaaggccaag gcaggcarrtj
551 iCATGAGGTCA ggagatcgag accatcctgg scaacatggt gaaaacccca!
601 ITCTCTTCTAA aaatacaaaa attasykggg tgtkgtggtg tgtgcctgtaI
651 Tatctcagcta cttgagaggc tgaggcagga gaatcacttg aacccgggag
701 igtggaggttg j^agtgagcca agatcgcacc _ attgcactcc .agcctggcg4
751 lcagagtgaga_cxccatctc_a.mMPaaaaa.cammcaaa aacaaaacat:
8 01 : AAGCTGCCAT
. GTCGTTGATA ACCTAATCTC . AAAAGTGACA. TACAATCACT
851 : TCTGATATAT 'TTTATTGGCC ' ACTCTGATGA' CCAGGACCCC ' TGCTTCATTG
901 :TGAGACGTGA.CTACACGAGG GTATGACCAC CAGGCAGTCA GGATCACCGG
951 ITGGCCATCTC AGAGGCTGGC TACCACAGGT CCCATCCCAA AGAAGGAACA
1001 AACGCATGGG TATCTACCGT GTCCACTGTG CTCCAGGCCT TGATGlfTAGGl
1051 1 "tagatgtgat tatctccatt ttgcaggtga ggaaataggc ccagaaatgtI










B) Sequence comparison of CSC clone 11B6 and cDNA clone 31 obtained from
screening a foetal brain cDNA library with the CSC clone 11B6. There is only 64%
identity despite stringent hybridisation conditions.
64.2% identity in 193 bp overlap
11B6
cDNA
10 20 30 40 50
GAATTCAGACACTGGTATGCATCTCTATTAATGTGTAATAAGTGGCTCCTCAAA
I I I I I I I III I I I I I I
TTCTTCAACATTAGAGCCTGTAGCAGGGAGCTTTTGATGCATGACAGAT—TTCCCCCAA
130 140 150 160 170
11B6
cDNA
60 70 80 90 100 110
CTTCATAGCTTGAAACAACAAACCTTTATCTCTCACAGTCTCTGAGAGACAGGAGTCCAG
I I I I I I I I I I I II I I I I I I I I II I III I I I I I I
CTTAGCAGCTACAGATAACAAACATTTAT-TATCTTA-TACCTGAAGTTCAGGAAT-TGG
180 190 200 210 220 230
120 130 140 150 160 170
11B6 AGTGACTTAGCTGGGTGGCTCTGACTCAGGGTCTCATAAGGTCGCTGTTAAGACACACTT
II II I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I
cDNA AGCAGCTCGGCTGGGTGGTTCTGGCTCAGGGTCTCCAGAGGTTG-TAGTCAGAGGTTGCT
240 250 260 270 280 290
180 190 200 210 220 230
11B6 TGGAGCTGCAGTCGTCTAAAGGCTTGGCTGGGGCTGAAAGATCACAGAGGCATGGGCACT
I I I I I I II I I I II 11:11111 I I I I II I I II I
cDNA CAGAGCTGCAGTCATCAGAARGCTTGACTGGGGCAAGAGGAGCTGTGTCCAAGATGGCGT
300 310 320 330 340 350
11B6
240 250 260 270 280 290
GTGTTCTAAGTGGTCACTGCACTGATTCAGAACAGCAGGGGCTGGCTCTGTACTGGGTGG
cDNA CCTCCCATGGCTGTTGGCTGGAGGCCTCAGTTCCTTGCCATGTGGGCCTCTCAACATAGG
360 370 380 390 400 410
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11B6 the identity was only 64% (Figure 6.17B). Since the hybridisation and washing
conditions had been stringent (68°C, 0.1X SSC) this was surprising. Database
searches against the GENBANK and "repeat masker" databases (HGMP, Hinxton
Hall, Cambridge) showed that in fact the sequence of the cDNA clone 311 was
largely composed of repetitive elements (see Figure 6.17A).
The CSC clone 11B6 used to screen the cDNA library contains a repetitive element.
However, as the cDNA library screening was carried out prior to the full sequence of
the clone being known, this repetitive element was not blocked prior to the library
screening. The clone from the cDNA library has been identified due to homology
with this repetitive element. This CSC clone has not therefore been proved to be a
cDNA by this library screening.
A foetal heart cDNA library has also been screened with this clone (in which the
repeat has been competed out) and has resulted in several strong positives which
are currently being reduced to single plaques.
• Mapping the clone 11B6 to the somatic cell hybrid panel:
It is not possible to tell from the hybridisation to digests of the PAC and cosmids
whether the CSC clone 11B6 maps proximal or distal to the chromosome 1
translocation breakpoint. In order to determine this, the clone insert was hybridised
in Southern blot hybridisation analysis to a panel of somatic cell hybrids containing
the chromosome 1 only hybrid A9, total human genomic DNA and the translocation
hybrids MAR1 and MAR12. The result of this hybridisation is displayed in Figure
6.18. A band at approximately 7Kb is present in the chromosome 1 only hybrid A9,
in total human genomic DNA and in MART This indicates that the clone 11B6 lies
distal to the chromosome 1 breakpoint. In the total human genomic lane several
bands can be seen. This is probably due to the repetitive element in the clone but
also may indicate that this clone has other related genes or pseudogenes present
elsewhere in the genome since not all of these extra bands are not seen in the
chromosome 1 only hybrid A9.
• Hybridisation of CSC clone 11B6 to the CSC library:
The whole 11B6 clone insert was also hybridised onto the CSC library in order to
determine if any other related clones were contained in the library. No other
positives clones were identified during this screening.
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Figure 6.18: Southern blot hybridisation of clone 11B6 hybridised to the




Several gene fragments have been identified as residing around the region of the
translocation breakpoint using several differing methods. These gene fragments are
currently being investigated (ongoing work by Kirsty Millar, Susan Anderson and
Sheila Christie. See section 7.2)). The Human Transcript Map (Schuler et al 1996)
has allowed further gene fragments residing around this region to be isolated. This
region of chromosome 1 appears to be gene rich since the Human Transcript Map
identified approximately 60 genes in a 1Mb region around the translocation
breakpoint.
The average density of genes in the human genome is 1 every 40Kb. The region
around the chromosome 1 breakpoint appears to be very gene rich in comparison to
the chromosome 11 breakpoint around which there appears to be a paucity of
genes. Many of the gene fragments isolated around the chromosome 1 breakpoint
may turn out to be parts of the same gene or constitute several genes residing in
the region. The region considered in this experiment was approximately 140Kb in
size and would therefore be expected to contain 3-4 genes on this basis. If the two
DNA clones identified prove to be real gene fragments then despite the severe
contamination problems encountered the experiment can be counted as successful.
The two DNA clones will be further investigated to determine their candidacy as
causal elements involved in the psychiatric diagnosis in the K26 translocation
pedigree.
Several criteria were used in this experiment to assess the products which were
obtained from the CSC experiment. These criteria are listed in Table 6.7
Table 6.7: Criteria for assessing cloned products derived from CSC experiment
CRITERIA
Clone must be derived from genomic resource starting material
Clone must be derived from original cDNA starting resource
Clone must be shown to be of human origin by mapping to total
human genomic DNA and A9 chromosome 1 only hybrid
Clone sequence should be compared to sequences in the
GENBANK, dbEST and repeat databases to determine if it is novel
or of known sequence and it does not consist entirely of repetitive
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elements or vector sequences
Clones should be correctly linkered and contain the correct vector
sequence at the beginning and end of the sequence
The two clones identified in this experiment have met all but one of these criteria.
Neither of the two clones have been shown to be derived from the original cDNA.
In the case of clone 11B6 the CSC clone sequence matches that of two ESTs in the
database. Whereas this does not prove that it is a cDNA it does show this clone to
be interesting, even if it does correspond to a chimaeric/genomic clone, since it
maps to a region close to the breakpoint (if it is a chimaeric clone then one segment
contains the EST match which is of interest and the other smaller segment contains
repetitive sequence). The EST matches are derived from two different libraries. This
would imply that the EST matches are not coincidental matches resulting from a
mutual contaminant occurring in the CSC library and the cDNA library from which
the ESTs were derived. This clone has also given strong positive results when used
as a probe onto a foetal heart library (the same tissue from which one of the EST
matches was derived). Although sequence has yet to be obtained from these
positive clones from this library screening this provides further evidence that this
clone contains expressed sequence which resides in close proximity to the
breakpoint and it is therefore of further interest.
The 3A6 clone does not have any evidence of containing expressed sequences and
must be shown to be derived from foetal brain cDNA (or be genie in nature) in order
to be of further interest. It is likely that this clone is either chimaeric or a genomic
artefact due to its large size and multiple Sau3AI restriction sites. The end ligation
procedure is very stringent and in order to be a genuine product this clone would
have to have hybridised to a cDNA of similar size which would also have to have
been partially digested in order for the capture oligonucleotides to be ligated
properly. If the clone is either chimaeric or a genomic artefact, it may be difficult to
assess the true nature of this clone.
The CSC technique is sensitive to contamination from various sources due to its
amplification stages which amplify the contaminant as well as genuine products. All
such contamination is problematic, as has been clearly demonstrated in these
experiments but particularly so if it is derived from the original genomic resource,
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emphasising the importance of demonstrating that the clones are genie in nature
and derived from both the original starting resources.
Although the CSC experiment recovered two novel products from the region around
the translocation breakpoint on chromosome 1 the high contamination level of the
library was undoubtedly detrimental to the isolation of further transcripts. It would be
appropriate to repeat the CSC experiment either using PAC DNA of a purer quality,
which could be achieved by further gel purification steps to remove contaminating
E.coli sequences, or just using the cosmid DNA as the genomic resource. This may
circumvent the severe contamination problems experienced during the course of
these experiments. The high level of contamination of the library was also probably
the reason that the hybridisation with DNA probes known to map to the region (i.e.
the 7Kb wild type chromosome 1 fragment spanning the breakpoint and the EST
probe which lies within the PAC) did not result in the isolation of any positive clones.
It would also be worth persevering to resolve the non-specific binding of the cDNA
resource to the streptavidin coated magnetic beads experienced in the hybrid
fishing technique, since the end ligation method, although more stringent, favours
the isolation of intra exonic fragments which will fail to recover some genuinely
coincident products. The combination of the hybrid fishing and the end ligation
methods would result in more gene fragments being isolated.
The most significant drawback of the coincident sequence cloning technique is its
limitation to only identify genes expressed in the tissue chosen to make the cDNA
resource. The selection of the tissue in which the causative gene will be expressed
is therefore critical to the procedure. Similarly, the developmental stage of the tissue
chosen may be critical for the gene to be expressed. In this experiment using foetal
brain tissue from three stages of development was aimed at circumventing these
problems as far as possible, since foetal brain expresses a large percentage of the
genes of the genome (>50%) and a gene involved in psychiatric illness would most
likely be expressed in the brain. However, complementary gene isolation techniques
should also be considered such as exon trapping or direct screening of cDNA
libraries. cDNA selection appears to be the preferred method for gene isolation in
the literature and Harshmann et al (1995) showed that this method was more
efficient than direct library screening or exon trapping contributing to 39/45
candidate gene fragments isolated from the BRCA1 region on chromosome 17q.
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The CSC experiment has allowed the isolation of two novel clones in close proximity
to the chromosome 1 translocation breakpoint. These clones can now be further
investigated as potential candidate genes involved in the psychiatric diagnosis in the
K26 translocation pedigree.
Further investigation of these clones to assess their candidacy would firstly need to
confirm that the clones were derived from foetal brain cDNA (especially in the case
of 3A6). This could be achieved by screening foetal brain cDNA libraries with
different probes derived from the clone sequence. In the case of 3A6 this may be
important if this clone is chimaeric as only a small portion of the clone may contain
the cDNA fragment.
Once it has been established that the clones are derived from foetal brain cDNA,
the sequences should be extended to full length by repeated screening of full length
foetal brain cDNA libraries(or libraries derived from other tissues). Sequences which
are not extended fully by this procedure could be extended using the technique for
5' or 3' Rapid Amplification of cDNA Ends (RACE).
The information gained from the additional sequence obtained using these
techniques will allow further database searching to identify matches to known genes
at the nucleotide and protein level. Analysis of the predicted proteins structure by
hydrophobicity profiling and identification of protein domains (such as membrane
spanning domains) may provide clues as to the function of the gene products
corresponding to these clones.
The clone sequences once extended should be mapped at high resolution with
respect to the translocation breakpoint. This could be achieved by restriction
enzyme mapping of the PAC and cosmids from which the clones were derived.
Determining the proximity of these clones to the breakpoint in combination with
extension of the sequences to full length will indicate how far these clones extend
towards the breakpoint and if either of them cross the breakpoint. Several other
gene fragments have been identified in close proximity to the breakpoint (work
carried out by Kirsty Millar, Susan Anderson and Sheila Christie). These sequences
may be related to, or part of the same gene as the CSC clones. Fine mapping in
relation to these other gene fragments is therefore desirable.
Information on the genomic structure of the gene and its control elements would
also be useful to determine if any of these elements are disrupted by the
translocation event should the genes prove to be in very close proximity to the
breakpoint. The genomic structure of the gene would also be useful to know in
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order to characterise intron/exon boundaries. Comparison of the gene in normals
and a translocation carrier could also be important in determining differences in the
gene structure due to the translocation event.
Analysis of the encoded proteins themselves may reveal information about the
function of the genes. Western blot analysis could determine the size of the protein
in different tissues and techniques such as immunofluorescence may reveal the
localisation of the protein within the cell. Co-immunoprecipitation experiments and
the yeast two hybrid system would reveal protein-protein interactions.
Expression analysis by Northern blot, RT-PCR and RNA in situ hybridisation
techniques would be valuable to determine the expression pattern of the genes
relating to these clones. Analysis in different tissues and developmental ages could
suggest a possible functional role for these genes. Northern blot analysis would also
provide an indication of the size of the genes corresponding to these clones.
In the longer term, if these clones prove to be interesting candidate genes, the
elucidation of homologous genes in other species such as the mouse (assessed by
zoo blots initially and then isolation of homologous genes by screening a mouse
library) would be valuable. These homologous genes may be of known function
helping to further elucidate the role of the genes in the pathogenesis of the
psychiatric disorders seen in the translocation family.
Transgenic animal models will undoubtedly play a central role in the determination
of the effect of the gene in vivo. Gene knock-outs may establish the importance of
the genes role in development and manipulations of the gene such as the effects of
point mutations, partial deletions or over-expression can be tested to determine
their effect by assessing the resultant phenotype. Insertion of a reporter gene such








Having identified a family carrying a balanced translocation between chromosome 1
and 11 which cosegregates with mental illness, a positional cloning strategy has
been employed in order to elucidate the relationship between the translocation and
the psychiatric diagnosis in this family. This positional cloning strategy is based on
the hypothesis that a gene or genes involved in mental illness reside at or near the
translocation breakpoint on chromosome 1 and/or chromosome 11.
A schema of a general positional cloning strategy is illustrated in Figure 7.1. This
schema indicates the many sequential stages which can be taken when employing
such a positional cloning strategy. Ultimately, despite the route taken, the final
outcome should be the identification of disease associated gene(s). The work
described in this thesis has used four of the approaches outlined in this schema
(these are highlighted in the figure). Although different, these complementary
approaches have been employed to identify genes which may be involved in the
psychiatric diagnosis in the translocation family.
One of the most obvious and potentially productive ways to determine genes
involved with disease processes, is to look initially at those genes already known to
reside in the region to which linkage has been found, or which reside close to the
cytogenetic abnormality of interest, as in our case. These genes may be determined
as candidates due to their known biological function or, initially, solely due to their
close proximity to a chromosomal abnormality. The first approach taken in this
thesis, to determine genes involved in the psychiatric diagnosis in the t(1:11)
translocation family, was such a candidate gene approach. Two a-actinin genes,
ACTN 2 and ACTN 3, were considered. These two genes were known to reside in
reasonable proximity to the translocation breakpoint and were of additional interest
as they were located on both chromosome 1 and 11. High resolution mapping of
these genes employing somatic cell hybrids and YACs from the region, allowed
these genes to be excluded from further consideration based on their position out
with the YAC contigs and their relatively remote location from the translocation
breakpoint. Alternative approaches were pursued to determine other candidate
genes residing in the region of the translocation breakpoint.
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The Human Genome Project has greatly aided positional cloning. One of the aims
of the Human Genome Project is to produce a human transcript map by the year
2005. Towards this aim, a great number of expressed sequence tags (ESTs),
representing the ends of cDNA clones derived from various tissues, have been
generated and are available in a number of databases including GENBANK and
dbEST. Since ESTs are derived from the ends of cDNA clones they should
represent gene transcripts and provide an excellent resource for determining the
mapping positions of these gene transcripts. The sequence of many thousands of
ESTs are now available in several databases. The dbEST database currently
contains 819,082 ESTs (September 1997). It is however unclear what percentage of
the total number of the estimated 100,000 genes in the human genome this number
truly represents as the level of redundancy within this database is uncertain
Although many thousands of ESTs are available in the database remarkably few of
these ESTs have been assigned to precise mapping locations to date, limiting their
immediate usefulness. This situation will undoubtedly change as the Human
Transcript Mapping phase of the Human Genome Project picks up speed and
moves towards completion of the Human Transcript Map.
The second approach taken in this thesis was high resolution mapping of a number
of ESTs which had been described as mapping to the general region of the
chromosome 11 translocation breakpoint by Rosier et al (1995). These experiments
utilised somatic cell hybrids and YACs from the region and allowed the location of
the ESTs in relation to the translocation breakpoint on chromosome 1 to be
determined. All of the ESTs considered were excluded from further study due to
their remote location from the translocation breakpoint on chromosome 11.
However, this mapping approach highlighted difficulties that the presence of
repetitive elements can impose (see chapter four). The generation of ESTs from the
3'UTRs of genes is beneficial in that these regions tend to be less conserved than
coding regions of genes making it easier to distinguish between individual genes
and paralagous gene family members that may be closely related in coding
sequence which is desirable for mapping purposes. However, the 3'UTR sequences
often contain repeat elements which can cause difficulties when trying to map the
precise location of these ESTs as highlighted in chapter four. The use of 3'UTR
generated ESTs is less desirable for database searching and sequence analysis as
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there is often little coding sequence data and makes extension of these sequences
into full length cDNA representing a gene more challenging.
The third approach described in this thesis was an allelic association study with
polymorphic markers residing in close proximity to the translocation breakpoint on
both chromosome 1 and 11. The allele frequencies of these markers in affected and
control populations were compared. Two affected populations were considered;
schizophrenia subjects and unipolar depressed subjects (a diagnosis which is also
prominent in the translocation family). Such a study provides an opportunity to
investigate a possible association between the translocation breakpoint region and
a postulated schizophrenia susceptibility gene in a random population of affected
subjects versus normal controls. No association was demonstrated in either the
schizophrenia subjects or the unipolar depressed subjects, evidence against a
nearby gene of major effect. As alluded to in the discussion section of chapter 5,
this may imply that either the postulated gene in close proximity to the breakpoint is
not in linkage disequilibrium with the marker used or that the gene is of major effect
in the translocation family, but not in the general population of schizophrenics
tested. Many of the issues related to the procedural aspects of association studies
have been previously referred to, such as that of population stratification (see
chapter 5 discussion). However, the question remains of what should be regarded
as positive/negative association in terms of statistical significance and, if present,
what this difference means (Berrettini 1997, Paterson 1997, Baron 1997). These
issues have been widely discussed in the literature, particularly that of statistical
significance (Lander and Kruglyak 1995, Carey 1994).
Since we lack any clear evidence to distinguish candidate genes we must rely
heavily on statistical argument and on what is technically and practically possible.
The level of statistical significance is ideally set at a value which does not preclude
the detection of true small associations but that does eliminate the vast majority of
false negative results. However, this precise value at which it should be set is highly
debated in the literature. If a p value is set at 0.05 then by definition the observed
finding would have occurred by chance one time in twenty if the null hypothesis
were true. False positive results are, according to Crowe (1993) more likely to occur
due to the low prior probability of any chosen gene being involved in
neuropsychiatric disorder (due to our ignorance of the complex genetic architecture
of the higher central nervous system). For each candidate gene considered there
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are probably hundreds of equally likely genes which we, as yet, have not identified. X
Crowe demonstrates that because the prior likelihood is so low, the significance
level required to have a 5% false positive rate equates to a p value of <0.00001.
Further statistical complications arise from the concept of multiple testing (the more
loci tested the more likely that a false positive result will be produced purely by
chance). This is a serious complication at a time when it is practical to carry out high
density genome scans (multiple testing) but there is little to distinguish one or other
candidate gene from the long list of possible candidates (specific locus testing).
Such complications have lead many researchers to conclude that the only way to
interpret positive association findings is to consistently replicate the result in several
populations and thus confirm the "true" association (Paterson 1997, Baron 1997).
However, if further studies in ethnically diverse populations fail to replicate the
original positive findings, this does not negate the original result, since genetic
heterogeneity and several different biochemical mechanisms and pathways may be
responsible and indeed is highly likely in psychiatric diseases. The degree of locus
heterogeneity and the number of genes involved in many complex diseases may be
high. If in different populations different genes are involved, then this would result in
unreplicable positive results from different samples. Similarly, allelic variants which
are not associated in one population may be associated with the disease in a
different population and therefore for the same reasons negative results can not be
ruled out.
The reported association between alcoholism and the Taql A1 RFLP in the
dopamine D2 receptor gene (Blum et al 1990), provides a pertinent example of the
difficulties that can be incurred in the replication of association studies and
highlights many of the problems in the design of association studies. Several groups
have replicated the original positive association (Blum et al 1990, Comings et al
1991, Amadeo et al 1993) but many others have failed to do so (Turner et al 1992,
Arinami et al 1993, Suarez et al 1994). One suggestion for the failure of some
groups to replicate the original finding is due to the differences in phenotype
definition which varies slightly from study to study. Exact phenotype definition is
problematic in psychiatric disorders such as schizophrenia and any replication




Further explanations for failure to demonstrate consistent replication have included;
a) population stratification
b) the use of "Super normal" controls (which have been screened to exclude all
psychopathology and may result in over-estimation of comorbid association)
c) a related phenotype, which as yet has not been defined, is associated to this
marker (Neiswanger et al 1995).
Many of these problems can be overcome by using family based association
methods. Interestingly when these methods have been employed in the case of the
Taql A1 allele and alcoholism, the results have been negative as have those of
linkage analysis, lending support to the artefactual nature of the initial positive
associations. (It is important to note that association and linkage may not always
occur together for several reasons including the fact that linkage is more likely to
determine genes of moderate to major effect). However, population based
association studies are relatively easy and inexpensive to carry out and once
collected, many markers can be typed with relative ease. In this respect such
population based studies are still appealing. Since association studies are so
dependent on statistical analysis by their very nature, large sample populations
should be employed to improve the power of such analysis. There is also
undoubtedly a role for pooling samples and meta-analysis of data produced.
The fourth and final approach described in this thesis was to directly isolate gene
transcripts around the region of the chromosome 1 breakpoint employing a cDNA
selection technique, coincident sequence cloning. By using foetal brain cDNA and
cloned genomic DNA from the region of the chromosome 1 breakpoint, in the form
of a PAC and 2 cosmids, it was possible to isolate gene fragments expressed in
foetal brain from this region of the breakpoint. This technique allowed the isolation
of two fragments which will require further investigation to determine their
candidacy. Both of these fragments lie in relatively close proximity to the
chromosome 1 breakpoint. One appears to be novel, as judged by database
searching, the other shows strong identity to two ESTs in the database. One of
these ESTs is expressed in foetal lung and the other in foetal heart. Future work
resulting from this thesis will primarily consist of the continued investigation of these
two clones as alluded to in the discussion of chapter 6.
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The four approaches taken in this thesis have proved successful in including or
excluding gene fragments residing in proximity to the breakpoint from further study.
Exclusion of fragments is of course as important as inclusion, particularly in regions
in which there are a plethora of genes and no strong prior hypotheses regarding
function. The majority of the gene fragments considered in this thesis have been
excluded based on their remote location from the breakpoint rather than on their
biological function. With the exception of a gene fragment which spans the
breakpoint and is disrupted by it, it will of course become increasingly difficult to
exclude gene fragments which lie in close proximity to the breakpoint particularly
when they are of unknown function. Exclusion of such gene fragments will require
additional work on more functional aspects of these genes such as further analysis
of the DNA sequence and translated product sequence (to determine functional
domains) as well as assessment of expression patterns (RT-PCR and RNA insitu).
The examples of the difficulties incurred when using these approaches indicates the
importance of using differing strategies to solving difficult problems. Different
approaches allow the independent confirmation of a result which is increasingly
important in the study of complex disorders.
Future work resulting from this thesis will consist primarily of following up the clones
ascertained from the CSC experiment (see chapter 6 discussion).
7.2 Progress in the physical mapping of the t(1:11) translocation
breakpoint and flanking genomic regions during the course of this
thesis:
During the course of this thesis, work carried out by other members of the
psychiatric genetics group has continued and advanced the physical mapping of the
translocation breakpoint region.
On chromosome 11, once the breakpoint spanning YAC D0485 had been identified
it was screened for genes using a coincident sequence cloning strategy. This
resulted in the identification of several gene fragments. These included a tubulin
pseudogene which mapped ~250Kb proximal to the chromosome 11 breakpoint as
well as a number of novel fragments. These fragments have been further
characterised and extended in sequence. The novel fragments made up three novel




The YAC D0485 was also subcloned into cosmids. The cosmid sub-clones were
used to produce a contig around the chromosome 11 breakpoint region. Three
cosmids were identified as crossing the breakpoint by FISH on metaphase
chromosomes from a cell line bearing der 1 and der 11 chromosomes (MAFLI).
Restriction enzyme mapping indicated a limited overlap between these cosmids.
EcoRI restriction enzyme digestion identified three common fragments from these
three cosmids. The largest fragment (2.5Kb) contained a repeat element which was
removed by Hindi11 digestion, producing a 2.15Kb fragment. This fragment was
shown to span the translocation breakpoint by FISH on the somatic cell hybrid
MAFLI, and by Southern blot hybridisation to a somatic cell hybrid panel containing
the derl and derl 1 only hybrids MIS39.8 and MIS7.4. This 2.15Kb fragment
hybridised to a single 2.5Kb fragment in human genomic control DNA but to two
additional fragments at 2.7Kb (resulting from the derl chromosome) and 7Kb (from
der11 chromosome) in DNA derived from an affected family member carrying the
translocation chromosomes.
In collaboration with a past member of the Edinburgh group (Benoit Arvileiler,
Bordeaux) a chromosome 1 YAC contig was established using several of the
microdissection clones which mapped to chromosome 1 to isolate YACs from
commercial YAC libraries. Marker analysis using the microdissection clones, YAC
end clones and published AFM markers allowed the contig to be attained.
In order to cross over to chromosomel, the 2.15Kb wild-type 11 fragment was used
as a probe to screen a genomic DNA library made from a family member carrying
the translocation chromosomes (MAFLI). This resulted in the isolation of the der 1
breakpoint spanning clone. This clone was then used as a probe onto the library
and resulted in the isolation of the chromosome 1 wild-type breakpoint fragment
(7.3Kb). The der 11 breakpoint fragment was also isolated from this library using
the wild-type 11 fragment. The sequence of the breakpoint spanning clones showed
that the breakpoint did not contain any substantial deletions or insertions. However,
above the breakpoint on chromosome 11, the sequence TCAG was substituted with
AA. Otherwise, the breakpoint appeared to be clean. No mechanism for the
occurrence of the breakpoint event (such as repeat homology on either side of the
breakpoint) was apparent from the sequence obtained around the breakpoint on
either chromosome 1 or 11. The wild-type chromosome 1 7.3 Kb sequence
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indicated several exon predictions as determined by GRAIL (Xu et al 1996) and
several EST matches were detected when the sequence was compared to
sequences in the EST and GENBANK databases. One of the exons has been
shown to cross the breakpoint on chromosome 1. As such, this cDNA fragment
constitutes the best candidate gene for involvement in the psychiatric diagnosis in
the translocation family and is currently being extended to full length sequence and
is undergoing expression analysis by RT-PCR and RNA insitu.
The isolation of a gene fragment which spans the breakpoint on chromosome 1
provides an excellent candidate gene for involvement in the psychiatric diagnosis in
the translocation family. Characterisation of this gene and its associated elements
will hopefully reveal a great deal about the effect the translocation event has on the
function of this gene and in turn elucidate the role this gene may play in evoking the
psychiatric diagnosis seen in the translocation family.
The chromosome 1 YAC contiguous clone map has been further added to by
screening cosmid and PAC libraries from chromosome 1 with probes identified from
the chromosome 1 breakpoint region. This resulted in the identification of a PAC
and several cosmids which reside around the chromosome 1 breakpoint region.
Further information on genes located in the breakpoint region was obtained from
the Human Transcript Map (Schuler et al 1996) which indicated that several ESTs
resided in the general region around the chromosome 1 breakpoint (as determined
by STS markers mapped to the region).
The number of ESTs mapped to the general region of the chromosome 1 YAC
contig was large (>40) and seem to indicate that this region of chromosome 1 is
extremely gene rich in comparison with chromosome 11 which appears to have a
paucity of genes. (Of course many of these ESTs may represent parts of the same
gene). However, the ESTs from the Human Transcript Map were located at
distances >40Kb from the breakpoint. To date the cDNAs in close proximity to the
chromosome 1 breakpoint and the cDNA which has been shown to span the
breakpoint, are the highest priority candidates for involvement in the psychiatric
diagnosis in the translocation family and, as such, will be vigorously pursued to
elucidate their role in this process.
231
Chapter 7 Discussion
7.3 How close are we to finding a schizophrenia gene?
Schizophrenia has to date proved refractory to ail attempts to extract its underlying
genetic cause. Non Mendelian inheritance, genetic heterogeneity, uncertainty of
phenotype and incomplete penetrance all conspire to make schizophrenia a
complex and challenging disorder to investigate. Until recently, the progress made
in investigating the genetics of this disorder were disillusioning with advances being
followed closely by retreat. Recently, changes in methodology and inventive new
modifications of older method designs have cracked opened the door to the mystery
of schizophrenia, if only slightly. Replicated data from large collaborative linkage
studies (as well as smaller studies) have indicated regions on chromosome 6p
(Straub et al 1995, Wang et al 1995, Moises et al 1995, Antonarakis et al 1995), 8p
(Pulver et al 1995, Moises et al 1995) and 22q (Pulver et al 1994, Coon et al 1994,
Vallda et al 1995) as possible regions for the presence of a susceptibility gene for
schizophrenia. Chromosome 22q12-q13 has also demonstrated statistically
significant association with markers D22S283 and D22S278 lending further support
to the possible location of a schizophrenia susceptibility gene in this region.
However, every positive linkage and association result has been accompanied by a
negative result and although encouraging, more work is needed to confirm these
results.
Further interesting data has come from work on the dopamine D3 receptor gene
polymorphism in exon 1. A number of groups have reported excess homozygosity in
the patient group compared to that of the control group (Crocq et al 1992, Mant et al
1994, Nimgaonkar et al 1993). However, the familiar story of several other groups
failing to find this observation (Jonsson et al 1993, Yang et al 1993, Nothen et al
1993) is also apparent in this case. The T to C polymorphism at nucleotide 102 of
the serotonin receptor with schizophrenia reported in a Japanese study (Inayama et
al 1994, Williams et al 1996) is also of interest, not least because (as with the
dopamine D3 receptor polymorphism) there are many unanswered questions about
the relationship of the polymorphism with the neuroreceptor genes and
schizophrenia. Further work on the functional nature of these polymorphisms is
required to establish the nature of this relationship.
The recent interest in expanded trinucleotide repeats (the hallmark of which is the
phenomenon of anticipation) has added yet another thread to the web of intrigue
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(Gorwood et al 1996, O'Donnovan et al 1996, Vincent et ai 1996). Although the
phenomena of anticipation in schizophrenia is widely debated, as many believe that
systematic sampling biases are responsible for anticipation being reported, several
groups have provided molecular data that some trinucleotide repeats (CAG/CTG)
are expanded in schizophrenia subjects (O'Donovan et al 1995, Morris et al 1995).
The size of contribution to the overall variance of schizophrenia is however unclear
but as with all the other examples mentioned above is likely to be relatively small.
We will doubtless learn much from the rapidly progressing research being carried
out in neurodegenerative disorders such as Alzheimer's disease and Huntington's
disease. Elucidation of the pathological mechanisms by which such specific
neurone damage can occur in these disorders will advance our knowledge of the
pathophysiological processes involved in such late onset neurodegenerative
disorders. Both of these disorders, particularly Huntingtons disease, have indicated
new mechanisms (i.e. triplet repeat expansions) by which brain function can be
specifically altered. Increasing the general knowledge of the ways in which such
alterations can occur will allow improved understanding of the complex mechanisms
which may interact to result in altered function of the brain.
Positional cloning of the t(1;11)translocation breakpoint in the K26 pedigree
provides an alternative approach for determining schizophrenia susceptibility genes,
to the more traditional linkage analysis approaches being employed in the field. This
study allows the hypothesis that the translocation event in some way disrupts a
gene in close proximity to the breakpoint resulting in the diagnosis of mental illness
in this family, to be directly tested. By isolating genes in the region of the breakpoint
it may be possible to determine how the pathological process which leads to the
psychiatric diagnosis in this family occurs. Description of a gene which is causally
associated with mental illness, albeit in this one family, would represent a significant
step towards the ultimate aim of understanding the multiple interacting genetic and
environmental effects which lead to schizophrenia.
Future research into the complex pathophysiology of schizophrenia may benefit
from complementary strategies currently being employed in the field which are
converging to produce interesting data on the brain abnormalities which underlie the
disease. Such research includes the plethora of work being produced from
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functional brain imaging studies (reviewed by Velakoulis and Pantelis 1996). Such
studies allow visualisation of brain areas that are activated by a variety of sensory,
motor or cognitive tasks. Metabolic processes linked to neuronal activity such as
cerebral blood flow, cerebral metabolism as well as receptor occupancy and density
etc. are most often looked at in such studies. Functional imaging technology is
providing increasing insights into schizophrenia and its treatment, proving to be a
reliable, reproducible non invasive technique for visualising regions of the brain
which may be involved in psychiatric disorders.
Studies which dissect complex human disease phenotypes into constituent
behaviours in animal models are currently finding application in psychiatric genetics.
These approaches utilise gene targeting and selectively bred recombinant inbred
and transgenic strains and are a powerful way of mapping genes of lesser effect
which influence behaviour. An example of such an approach is the recent work by
Lijam et al (1997) in which mice completely deficient for Dvl1 (one of three mouse
homologs of the Drosophila segment polarity gene Deshevelled) were created.
These mice were shown to exhibit reduced social interaction and had sensorimotor
gating abnormalities. Such abnormalities have been seen in patients with
schizophrenia and other mental disorders and therefore Dvl1 mouse mutants may
provide a model for aspects of several human psychiatric disorders. Ultimately it is
hoped that this may lead to the identification of candidate loci for genetic analysis in
humans and provide a model system to study putative disease pathophysiology.
Transgenic animal approaches are also helping to clarify the actions of various
candidate genes such as the dopamine D4 receptor (DRD4) which has previously
received considerable attention due to its high affinity for the atypical antipsychotic
clozapine (Seeman and Van Tol 1994) and the polymorphic nature of this gene
(Van Tol et al 1992). No allele of the DRD4 receptor has been associated with any
particular mental disorder but there have been a number of reports showing that
certain alleles may predispose an individual to alcoholism (Muramatsu et al 1996),
novelty seeking behaviour (Ebstein et al 1996) and opiate abuse (Kotler et al 1997).
Mice which lack this protein (DRD4"A) have been produced to clarify the in vivo role
of the DRD4 receptor (Rubinstein et al 1997). The results from this study Rubinstein
et al 1997) demonstrated that the mutant DRD4 deficient mice were supersensitive
to ethanol, cocaine and methamphetamine and less active that wildtype mice in
open field tests. Biochemical analysis showed that dopamine synthesis and its
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conversion to DOPAC were elevated in the dorsal stratium compared to wildtype
mice. The authors propose that DRD4 acts at the cellular level as an inhibitory
postsynaptic receptor that primarily modulates the firing of neurones in the frontal
cortex and basal ganglia. DRD4 therefore could modulate normal, co-ordinated and
drug-stimulated motor behaviours as well as the activity of nigrostriatal dopamine
neurons. However, more studies are needed to confirm this.
A recent interesting animal study was carried out by Jentsch et al (1997) in which
they treated vervet monkeys with phenylcyclidine (PCP) twice a day for fourteen
days. PCP can cause schizophrenia symptoms in humans and if used repeatedly
can result in a long lasting syndrome marked by neuropsychological deficits, social
withdrawal and affective blunting. Cognitive dysfunction (seen in schizophrenia) and
frontal lobe damage is also observed in long term abuse of PCP. Since this may
represent a pharmacological model of cognitive deficits of the frontal cortex that are
associated with schizophrenia, the behavioural and neurochemical effects of long
term exposure to PCP were investigated by this group (Jentsch et al 1997). They
reported that monkeys treated with PCP for fourteen days displayed performance
deficits on tasks that were sensitive to prefrontal cortex function and that these
deficits were ameliorated by the atypical antipsychotic drug clozapine. Biochemical
studies showed that repeated exposure to PCP caused a reduction in both basal
and evoked dopamine utilisation in the dorsolateral prefrontal cortex (associated
with cognitive function). These effects were demonstrated not to be the result of
direct drug effects, continuing after administration of PCP was stopped. This model
may therefore prove useful to study psychiatric disorders, such as schizophrenia,
which are associated with cognitive dysfunction and dopamine hypofunction in the
prefrontal cortex.
Several areas of research are beginning to converge to provide important
information about several aspects of psychiatric illness, demonstrating that taking a
multidisciplinary approach to solving complex problems is beneficial. Convergence
of all these areas of science - biochemistry, pharmacology, functional imaging
analysis, genetics and many others, provides a holistic approach to solving the
mystery of schizophrenia which will benefit those afflicted with the disorder. Greater
understanding of the pathophysiology of this disorder will lead to improved, more
effective treatments for the majority of sufferers. Such progress is both
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economically and socially desirable and will hopefully lead to a better quality of life
for sufferers and their families who are at present left to cope with an inadequate
system of "care in the community". With greater understanding of the condition and
its cause perhaps the community will begin to care and patients and their families
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We report a case control association study using polymorphic markers D1S1621 and
D11S931 in unrelated subjects with schizophrenia, unipolar depression and a matched
control group. The two polymorphic markers were identified during the positional
cloning of the translocation breakpoint t(l:ll)(q43:ql4.3) which cosegregates with
schizophrenia and affective disorders. These markers provided an opportunity to
investigate linkage disequilibrium with a postulated schizophrenia susceptibility gene
close to the translocation breakpoint in random populations of schizophrenia and
unipolar depression subjects compared to a normal control population.
No significant differences between allele frequencies for either of the markers in the
affected populations were observed in comparison to the control group, evidence
against a nearby gene of major effect in the populations studied.
Keywords: Association - schizophrenia - unipolar depression
INTRODUCTION
Schizophrenia is a serious and debilitating mental illness with a life time risk of ~l% in the
human population. Family, twin and adoption studies have provided strong evidence for there
being a genetic component involved in schizophrenia but the nature of this component is still
unclear. Genetic linkage studies have failed to provided clarification of the gene(s) involved
in schizophrenia, most likely due to the complex nature of the disorder, namely the polygenic
non-Mendelian inheritance, probable aetiologic heterogeneity and difficulties with precise
phenotype definition. However, recent world-wide collaborations and methodological
refinements have enabled large numbers of families to be studied, thus improving the power
of the technique and have enabled the detection of several candidate regions for involvement
with schizophrenia, most notably chromosome 6p (Wang et al, 1995, Straub et al 1995) and
22q (Pulver et al, 1994; Coon et al, 1994). Further replication and refinement of these
regions is needed. Population based association studies, in which the frequency of an allele at
the marker locus in disease population is compared to that of an ethnically matched control
population, provide an alternative approach to family based linkage analysis and have been
successfully performed in a number of complex disorders such as late onset Alzheimer's
disease with apolipoprotein E allele (Corder et al 1994) and myocardial infarction with
angiotensin converting enzyme (Cambien et al 1992).
The identification of cytogenetic abnormalities associated with disease has played an
important part in localising genes causing several human diseases. We have identified a
balanced translocation t( I: I I )(q42.2.q 14.3) which cosegregates with schizophrenia and
affective disorders in a large Scottish pedigree (St Clair et al 1990). A positional cloning
strategy has been employed to elucidate the relationship between the translocation and the
psychiatric diagnosis in this family, based on the hypothesis that a gene or genes involved in
mental illness in this family reside at or near the translocation breakpoint on chromosome 1
and/or I I (Fletcher et al 199.3, Muir et al 1995, Evans et al 1995).
A polymorphic triplet repeat, D1SI621, has been identified which lies in close proximity to
the translocation breakpoint on chromosome 1. A dinucleotide repeat polymorphic marker,
DI 1S93 I, was also available on chromosome 1 1 in close proximity to the breakpoint.
These two markers provided an opportunity to investigate an association between the
translocation breakpoint region and a possible schizophrenia susceptibility gene in a random
population of affected subjects versus normal controls.
We therefore studied the frequencies of the alleles of DI 1S931 and DIS 1621 in random
populations of subjects with schizophrenia and unipolar depression (a diagnosis also
prominent in the t(l;l 1) family) compared to ethnically matched control subjects in order to




Subjects with schizophrenia subjects (n=l05) and unipolar depression (n=84) were all either
in-patients or out-patients at the Royal Edinburgh Hospital. All patients were interviewed by
psychiatrists using the Schedule for Affective Disorder and schizophrenia-lifetime version
(SADS-L) (Endicott and Spitzer 1978). Diagnoses were based on RDC and DSM IV criteria
(Spitzer et al 1978 and American Psychiatric Association 1994). Control subjects were
obtained from the general population and were excluded from the study if they had a personal
or family history of psychiatric illness. All subjects originated from the south east of
Scotland and gave informed consent to take part in this study.
Standard procedures were used to extract DNA from peripheral blood samples.
Subjects were genotyped for markers Dl 1S931 and D1S1621 by polymerase chain reaction
(PCR) using a fluorescent primer and electrophoresis was carried out using a 40-lane
automated laser fluorescence (ALF) sequencer.
PGR:
Amplification of D IS 1621 marker was achieved using primers
5' -TTTCTCACCTTTAAATGTCATCA-3' and 5' -CCAGTACGCAGATGGTCCTA-3'.
DIIS93I was amplified with oligonucleotide primers 5'- ATGTTGGTAGGTATTCT- 3'
and 5'-GAGAAATAGTATGTGTTTGCC -3'. PCR for both markers was performed in a
final volume of 25pl containing 200pM of each dNTP, 150ng primer, 1.5mM MgCL 10mM
Tris/HCL. pH 8.3, 50mM KC1, 0.01% (w/v) gelatin, 0.1% Triton X-100, 1 Unit Taq DNA
polymerase (Perkin Elmer, Norwalk, Connecticut).
PCR conditions were as follows for DIS 1621: 30 seconds at 94°C, 1 min 15 sec at 55°C, 15
sec at 72°C (27 cycles), 30 sec at 94°C, I min 15 sec at 55°C, 6 min at 72°C (last cycle). For
D1 1S931 PCR conditions were 5 min at 94°C, 30 sec at 47°C, 1 min at 72°C (1 cycle), lmin
at 94°C, 30 sec at 47°C, I min at 72°C (30 cycles), I min at 94°C, 30 sec at 47°C, 2 min at
72°C (last cycle).
Electrophoresis was carried out on a 40-lane automated laser fluorescence (ALF) sequencer
(Pharmacia). Gels were made up with 6% Hydrolink (Long Ranger , AT Biochemicals Ltd)
in 0.6X TBE (0.06 M Tris base, 0.05M boric acid. 0.6mM EDTA)containing 7 M urea and
run in the same buffer at constant power (55W) and constant temperature (50°C).
After the PCR reaction the products from both reactions (D1 1S931 and DIS1621), for the
same patient, were run in the same lane on the ALF sequencer (since the products are of
different size) with appropriate size markers and gold standards. Automated genotyping was
carried out using 'ALF' manager and 'ALP' software.(Fie etal 1995, Mansfield et al 1994 ).
All gel results were also checked manually.
The presence of an allelic association was sought using CLUMP (Sham et al. 1995).
RESULTS
Genotypes were obtained for 143 control subjects 100 schizophrenia subjects and 84 random
unipolar depressed subjects with markers DIS1621 and D1IS931. Allele frequencies in
affecteds and controls for both markers tested are shown in Tables I and II.
No significant statistical difference in allele frequency or genotype was found for marker
D1SI62I in either the schizophrenia subjects {y~ = 3.4 P= 0.65) or the unipolar depressed
subjects (x~ = 5.0 P= 0.39) as compared to the control population. Marker DI1S931
similarly did not show any statistically significant differences between the control population
and either schizophrenia subjects {yj = 1.6 P= 0.66) or unipolar depressed subjects (%: = 1.8
P=0.63).
The Dl 1S93I sample has 76% power to detect a 20% difference in allele frequency and 23%
power to detect a 10% difference.
The DISI62I sample has 68% power to a detect 20% difference in allele frequency and 19%
power to detect a 10% difference (Cohen 1988).
TABLE I: Percentage Allele Frequency at marker Dl IS931. (Numbers in
parentheses represent actual allele frequency)
Allele sizes (bp)
~™
149 159 163 165
Controls (n= 143) 30 (86) K) ( 29) 22 (64) 38(107)
Schizophrenics (n= 100) 28.5 (57) 13.5 (27) 23.5 (47) 34.5 (69)
Unipolar depression (n=84) 30(50) 12.5 (21) 25.5 (43) 32 (54)
TABLE II: Percentage Allele frequency at marker D1S1621. (Numbers in
parentheses represent actual allele frequency)
Allele size (bp)
252 255 258 261 264 267
Controls (n=l43) 13(36) 25 (73) 33 (94) 16 (45) 11 (31) 2(7)
Schizophrenia (n=105) 10 (21) 27 (57) 31 (66) 18 (37) 9(19) 5(10)
Unipolar Depression (n=84) 12 (20) 31.5 (53) 31.5 (53) U (18) 9(16) 5(8)
DISCUSSION
We observed no significant differences in the allele frequencies of markers D1S1621 or
D1IS93I in our population of schizophrenic subjects and unipolar depressed subjects in
comparison to a control population.
This lack of association may indicate that the two markers investigated are not in linkage
disequilibrium with a major gene of high prevalence in the population tested. Alternatively, it
may be that this postulated gene in close proximity to the translocation breakpoint is of major
effect in the translocation family but is prominent in only a minority of the affected
population studied and is therefore not of strong enough effect to be picked up in the
association study.
It is unlikely that we have failed to demonstrate an association due to population stratification
as the control and affected populations have been selected from the same geographical region
as far as possible. Family based controls should however be considered wherever possible to
lessen this problem (Rubinstein et al 1981, Falk and Rubinstein 1987).
In conclusion, the present study does not reveal an association between the markers D1SI621
and DI 1S93I with either schizophrenia or unipolar depression in this Scottish population,
evidence against a nearby gene of major effect.
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